Guided Therapeutics (GTHP) S-1/A 12 Jul 22 IPO registration (amended) Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2022
Cover [Abstract]
Entity Registrant Name	GUIDED THERAPEUTICS, INC.
Entity Central Index Key	0000924515
Document Type	S-1/A
Amendment Flag	true
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Filer Category	Non-accelerated Filer
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	58-2029543
Entity Address Address Line 1	5835 Peachtree Corners East
Entity Address Address Line 2	Suite B
Entity Address City Or Town	Norcross
Entity Address State Or Province	GA
Entity Address Postal Zip Code	30092
City Area Code	770
Amendment Description	The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine.
Local Phone Number	242-8723

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash And Cash Equivalents	$ 725,000	$ 643,000	$ 182,000
Accounts Receivable, Net Of Allowance For Doubtful Accounts	39,000	46,000	24,000
Inventory, Net Of Reserves	570,000	571,000	605,000
Other Current Assets	453,000	377,000	85,000
Total Current Assets	1,787,000	1,637,000	896,000
Non-current Assets:
Property And Equipment, Net	28,000	14,000	1,000
Operating Lease Right-of-use Asset, Net Of Amortization	355,000	372,000	453,000
Other Assets	17,000	17,000	0
Total Non-current Assets	400,000	403,000	454,000
Total Assets	2,187,000	2,040,000	1,350,000
Current Liabilities:
Accounts Payable	2,476,000	2,362,000	2,419,000
Accounts Payable, Related Parties	80,000	87,000	116,000
Accrued Liabilities	1,228,000	1,768,000	2,995,000
Deferred Revenue	514,000	337,000	42,000
Current Portion Of Lease Liability	70,000	67,000	56,000
Current Portion Of Long-term Debt	67,000	88,000	28,000
Notes Payable In Default		0	328,000
Notes Payable In Default, Related Parties		0	1,000
Short-term Notes Payable	12,000	48,000	45,000
Short-term Notes Payable, Related Parties	31,000	40,000	51,000
Convertible Notes Payable In Default	161,000	161,000	0
Convertible Notes Payable, Past Due		0	1,930,000
Short-term Convertible Notes Payable	745,000	736,000	951,000
Derivatives Liability current	38,000	0
Current portion of long-term debt, related parties	27,000	0
Total Current Liabilities	5,449,000	5,694,000	8,962,000
Long-term Liabilities
Warrants, At Fair Value		0	2,203,000
Long-term Lease Liability	307,000	325,000	392,000
Derivative Liability	0	32,000	25,000
Long-term Convertible Debt	852,000	820,000	23,000
Long-term Debt	0	22,000	0
Long-term Debt, Related Parties	568,000	592,000	600,000
Total Long-term Liabilities	1,727,000	1,791,000	3,243,000
Total Liabilities	7,176,000	7,485,000	12,205,000
Stockholders' Deficit:
Common Stock Value	3,410,000	3,403,000	3,403,000
Additional Paid In Capital	129,042,000	126,800,000	123,109,000
Treasury Stock At Cost	(132,000)	(132,000)	(132,000)
Accumulated Deficit	(143,442,000)	(142,387,000)	(139,956,000)
Total Stockholders Deficit	(4,989,000)	(5,445,000)	(10,855,000)
Total Liabilities And Stockholders Deficit	2,187,000	2,040,000	1,350,000
Series C Convertible Preferred Shares
Stockholders' Deficit:
Preferred Stock Value	105,000	105,000	105,000
Series C1 Convertible Preferred Shares
Stockholders' Deficit:
Preferred Stock Value	170,000	170,000	170,000
Series C2 Convertible Preferred Shares
Stockholders' Deficit:
Preferred Stock Value	531,000	531,000	531,000
Series D Convertible Preferred Shares
Stockholders' Deficit:
Preferred Stock Value	276,000	276,000	276,000
Series E Convertible Preferred Shares
Stockholders' Deficit:
Preferred Stock Value	914,000	1,639,000	1,639,000
Series F Convertible Preferred Shares
Stockholders' Deficit:
Preferred Stock Value	1,174,000	1,187,000	0
Series F-2 Convertible Preferred Shares
Stockholders' Deficit:
Preferred Stock Value	2,963,000	2,963,000	0
Series G Convertible Preferred Shares
Stockholders' Deficit:
Preferred Stock Value	$ 0	$ 0	$ 0

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounts receivable, net of allowance	$ 126,000	$ 126,000	$ 126,000
Inventory, net of reserves	$ 785,000	$ 785,000	$ 758,000
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, authorized	500,000,000	500,000,000	500,000,000
Common stock, issued	22,316,000	13,673,000	13,138,000
Common stock, outstanding	22,316,000	13,673,000	13,138,000
Series C Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	9,000	9,000	9,000
Preferred stock, liquidation preference	$ 286,000	$ 286,000	$ 286,000
Preferred stock, issued	300	300	300
Preferred stock, outstanding	300	300	300
Series D Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	6,000	6,000	6,000
Preferred stock, liquidation preference	$ 763,000	$ 763,000	$ 763,000
Preferred stock, issued	800	800	800
Preferred stock, outstanding	800	800	800
Series E Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	5,000	5,000
Preferred stock, liquidation preference	$ 968,000	$ 1,736,000	$ 1,736,000
Preferred stock, issued	1,000	1,700	1,700
Preferred stock, outstanding	1,000	1,700	1,700
Series F Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	1,500	1,500	1,500
Preferred stock, liquidation preference	$ 1,411,000	$ 1,426,000	$ 0
Preferred stock, issued	1,400	1,400	0
Preferred stock, outstanding	1,400	1,400	0
Series F-2 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	5,000	3,500	3,500
Preferred stock, liquidation preference	$ 3,237,000	$ 3,237,000	$ 0
Preferred stock, issued	3,200	3,200	0
Preferred stock, outstanding	3,200	3,200	0
Series C-1 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	20,300	20,300	20,300
Preferred stock, liquidation preference	$ 1,049,000	$ 1,049,000	$ 1,049,000
Preferred stock, issued	1,000	1,000	1,000
Preferred stock, outstanding	1,000	1,000	1,000
Series C-2 Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	5,000,000	5,000,000	5,000,000
Preferred stock, liquidation preference	$ 3,263,000	$ 3,263,000	$ 3,263,000
Preferred stock, issued	3,300	3,300	3,300
Preferred stock, outstanding	3,300	3,300	3,300
Series G Convertible Preferred Shares
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, authorized	1,000,000	1,000,000	1,000,000
Preferred stock, liquidation preference	$ 0	$ 0	$ 0
Preferred stock, issued	0	0	0
Preferred stock, outstanding	0	0	0

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
CONSOLIDATED STATEMENTS OF OPERATIONS
Sales - devices and disposables	$ 5	$ 0	$ 81	$ 102
Cost of goods sold	1	0	61	(41)
Gross profit	4	0	20	143
Operating Expenses:
Research and development	21	16	69	143
Sales and marketing	40	36	141	139
General and administrative	386	771	2,172	913
Total Operating Expenses	447	823	2,382	1,195
Loss From Operations	(443)	(823)	(2,362)	(1,052)
Other Income (expenses):
Interest expense	(101)	(141)	(1,150)	(1,056)
Change In Fair Value Of Derivative Liability	(6)	(88)	(91)	(25)
Gain from extinguishment of debt	41	87	578	(296)
Change in fair value of warrants	0	448	448	1,879
Other expenses	2	0
Other Income			507	271
Total other income (expense)	(64)	306	292	773
Loss Before Income Taxes	(507)	(517)	(2,070)	(279)
Provision for income taxes	0	0	0	0
Net Loss	(507)	(517)	(2,070)	(279)
Preferred stock dividends	(548)	(55)	(361)	(122)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (1,055)	$ (572)	$ (2,431)	$ (401)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.05)	$ (0.04)	$ (0.18)	$ (0.04)
Diluted	$ (0.05)	$ (0.04)	$ (0.18)	$ (0.04)
Weighted Average Shares Outstanding
Weighted Average Shares Outstanding Basic	20,683	13,172	13,377	10,767
Weighted Average Shares Outstanding Diluted	20,683	13,172	13,377	10,767

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (507,000)	$ (517,000)	$ (2,071,000)	$ (279,000)
Adjustments To Reconcile Net Loss To Net Cash Used In Operating Activities:
Bad Debt Expense			0	12,000
Amortization of debt issuance costs and discounts	41,000	64,000	320,000	394,000
Amortization of beneficial conversion feature	0	8,000	8,000	102,000
Stock based compensation	44,000	62,000	228,000	310,000
Depreciation			1,000	0
Change In Fair Value Of Warrants	0	(448,000)	(448,000)	(1,879,000)
Extinguishment Of Derivative Liability			(84,000)	0
Inventory Reserve			0	(73,000)
Change In Fair Value Of Derivatives	6,000	88,000	91,000	25,000
Loss On Extinguishment Of Debt			0	296,000
Amortization of lease right-of-use-asset	16,000	0	82,000	0
Expense for warrants issued to consultants	79,000	398,000	664,000	0
Gain From Forgiveness Of Debt	(41,000)	(87,000)	(578,000)	0
Other Non-cash Expenses (income)	6,000	0	117,000	0
Change In Operating Assets And Liabilities:
Accounts Receivable	6,000	0	(22,000)	(23,000)
Inventory	1,000	(1,000)	33,000	(483,000)
Other Current Assets	(76,000)	46,000	(292,000)	(15,000)
Other Non-current Assets	0	18,000	(17,000)	18,000
Accounts payable and accrued liabilities	84,000	65,000	136,000	(221,000)
Lease Liabilities	(15,000)	0	(56,000)	0
Deferred revenue	177,000	20,000	296,000	(59,000)
Net Cash Used In Operating Activities	(179,000)	(320,000)	(1,592,000)	(1,875,000)
Cash Flows From Investing Activities:
Purchase of property and equipment	(14,000)	(1,000)	(14,000)	(1,000)
Net Cash Used For Investing Activities	(14,000)	(1,000)	(14,000)	(1,000)
Cash Flows From Financing Activities:
Note Payable Default Penalty			398,000	0
Proceeds From Issuance Of Series D Preferred Stock			0	102,000
Proceeds From Issuance Of Series E Preferred Stock			0	1,639,000
Payments Of Debt Issuance Costs			(86,000)	0
Proceeds From Issuance Of Common Stock, Net Of Costs			0	0
Redemption Of Series G Preferred Stock			(125,000)	0
Proceeds From Series F-2 Offering, Net Of Costs			539,000	0
Proceeds From Debt Financing			1,248,000	519,000
Proceeds from warrant exercises	365,000	0
Payments made on notes payable	(90,000)	(557,000)	(1,468,000)	(1,101,000)
Proceeds from Series F offering, net of costs	0	1,818,000	1,436,000	0
Proceeds from Series G offering, net of costs	0	125,000	125,000	0
Net Cash Provided By Financing Activities	275,000	1,386,000	2,067,000	1,159,000
Net Change In Cash	82,000	1,065,000	461,000	(717,000)
Cash At Beginning Of Period	643,000	182,000	182,000	899,000
CASH AT END OF PERIOD	725,000	1,247,000	643,000	182,000
Supplemental Disclosure For Operating Activities:
Cash paid for interest	6,000	405,000	557,000	295,000
Supplemental Disclosure For Non-cash Investing And Financing Activities:
Dividends on preferred stock	548,000	55,000	361,000	122,000
Common stock issued for payment of interest	81,000	0
Common stock issued for payment of dividends	592,000	14,000
Conversion of Series E Preferred Shares into Common Stock	725,000	1,755,000
Issuance of warrants to finders in connection with Series F and Series F-2 preferred stock	0	151,000	377,000	0
Issuance of series F-2 preferred stock	0	2,559,000	2,236,000	0
Debt From Related Parties Exchanged For Preferred Series F-2			323,000	0
Settlement Of Dividends Through Common Stock Issuance			171,000	40,000
Settlement Of Accounts Payable Through Common Stock Issuance			62,000	0
Warrants Exchanged For Fixed Price Warrants			1,755,000	131,000
Warrants Issued With Debt			304,000	0
Settlement Of Accounts Payable Through Issuance Of Promissory Note			97,000	0
Issuance Of Common Stock As Debt Repayment			0	2,929,000
Conversion Of Preferred Series F To Common Stock	$ 13,000	$ 0	8,000	0
Subscription Receivable			$ 0	$ 635,000

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)	Total	Preferred Stock Series C [Member]	Preferred Stock Series C1 [Member]	Preferred Stock Series C2 [Member]	Preferred Stock Series D [Member]	Preferred Stock Series E [Member]	Preferred Stock Series F [Member]	Preferred Stock Series F-2 [Member]	Preferred Stock Series G [Member]	Common Stock [Member]	Additional Paid-In Capital	Treasury Stock [Member]	Accumulated Deficit [Member]
Balance, Shares at Dec. 31, 2019			1,000	3,000						3,319,000
Balance, Amount at Dec. 31, 2019	$ (16,935,000)	$ 105,000	$ 170,000	$ 531,000	$ 0					$ 3,394,000	$ 118,552,000	$ (132,000)	$ (139,555,000)
Issuance Of Preferred Stock In Financing, Shares					1,000	2,000
Issuance Of Preferred Stock In Financing, Amount	1,915,000	0	0	0	$ 276,000	$ 1,639,000	$ 0	$ 0	$ 0
Conversion Of Debt Into Common Stock		0	0	0	0
Conversion Of Debt Into Common Stock, Shares										8,132,000
Conversion Of Debt Into Common Stock, Amount	2,929,000									$ 8,000	2,921,000
Issuance Of Common Stock In Financing		0	0	0	0
Warrants Exchanged For Fixed Price Warrants	131,000	0	0	0	0
Issuance Of Common Stock In Financing, Shares										1,526,000
Issuance Of Common Stock In Financing, Amount	461,000									$ 1,000	460,000
Issuance Of Common Stock For Manufacturing Agreements		0	0	0	0
Issuance Of Common Stock For Payment Of Series D Preferred Dividends		0	0	0	0
Issuance Of Warrants In Financing	117,000										117,000
Beneficial Conversion Feature Of Convertible Debt	82,000	0	0	0	0						82,000
Issuance Of Common Stock For Manufacturing Agreements, Shares										12,000
Adjustment To Warrant Liability For Adoption Of Asu 2017-11	627,000	0	0	0	0						627,000
Stock Based Compensation	310,000	0	0	0	0						310,000
Issuance Of Common Stock For Payment Of Series D Preferred Dividends, Shares										149,000
Accrued Series D Preferred Stock Dividends	(122,000)	0	$ 0	$ 0	$ 0								(122,000)
Issuance Of Common Stock For Payment Of Series D Preferred Dividends, Amount	40,000										40,000
Net Loss	(279,000)	0											(279,000)
Stock-based compensation	310,000
Expense for warrants issued to consultants	$ 0
Balance, Shares at Dec. 31, 2020	13,138,282		1,000	3,000	1,000	2,000				13,138,000
Balance, Amount at Dec. 31, 2020	$ (10,855,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000		0	0	$ 3,403,000	123,109,000	(132,000)	(139,956,000)
Issuance Of Common Stock For Payment Of Series D Preferred Dividends, Shares										42,000
Issuance Of Common Stock For Payment Of Series D Preferred Dividends, Amount											14,000
Net Loss	(517,000)												(517,000)
Issuance of warrants to consultants											398,000
Conversions of warrants from liability to equity											1,755,000
Accrued preferred dividends													(55,000)
Stock-based compensation	62,000										62,000
Series F preferred offering, shares							2,000
Series F preferred offering, amount	1,667,000								$ 1,667,000
Series G preferred offering, shares									153,000
Issuance of warrants to finders						$ 2,559,000					151,000
Expense for warrants issued to consultants	$ 398,000
Balance, Shares at Mar. 31, 2021	13,180,417		1,000	3,000	1,000	2,000	4,000		153,000	13,180,000
Balance, Amount at Mar. 31, 2021		105,000	$ 170,000	$ 531,000		$ 1,639,000				$ 3,403,000	125,489,000	(132,000)	(140,528,000)
Balance, Shares at Dec. 31, 2020	13,138,282		1,000	3,000	1,000	2,000				13,138,000
Balance, Amount at Dec. 31, 2020	$ (10,855,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000		0	$ 0	$ 3,403,000	123,109,000	(132,000)	(139,956,000)
Warrants Exchanged For Fixed Price Warrants	1,755,000
Issuance Of Common Stock For Payment Of Series D Preferred Dividends		0	0	0	0	0	$ 0	0	0
Stock Based Compensation	227,000	0	0	0	0	0	0	0	0	$ 0	227,000	0	0
Issuance Of Common Stock For Payment Of Series D Preferred Dividends, Shares										109,000
Issuance Of Common Stock For Payment Of Series D Preferred Dividends, Amount	53,000									$ 0	53,000	0	0
Net Loss	(2,070,000)	0	0	0	0	0	0	0	0	0	0	0	(2,070,000)
Series G preferred offering	0	0	0	0	0					0	0	0	0
Issuance of warrants to consultants	1,172,000	0	0	0	0	0	0	0	0	0	1,172,000	0	0
Accrued preferred dividends	(361,000)	0	0	0	0	0	$ 0	0	0	0	0	0	(361,000)
Stock-based compensation	228,000
Series F preferred offering, shares							1,000
Series G preferred offering, amount						0	$ 0	0	0
Series F preferred offering	1,195,000									0	0	0	0
Series F preferred offering, amount						0	1,195,000	$ 0	$ 0
Series G preferred offering, shares									153,000
Series F-2 Preferred Offering	404,000									0	0	0	0
Conversion Of Debt And Expenses For Series F-2 Preferred Stock	2,559,000									0	0	0	0
Issuance Of Common Stock To Finders, Amount	54,000									0	54,000	0	0
Series F-2 Preferred Offering, Shares								1,000
Series G Redemption	0	0	0	0	0					$ 0	0	0	0
Conversion Of Debt And Expenses For Series F-2 Preferred Stock								2,000
Issuance Of Common Stock For Payment Of Series E Preferred Dividends, Shares										288,000
Series F-2 Preferred Offering, Amount						0	0	$ 404,000	$ 0
Issuance Of Common Stock For Payment Of Series E Preferred Dividends, Amount	118,000									$ 0	118,000	0	0
Warrants Issued With Debt	304,000	0	0	0	0	0	0	0	0	0	304,000	0	0
Conversion Of Debt And Expenses For Series F-2 Preferred Stock, Amount						0	0	2,559,000	0
Conversion Of Warrants From Liabilities To Equity	1,755,000	0	0	0	0	0	0	0	0	$ 0	1,755,000	0	0
Conversion Of Series F Preferred Shares Into Common Stock, Shares										40,000
Conversion Of Series F Preferred Shares Into Common Stock, Amount	0									$ 0	8,000	0	0
Issuance Of Common Stock For Payment Of Series E Preferred Dividends		0	0	0	0	0	0	0	$ 0
Series G Redemption, Shares									(153,000)
Series G Redemption, Amount						0	0	0	$ 0
Conversion Of Series F Preferred Shares Into Common Stock		0	$ 0	$ 0	$ 0	$ 0	$ (8,000)	$ 0	0
Expense for warrants issued to consultants	$ 664,000
Balance, Shares at Dec. 31, 2021	13,607,609		1,000	3,000	1,000	2,000	1,000	3,000		13,673,000
Balance, Amount at Dec. 31, 2021	$ (5,445,000)	105,000	$ 170,000	$ 531,000	$ 276,000	$ 1,639,000	$ 1,187,000	$ 2,963,000	$ 0	$ 3,403,000	126,800,000	(132,000)	(142,387,000)
Issuance Of Common Stock For Payment Of Series D Preferred Dividends, Shares										23,000
Issuance Of Common Stock For Payment Of Series D Preferred Dividends, Amount	15,000										$ 15,000
Net Loss	(507,000)												(507,000)
Accrued preferred dividends	(548,000)					(725,000)							(548,000)
Stock-based compensation	$ 44,000
Issuance Of Common Stock For Payment Of Series E Preferred Dividends, Shares	64,000						(13,000)				64,000
Issuance Of Common Stock For Payment Of Series E Preferred Dividends, Amount	$ 8,000									$ 13,000	$ 8,000
Common stock warrants exercised, shares										4,478,000
Common stock warrants exercised, amount	$ 716,000									$ 4,000	$ 712,000	0	0
Issuance of common stock for payment of Series F preferred dividends, shares	105,000									158,000	105,000
Issuance of common stock for payment of Series F preferred dividends, amount	$ 81,000									$ 96,000	$ 81,000
Issuance of common stock for Series F and Series F-2 one-time 15% dividends	399,000					$ (1,000)					$ 399,000
Conversion of Series E preferred stock to common stock, shares										624,000	722,000
Conversion of Series F preferred stock to common stock, shares										3,070,000	13,000
Issuance of common stock for payment of interest, shares										3,000
Issuance of common stock for payment of interest, amount										$ 121,000
Expense for warrants issued to consultants	79,000										$ 79,000	0	0
expense for warrants issued to con										60,000
Balance, Shares at Mar. 31, 2022			1,000	3,000	1,000	1,000	1,000	3,000		22,316,000
Balance, Amount at Mar. 31, 2022	$ (4,989,000)	$ 105,000	$ 170,000	$ 531,000	$ 276,000	$ 914,000	$ 1,174,000	$ 2,963,000		$ 3,410,000	$ 129,042,000	$ (132,000)	$ (143,442,000)

ORGANIZATION BACKGROUND AND BAS

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION
ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION	1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers. During the year ended December 31, 2021, the Board simultaneously approved a 1-for-20 reverse stock split of our common stock and decreased the total number of authorized common shares to 500,000,000. On November 18, 2021, the Company submitted an Issuer Company Related Action Notification regarding the reverse stock split to the Financial Industry Regulatory Authority (“FINRA”). FINRA has not yet declared an effective date for the reverse stock split. The Company will adjust the number of shares available for future grant under its equity incentive plan and employee stock purchase plans and will also adjust the number of outstanding awards issued to reflect the effects of its reverse split. All historical share and per share amounts reflected throughout this report will be adjusted to reflect stock split at the time it becomes effective. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. Therefore, these financial statements should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities and Exchange Commission (“SEC”) pursuant to Section 13 or 15(d) under the Securities Exchange Act of 1934. The December 31, 2021 balances reported herein are derived from the audited consolidated financial statements for the year ended December 31, 2021. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of March 31, 2022 and December 31, 2021, and the consolidated results of operations and cash flows for the three-month periods ended March 31, 2022 and 2021 have been included. The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of March 31, 2022, it had an accumulated deficit of approximately $143.4 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development. The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision makers are the Chief Executive Officer and its Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas. Going Concern The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. At March 31, 2022, the Company had a negative working capital of approximately $3.7 million, accumulated deficit of $143.4 million, and incurred a net loss including preferred dividends of $1.1 million for the three months then ended. Stockholders’ deficit totaled approximately $5.0 million at March 31, 2022, primarily due to recurring net losses from operations. During the three-month period ended March 31, 2022, the Company raised $0.4 million of proceeds from warrant exercises. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection. The Company had warrants exercisable for approximately 25.4 million shares of its common stock outstanding at March 31, 2022, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in-the-money warrants would generate a total of approximately $4.7 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.	1. ORGANIZATION, BACKGROUND, AND BASIS OF PRESENTATION Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary, InterScan, Inc. (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”, is a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. The Company’s primary focus is the continued commercialization of its LuViva non-invasive cervical cancer detection device and extension of its cancer detection technology into other cancers, including esophageal. The Company’s technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers. During the year ended December 31, 2021, the Board simultaneously approved a 1-for-20 reverse stock split of our common stock and decreased the total number of authorized common shares to 500,000,000. On November 18, 2021, the Company submitted an Issuer Company Related Action Notification regarding the reverse stock split to the Financial Industry Regulatory Authority (“FINRA”). FINRA has not yet declared an effective date for the reverse stock split. The Company will adjust the number of shares available for future grant under its equity incentive plan and employee stock purchase plans and will also adjust the number of outstanding awards issued to reflect the effects of its reverse split. All historical share and per share amounts reflected throughout this report will be adjusted to reflect the stock split at the time it becomes effective. Basis of Presentation The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principals generally accepted in the United States of America, or U.S. GAAP. All intercompany transactions and balances have been eliminated in consolidation. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the Company as of December 31, 2021 and 2020, and the consolidated results of operations and cash flows for the years ended December 31, 2021 and 2020 have been included. The Company’s prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of December 31, 2021, it had an accumulated deficit of approximately $142.4 million. To date, the Company has engaged primarily in research and development efforts and the early stages of marketing its products. The Company may not be successful in growing sales for its products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. The Company’s products may not ever gain market acceptance and the Company may not ever generate significant revenues or achieve profitability. The development and commercialization of the Company’s products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue for the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals, build its marketing, sales, manufacturing and finance capabilities, and conduct further research and development. The Company is not organized by multiple operating segments for the purpose of making operating decisions or assessing performance. Accordingly, the Company operates in one reportable operating segment. The Company’s principal decision makers are the Chief Executive Officer and its Chief Financial Officer. Management believes that its business operates as one reportable segment because: a) the Company measures profit and loss as a whole; b) the principal decision makers do not review information based on any operating segment; c) the Company does not maintain discrete financial information on any specific segment; d) the Company has not chosen to organize its business around different products and services, and e) the Company has not chosen to organize its business around geographic areas. Going Concern The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. At December 31, 2021, the Company had a negative working capital of approximately $4.1 million, accumulated deficit of $142.4 million, and incurred a net loss including preferred dividends of $2.4 million for the year then ended. Stockholders’ deficit totaled approximately $5.4 million at December 31, 2021, primarily due to recurring net losses from operations. During the year ended December 31, 2021, the Company raised $3.2 million of funds from the sale of preferred stock and 10% convertible debentures. The Company will need to continue to raise capital in order to provide funding for its operations and FDA approval process. If sufficient capital cannot be raised, the Company will continue its plans of curtailing operations by reducing discretionary spending and staffing levels and attempting to operate by only pursuing activities for which it has external financial support. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection. The Company had warrants exercisable for approximately 27.7 million shares of its common stock outstanding at December 31, 2021, with exercise prices ranging between $0.15 and $0.80 per share. Exercises of in-the-money warrants would generate a total of approximately $5.1 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the public or private sale of debt or equity, and grants, if available.

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants. Accounting Standard Updates A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. Accounts Receivable The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable. Concentrations of Credit Risk The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk. Inventory Valuation All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. As of March 31, 2022 and December 31, 2021, our inventories were as follows: (in thousands) March 31, 2022 December 31, 2021 Raw materials $ 1,254 $ 1,255 Work-in-progress 69 69 Finished goods 32 32 Inventory reserve (785 ) (785 ) Total inventory $ 570 $ 571 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at March 31, 2022 and December 31, 2021: (in thousands) March 31, 2022 December 31, 2021 Equipment $ 1,049 $ 1,048 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress 21 8 Subtotal 1,775 1,761 Less accumulated depreciation (1,747 ) (1,747 ) Property, equipment and leasehold improvements, net $ 28 $ 14 Depreciation expense related to property and equipment for the three months ended March 31, 2022 and 2021 was not material. Debt Issuance Costs Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount. Patent Costs (Principally Legal Fees) Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs were not material for the three months ended March 31, 2022 and 2021. Leases A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 7 - Commitments and Contingencies. Accrued Liabilities Accrued liabilities as of March 31, 2022 and December 31, 2021 are summarized as follows: (in thousands) March 31, 2022 December 31, 2021 Compensation $ 573 $ 621 Professional fees 41 98 Stock Subscription Payable - 351 Interest 232 261 Vacation 42 39 Preferred dividends 299 349 Other accrued expenses 41 49 Total $ 1,228 $ 1,768 Stock Subscription Payable Cash received from investors for common stock shares that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet. Revenue Recognition ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue-based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 - Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. · Step 2 - Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. · Step 3 - Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. · Step 4 - Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. · Step 5 - Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company did not recognize material revenues during the three-month periods ended March 31, 2022 or 2021. The Company’s revenues do not require significant estimates or judgments. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of March 31, 2022 and December 31, 2021, the Company had $514,000 and $337,000 in deferred revenue, respectively. Significant Distributors As of March 31, 2022, accounts receivable outstanding was $165,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $39,000 which was from two distributors. As of December 31, 2021, accounts receivable outstanding was $172,000; the outstanding amount was netted against a $126,000 allowance, leaving a balance of $46,000, which was from two distributors. Research and Development Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred. Income Taxes The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed its 2021 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At March 31, 2022, the Company had approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations. Warrants The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model. Stock Based Compensation The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation - Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future. Derivatives The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.	2. SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of freestanding warrants. Accounting Standard Updates FASB ASU 2021-04, “ Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” - FASB ASU NO. 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” FASB ASU NO. 2019-12, “ Simplifying the Accounting for Income Taxes A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements. Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent. Accounts Receivable The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable. Concentrations of Credit Risk The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk. Inventory Valuation All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. As of December 31, 2021 and 2020, our inventories were as follows: (in thousands) December 31, December 31, 2021 2020 Raw materials $ 1,255 $ 1,276 Work-in-progress 69 80 Finished goods 32 7 Inventory reserve (785 ) (758 ) Total inventory $ 571 $ 605 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold. Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at December 31, 2021 and 2020: (in thousands) December 31, December 31, 2021 2020 Equipment $ 1,048 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress 8 - Subtotal 1,761 1,747 Less accumulated depreciation (1,747 ) (1,746 ) Property, equipment and leasehold improvements, net $ 14 $ 1 Depreciation expense related to property and equipment for the years ended December 31, 2021 and 2020 was not material. Debt Issuance Costs Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount. Patent Costs Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated to approximately $14,800 and $17,000 for the years ended December 31, 2021 and 2020, respectively. Leases A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 7 - Commitments and Contingencies. Accrued Liabilities Accrued liabilities as of December 31, 2021 and 2020 are summarized as follows: (in thousands) December 31, December 31, 2021 2020 Compensation $ 621 $ 1,094 Professional fees 98 83 Interest 261 1,517 Vacation 39 34 Preferred dividends 349 202 Stock subscription payable 351 - Other accrued expenses 49 65 Total $ 1,768 $ 2,995 Stock Subscription Payable Cash received from investors for common stock shares that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet. Revenue Recognition ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue-based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. • Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. • Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. • Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. • Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company did not recognize material revenues during the years ended December 31, 2021 or 2020. The Company’s revenues do not require significant estimates or judgments. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of December 31 2021 and 2020, the Company had $337,000 and $42,000 of deferred revenue, respectively. Significant Distributors As of December 31, 2021, accounts receivable outstanding was $172,000; the outstanding amount was netted against a $126,000 allowance, leaving a balance of $46,000 which was from two distributors. As of December 31, 2020, accounts receivable outstanding was $150,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $24,000 which was from one distributor. Research and Development Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred. Income Taxes The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed its 2020 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2021, the Company had approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations. Warrants The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model. Stock Based Compensation The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation - Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future. Beneficial Conversion Features of Convertible Securities The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of January 1, 2020. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence. During 2021, the Company adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity Derivatives The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
FAIR VALUE OF FINANCIAL INSTRUMENTS
FAIR VALUE OF FINANCIAL INSTRUMENTS	3. FAIR VALUE OF FINANCIAL INSTRUMENTS The guidance for fair value measurements, ASC 820, Fair Value Measurements and Disclosures · Level 1-Quoted market prices in active markets for identical assets and liabilities; · Level 2-Inputs, other than level 1 inputs, either directly or indirectly observable; and · Level 3-Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use. The Company records its derivative activities at fair value. As of March 31, 2022 we had one instrument that we valued for the derivative liability associated with the bifurcated conversion option of the Auctus loan for $400,000. There was no movement of instruments between fair value hierarchy tiers during the three months ended March 31, 2022. The following tables present the fair value of those liabilities measured on a recurring basis as of March 31, 2022 and December 31, 2021: Fair Value at March 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 $ - $ - $ (38 ) $ (38 ) Total short-term liabilities at fair value $ - $ - $ (38 ) $ (38 ) Fair Value at December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (32 ) (32 ) Total long-term liabilities at fair value $ - $ - $ (32 ) $ (32 ) The following is a summary of changes to Level 3 instruments during the three months ended March 31, 2022: (in thousands) Senior Secured Debt Derivative Total Balance, December 31, 2021 $ - $ (32 ) $ (32 ) Change in fair value during the period - (6 ) (6 ) Balance, March 31, 2022 $ - $ (38 ) $ (38 )	3. FAIR VALUE OF FINANCIAL INSTRUMENTS The guidance for fair value measurements, ASC 820, Fair Value Measurements and Disclosures, establishes the authoritative definition of fair value, sets out a framework for measuring fair value, and outlines the required disclosures regarding fair value measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy based upon observable and non-observable inputs as follow: · Level 1 – Quoted market prices in active markets for identical assets and liabilities; · Level 2 – Inputs, other than level 1 inputs, either directly or indirectly observable; and · Level 3 – Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use. The Company records its derivative activities at fair value. As of December 31, 2021 we had one instrument that we valued for the derivative liability associated with the bifurcated conversion option of the Auctus loan for $400,000 ($700,000 of the $1,100,000 was paid in during the year ended December 31, 2021). There was no movement of instruments between fair value hierarchy tiers during the years ended December 31, 2021 or 2020. The following tables present the fair value of those liabilities measured on a recurring basis as of December 31, 2021 and 2020: Fair Value at December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 $ - $ - $ (32 ) $ (32 ) Total long-term liabilities at fair value $ - $ - $ (32 ) $ (32 ) Fair Value at December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Warrants issued in connection with Senior Secured Debt $ $ $ (2,203 ) $ (2,203 ) Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (25 ) (25 ) Total long-term liabilities at fair value $ - $ - $ (2,228 ) $ (2,228 ) The following is a summary of changes to Level 3 instruments during the year ended December 31, 2021: (in thousands) Senior Secured Debt Derivative Total Balance, December 31, 2020 $ (2,203 ) $ (25 ) $ (2,228 ) Change in the terms of warrants previously recorded as a liability and now reclassified to equity 1,755 - 1,755 Change in value due to warrants expiring during the year 448 - 448 Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus - 84 84 Change in fair value during the year - (91 ) (91 ) Balance, December 31, 2021 $ - $ (32 ) $ (32 )

STOCKHOLDERS DEFICIT

STOCKHOLDERS DEFICIT	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Deficit:
STOCKHOLDERS' DEFICIT	4. STOCKHOLDERS’ DEFICIT Common Stock The Company has authorized 500,000,000 shares of common stock with $0.001 par value. As of March 31, 2022 and December 31, 2021, 22,316,412 and 13,673,583 shares were issued and outstanding, respectively. During the three months ended March 31, 2022, the Company issued 8,642,829 shares of common stock: Number of Shares Common stock warrants exercised 4,477,923 Issuance of common stock for payment of Series D preferred dividends 23,109 Issuance of common stock for payment of Series E preferred dividends 12,432 Issuance of common stock for payment of Series F preferred dividends 158,662 Issuance of common stock for payment of Series F-2 preferred dividends 95,535 Issuance of common stock for payment of interest 121,262 Issuance of common stock for Series F one-time 15% dividend 255,401 Issuance of common stock for Series F-2 one-time 15% dividend 368,505 Conversion of Series E preferred stock to common stock 3,070,000 Conversion of Series F preferred stock to common stock 60,000 Issued during the three months ended March 31, 2022 8,642,829 Summary table of common stock share transactions: Balance at December 31, 2021 13,673,583 Issued in 2022 8,642,829 Balance at March 31, 2022 22,316,412 Preferred Stock The Company has authorized 5,000,000 shares of preferred stock with a $0.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. Series C Convertible Preferred Stock The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C preferred stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At March 31, 2022 and December 31, 2021, there were 286 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total convertible of 572,000 common stock shares, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. Unpaid accrued dividends were $120,120 as of March 31, 2022. Upon conversion of the Series C preferred stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At March 31, 2022 and December 31, 2021, the “make-whole payment” for a converted share of Series C preferred stock would convert to 200 shares of the Company’s common stock. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. In addition, the purchasers of the Series C preferred stock received, on a pro rata basis, warrants exercisable to purchase an aggregate of approximately 1 share of Company’s common stock. The warrants contain anti-dilution adjustments in the event that the Company issues shares of common stock, or securities exercisable or convertible into shares of common stock, at prices below the exercise price of such warrants. As a result of the anti-dilution protection, the Company is required to account for the warrants as a liability recorded at fair value each reporting period. As of March 31, 2022, these warrants had expired. Series C1 Convertible Preferred Stock The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,049 shares were issued and outstanding at March 31, 2022 and December 31, 2021. In addition, some holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At March 31, 2022 and December 31, 2021, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock. At March 31, 2022 and December 31, 2021, there were 1,049.25 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C1 preferred stock would convert into approximately 2,000 shares of the Company’s common stock, for a total convertible of 2,098,500 common stock shares. The Series C1 preferred stock has terms that are substantially the same as the Series C preferred stock, except that the Series C1 preferred stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt. Series C2 Convertible Preferred Stock On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Preferred Stock, including the chairman of the Company’s board of directors, and the Chief Operating Officer and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At March 31, 2022 and December 31, 2021, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock, for a total convertible of 6,524,500 common stock shares. The terms of the Series C2 Preferred Stock are substantially the same as the Series C1 Preferred Stock, except that (i) shares of Series C1 Preferred Stock may not be convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing. Series D Convertible Preferred Stock The Board designated 6,000 shares of preferred stock as Series D Preferred Stock, 763 of which remained outstanding as of March 31, 2022 and December 31, 2021. On January 8, 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 common stock shares, 1,526,000 common stock warrants, exercisable at $0.25, and 1,526,000 common stock warrants, exercisable at $0.75. Each Series D Preferred Stock is convertible into 3,000 common stock shares. The Series D Preferred Stock will have cumulative dividends at the rate per share of 10% per annum. The stated value and liquidation preference on the Series D Preferred Stock is $763. The 763 Series D Preferred Shares are convertible into debt at the option of the holder during a prescribed time period. If the Series D Preferred Shares are converted, the Series D preferences are surrendered and the debt is then secured by the Company’s assets. As of March 31, 2022, none of the 763 Series D Preferred Shares have been converted to secured debt. Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the three months ended March 31, 2022, the Company issued 23,109 common stock shares for the payment of accrued Series D Preferred Stock dividends. As of March 31, 2022, the Company had accrued dividends of $14,306. Series E Convertible Preferred Stock The Board designated 5,000 shares of preferred stock as Series E Preferred Stock, 968 and 1,736 of which remained outstanding as of March 31, 2022 and December 31, 2021, respectively. Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. Each share of Series E Preferred Stock has a par value of 0.001 per share and a Stated Value equal to $1,000, subject to increase set forth in its Certificate of Designation. Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually in cash or, following the listing of the Company’s common stock on certain Canadian trading markets and at the option of the Company, shares of common stock. During the three months ended March 31, 2022, the Company issued 3,070,000 common stock shares for the conversion of 768 shares of Series E Convertible Preferred Stock. During the three months ended March 31, 2022, the Company issued 12,432 common stock shares for the payment of Series E Preferred Stock dividends accrued. As of March 31, 2022, the Company had accrued dividends of $71,099. Series F Convertible Preferred Stock The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 1,411 and 1,426 of which were issued and outstanding as of March 31, 2022 and December 31, 2021, respectively. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,436,000 the Company issued 1,436 shares of Series F Preferred Stock. Each Series F Preferred Stock is convertible into 4,000 common stock shares. The Series F Preferred Stock is entitled to cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F Preferred Stock is $1,411. Each share of Series F Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series F Preferred. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the three months ended March 31, 2022, the Company issued 60,000 common stock shares for the conversion of 15 shares of Series F Convertible Preferred Stock. During the three months ended March 31, 2022, the Company issued 158,662 common stock shares for the payment of annual Series F Preferred Stock dividends. Additionally, During the three months ended March 31, 2022, the Company issued 255,401 common stock shares for the payment of a one-time, non-recurring 15% dividend to the Series F Preferred shareholders (as required by the Series F Certificate of Designation in the event the Company did not uplist to the NASDAQ stock exchange or file its clinical data intended for FDA approval of LuViva by December 31, 2021). As of March 31, 2022, accrued dividends totaled $1,998. Series F-2 Convertible Preferred Stock The Company was oversubscribed for its Series F Convertible Preferred Stock, resulting in the requirement to file an additional Certificate of Designation for Series F-2 Convertible Preferred Stock with substantially the same terms as the Series F Convertible Preferred Stock. The Board designated 3,500 shares of preferred stock as Series F-2 Preferred Stock, 3,237 of which were issued and outstanding as of March 31, 2022 and December 31, 2021. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F-2 Investors”). In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock. Each Series F-2 Preferred Stock is convertible into 4,000 common stock shares. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value on the Series F-2 Preferred Stock is 3,237. Each share of Series F-2 Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by 0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holders of the Series F-2 Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the three months ended March 31, 2022, the Company issued 95,535 common stock shares for the payment of annual Series F-2 Preferred Stock dividends. Additionally, During the three months ended March 31, 2022, the Company issued 368,505 common stock shares for the payment of a one-time, non-recurring 15% dividend to the Series F-2 Preferred shareholders (as required by the Series F-2 Certificate of Designation in the event the Company did not uplist to the NASDAQ stock exchange or file its clinical data intended for FDA approval of LuViva by December 31, 2021). As of March 31, 2022, accrued dividends totaled $91,592. Powerup (Series G Convertible Preferred Stock) During January 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $78,500, net to the Company is $75,000, for 91,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock, then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. The Company has redeemed all of the Series G preferred stock and the balance is paid. During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. Due to the mandatory redemption feature of the Series G preferred stock, the total amount of 125,000 was recorded as a liability. On June 4, 2021, the Company redeemed the January 2021 investment of $75,000 for $114,597, this $39,597 difference was recorded as interest expense. On July 8, 2021, the Company redeemed the February 2021 investment of $50,000 for $78,094. The difference of 28,094 was recorded as interest expense. As of March 31, 2022 and December 31, 2021, the amount outstanding was nil. Warrants The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the three months ended March 31, 2022: Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, December 31, 2021 27,669,634 $ 0.29 Warrants exercised (2,284,324 ) $ 0.16 Outstanding, March 31, 2022 25,385,310 $ 0.30	4. STOCKHOLDERS’ DEFICIT Common Stock The Company has authorized 500,000,000 shares of common stock with $0.001 par value. As of December 31, 2021 and 2020, 13,673,583 and 13,138,282 shares were issued and outstanding, respectively. During the years ended December 31, 2021 and 2020 the Company issued 535,301 and 9,818,813 shares of common stock, respectively: Number of Shares Conversion of debt into common shares - exchange agreements 7,957,013 Conversion of debt into common shares 175,000 Shares issued for manufacturing agreements 12,147 Shares issued for payment of Series D dividends 148,653 Shares issued to investors 1,526,000 Issued during the year ended December 31, 2020 9,818,813 Shares issued for payment of Series D dividends 109,039 Shares issued for payment of Series E dividends 288,262 Shares issued for payment of finder fee 98,000 Conversion of Series F Preferred shares into common stock 40,000 Issued during the year ended December 31, 2021 535,301 Summary table of common stock share transactions: Outstanding at December 31, 2019 3,319,469 Issued in 2020 9,818,813 Outstanding at December 31, 2020 13,138,282 Issued in 2021 535,301 Outstanding at December 31, 2021 13,673,583 Conversion of Debt into Common Shares - 2020 Exchange Agreements On January 8, 2020, the Company exchanged $2,064,366 in debt for several equity instruments with an estimated fair value of $2,065,548, resulting in a loss on extinguishment of debt of $1,183 which is recorded in other income (expense) on the accompanying consolidated statements of operations. The Company also issued 6,957,013 warrants to purchase common stock shares; with exercise prices of $0.25, $0.75 and $0.20. In addition, one of the investors forgave approximately $29,000 of debt, which was recorded as a gain for extinguishment of debt during the year ended December 31, 2020. On June 3, 2020, the Company exchanged $328,422 of debt held by Auctus, (summarized in Note 10, “Convertible Notes ” , On June 30, 2020, the Company exchanged $125,000 of debt held by Mr. James Clavijo, for 500,000 shares of common stock and 250,000 warrants to purchase common shares. The fair value of the common shares was $250,000 and the fair value of the warrants was $99,963 (based on an estimated fair value of $0.40, as determined utilizing the Black-Scholes option pricing model). This resulted in a net loss on extinguishment of debt of $224,963 ($349,963 fair value less $125,000 of exchanged debt). On July 9, 2020, the Company entered into an exchange agreement with Mr. Bill Wells (one of its former employees) for an outstanding debt to him of $220,000. In lieu of agreeing to dismiss approximately half of what is owed by the Company, Mr. Wells will receive the following: (i) cash payments of $20,000 within 60 days of the signing of the agreement; cash payments over time in the amount of $90,000 in the form of an unsecured note with the Company to be executed within 30 days of a new financing(s) totaling at least $3.0 million. The note shall bear interest of 6.0% and mature over 18 months; (ii) 66,000 common share stock options that vest at a rate of 3,667 per month and have a $0.49 exercise price (if two consecutive payments in (iii) are not made the stock options will be canceled and a cash payment will be required; and (iv) the total amount of forgiveness by creditor of approximately $110,000 shall be prorated according to amount paid. During the year ended December 31, 2020, the Company made a payment of $20,000; this payment allowed the Company to reduce $40,000 in debt, with the corresponding $20,000 difference recorded as a gain. During the year ended December 31, 2021, the Company obtained the minimum amount of financing and issued the promissory note to Mr. Wells in accordance with the agreement described above. The following table summarizes the debt exchanges: Total Debt and Accrued Interest Total Debt Total Accrued Interest Common Stock Shares Warrants (Exercise $0.15) Warrants (Exercise $0.20) Warrants (Exercise $0.25) Warrants (Exercise $0.50) Warrants (Exercise $0.75) Aquarius $ 145,544 $ 107,500 $ 38,044 291,088 - - 145,544 - 145,544 K2 Medical (Shenghuo) 3 803,653 771,927 31,726 1,905,270 - 496,602 704,334 - 704,334 Mr. Blumberg 305,320 292,290 13,030 1,167,630 - 928,318 119,656 - 119,656 Mr. Case 179,291 150,000 29,291 896,456 - 896,456 - - - Mr. Grimm 51,110 50,000 1,110 255,548 - 255,548 - - - Mr. Gould 111,227 100,000 11,227 556,136 - 556,136 - - - Mr. Mamula 15,577 15,000 577 77,885 - 77,885 - - - Dr. Imhoff 2 400,417 363,480 36,937 1,699,255 - 1,497,367 100,944 - 100,944 Ms. Rosenstock 1 50,000 50,000 - 100,000 - - 50,000 - 50,000 Mr. James 2 2,286 2,000 286 7,745 - 5,291 1,227 - 1,227 Auctus 328,422 249,119 79,303 500,000 700,000 - - - Mr. Clavijo 125,000 125,000 - 500,000 - - - 250,000 - Mr. Wells 4 220,000 220,000 - - - - - - - $ 2,737,847 $ 2,496,316 $ 241,531 7,957,013 700,000 4,713,603 1,121,705 250,000 1,121,705 ____________ 1 2 3 4 Conversion of Debt into Common Shares - 2020 Effective September 10, 2014, the Company sold a secured convertible promissory note to an accredited investor, GHS Investments, LLC (“GHS”), with an initial principal amount of $1,275,000, for a purchase price of $570,000 (less an original issue discount of $560,000 and debt issuance costs of $145,000). The outstanding balance of the note was convertible into shares of common stock at a conversion price per share equal to 75% of the lowest daily volume average price of common stock during the five days prior to conversion. During 2020, GHS converted $50,454 of principal and interest owed for 175,000 shares of common stock. As of December 31, 2020, there was no remaining amount due on the note. Shares Issued for Manufacturing Agreements - 2020 During the year ended December 31, 2020, the Company issued 12,147 shares of common stock to Shandong Yaohua Medical Instrument Corporation (“SMI”), as compensation for manufacturing and distribution services. Refer to Note 7, “ Commitments and Contingencies Shares Issued to Investors - 2020 During the year ended December 31, 2020, the Company issued 1,526,000 shares of common stock to certain accredited investors as part of the Series D Preferred Stock offering (see “Series D Preferred Stock” below). Shares Issued as Payment for Finder’s Fee - 2021 During 2021, the Company issued 98,000 shares of common stock as compensation for the “finder’s fee” associated with the Series F and Series F-2 Preferred Stock offerings (see “Series F Convertible Preferred Stock” and “Series F-2 Convertible Preferred Stock” below). Conversion of Series F Preferred Shares into Common Stock - 2021 During the year ended December 31, 2021, 10 shares of Series F Preferred were converted into 40,000 shares of the Company’s common stock (see “Series F Convertible Preferred Stock” below). Preferred Stock The Company has authorized 5,000,000 shares of preferred stock with a $0.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. Series C Convertible Preferred Stock The board designated 9,000 shares of preferred stock as Series C Convertible Preferred Stock, (the “Series C Preferred Stock”). Pursuant to the Series C certificate of designations, shares of Series C preferred stock are convertible into common stock by their holder at any time and may be mandatorily convertible upon the achievement of specified average trading prices for the Company’s common stock. At December 31, 2021 and 2020, there were 286 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total of 572,000 common shares, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Series C certificate of designations. The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date (the “Dividend End Date”), payable in cash or, subject to certain conditions, the Company’s common stock. Unpaid accrued dividends were $120,120 as of December 31, 2021. Upon conversion of the Series C preferred stock prior to the Dividend End Date, the Company will also pay to the converting holder a “make-whole payment” equal to the number of unpaid dividends through the Dividend End Date on the converted shares. At December 31, 2021 and 2020, the “make-whole payment” for a converted share of Series C preferred stock would convert to 200 shares of the Company’s common stock. The Series C preferred stock generally has no voting rights except as required by Delaware law. Upon the Company’s liquidation or sale to or merger with another corporation, each share will be entitled to a liquidation preference of $1,000, plus any accrued but unpaid dividends. In addition, the purchasers of the Series C preferred stock received, on a pro rata basis, warrants exercisable to purchase an aggregate of approximately 1 share of Company’s common stock. The warrants contain anti-dilution adjustments in the event that the Company issues shares of common stock, or securities exercisable or convertible into shares of common stock, at prices below the exercise price of such warrants. As a result of the anti-dilution protection, the Company is required to account for the warrants as a liability recorded at fair value each reporting period. As of December 31, 2021, these warrants had expired. Series C1 Convertible Preferred Stock The board designated 20,250 shares of preferred stock as Series C1 Preferred Stock, of which 1,049 shares were issued and outstanding at December 31, 2021 and 2020. In addition, some holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At December 31, 2021 and 2020, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock. At December 31, 2021 and 2020, there were 1,049.25 shares outstanding with a conversion price of $0.50 per share, such that each share of Series C1 preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total of 2,098,500 common shares. The Series C1 preferred stock has terms that are substantially the same as the Series C preferred stock, except that the Series C1 preferred stock does not pay dividends (unless and to the extent declared on the common stock) or at-the-market “make-whole payments” and, while it has the same anti-dilution protections afforded the Series C preferred stock, it does not automatically reset in connection with a reverse stock split or conversion of our outstanding convertible debt. Series C2 Convertible Preferred Stock On August 31, 2018, the Company entered into agreements with certain holders of the Company’s Series C1 Preferred Stock, including the chairman of the Company’s board of directors, and the Chief Operating Officer and a director of the Company pursuant to which those holders separately agreed to exchange each share of the Series C1 Preferred Stock held for one (1) share of the Company’s newly created Series C2 Preferred Stock. In total, for 3,262.25 shares of Series C1 Preferred Stock to be surrendered, the Company issued 3,262.25 shares of Series C2 Preferred Stock. At December 31, 2021 and 2020, shares of Series C2 had a conversion price of $0.50 per share, such that each share of Series C preferred stock would convert into approximately 2,000 shares of the Company’s common stock; for a total of 6,524,500 common shares. The terms of the Series C2 Preferred Stock are substantially the same as the Series C1 Preferred Stock, except that (i) shares of Series C1 Preferred Stock may not be convertible into the Company’s common stock by their holder for a period of 180 days following the date of the filing of the Certificate of Designation (the “Lock-Up Period”); (ii) the Series C2 Preferred Stock has the right to vote as a single class with the Company’s common stock on an as-converted basis, notwithstanding the Lock-Up Period; and (iii) the Series C2 Preferred Stock will automatically convert into that number of securities sold in the next Qualified Financing (as defined in the Exchange Agreement) determined by dividing the stated value ($1,000 per share) of such share of Series C2 Preferred Stock by the purchase price of the securities sold in the Qualified Financing. Series D Convertible Preferred Stock The Board designated 6,000 shares of preferred stock as Series D Preferred Stock, 763 of which remained outstanding as of December 31, 2021. On January 8, 2020, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series D Investors”) pursuant to all obligations under the Series D Certificate of Designation. The Series D Investors included the Chief Executive Officer, Chief Operating Officer and a director of the Company. In total, for $763,000 the Company issued 763 shares of Series D Preferred Stock, 1,526,000 common stock shares, 1,526,000 common stock warrants, exercisable at $0.25, and 1,526,000 common stock warrants, exercisable at $0.75. Each Series D Preferred Stock is convertible into 3,000 common shares. The Series D Preferred Stock will have cumulative dividends at the rate per share of 10% per annum. The stated value and liquidation preference on the Series D Preferred Stock is $763. The 763 Series D Preferred Shares are convertible into debt at the option of the holder during a prescribed time period. If the Series D Preferred Shares are converted, the Series D preferences are surrendered and the debt is then secured by the Company’s assets. As of December 31, 2021, none of the 763 Series D Preferred Shares have been converted to secured debt. Each share of Series D Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the stated value by $0.25, subject to certain adjustments set forth in the Series D Certificate of Designation (the “Series D Conversion Price”). The conversion of Series D Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series D Preferred. If the average of the VWAPs (as defined in the Series D Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series D Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series D Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. During the year ended December 31, 2021, the Company issued 109,039 shares of common stock for the payment of accrued Series D Preferred Stock dividends. As of December 31, 2021, the Company had accrued dividends of $14,306. Series E Convertible Preferred Stock The Board designated 5,000 shares of preferred stock as Series E Preferred Stock, 1,736 of which remain outstanding. Each share of Series E Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series E Certificate of Designation (the “Series E Conversion Price”). The conversion of Series E Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series E Preferred. If the average of the VWAPs (as defined in the Series E Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series E Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series E Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. Each share of Series E Preferred Stock has a par value of $0.001 per share and a Stated Value equal to $1,000, subject to increase set forth in its Certificate of Designation. Each holder of Series E Preferred Stock is entitled to receive cumulative dividends of 8% per annum, payable annually on the Stated Value in cash or, following the listing of the Company’s common stock on certain Canadian trading markets and at the option of the Company, shares of common stock. During the year ended December 31, 2021, the Company issued 288,262 shares of common for the payment of Series E Preferred Stock dividends accrued. As of December 31, 2021, the Company had accrued dividends of $54,521. Series F Convertible Preferred Stock The Company was oversubscribed for its Series F Convertible Preferred Stock, resulting in the requirement to file an additional Certificate of Designation for Series F-2 Convertible Preferred Stock with substantially the same terms as the Series F Convertible Preferred Stock. The Board designated 1,500 shares of preferred stock as Series F Preferred Stock, 1,426 of which are issued and outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F Investors”). In total, for $1,436,000 the Company issued 1,436 shares of Series F Preferred Stock. Each Series F Preferred Stock is convertible into 4,000 common stock shares. The Series F Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series F Preferred Stock is $1,436. Each share of Series F Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the stated value by $0.25, subject to certain adjustments set forth in the Series F Certificate of Designation (the “Series F Conversion Price”). The conversion of Series F Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series F Preferred. If the average of the VWAPs (as defined in the Series F Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F Preferred, for cash in an amount equal to aggregate stated value then outstanding plus accrued but unpaid dividends. During the year ended December 31, 2021, 10 shares of Series F Preferred were converted into 40,000 shares of the Company’s common stock. As of December 31, 2021, the Company had not issued shares as payment of Series F Preferred Stock dividends. As of December 31, 2021, the Company had accrued dividends of $65,718. Series F-2 Convertible Preferred Stock The Board designated 3,500 shares of preferred stock as Series F-2 Preferred Stock, 3,237 of which are issued and outstanding. During 2021, the Company entered into a Stock Purchase Agreement with certain accredited investors (“the Series F-2 Investors”). In total, for $678,000 the Company issued 678 shares of Series F-2 Preferred Stock. In addition, the Company exchanged outstanding debt of $2,559,000 for 2,559 shares of Series F-2 Preferred Stock (see Note 9, “Convertible Debt”). Each Series F-2 Preferred Stock is convertible into 4,000 common stock shares. The Series F-2 Preferred Stock will have cumulative dividends at the rate per share of 6% per annum. The stated value and liquidation preference on the Series F-2 Preferred Stock is $3,237. Each share of Series F-2 Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holders of the Series F-2 Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. As of December 31, 2021, the Company had not issued shares as payment of Series F-2 Preferred Stock dividends. As of December 31, 2021, the Company had accrued dividends of $94,907. Powerup (Series G Convertible Preferred Stock) During January 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $78,500, net to the Company is $75,000, for 91,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. The Company has redeemed all of the Series G preferred stock and the balance is paid. During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred. Due to the mandatory redemption feature of the Series G preferred stock, the total amount of proceeds of $125,000 was recorded as a liability. On June 4, 2021, the Company redeemed the January 2021 investment of $75,000 for $114,597, this $39,597 difference was recorded as interest expense. On July 8, 2021, the Company redeemed the February 2021 investment of $50,000 for $78,094. The difference of $28,094 was recorded as interest expense. As of December 31, 2021, the amount outstanding was nil. Warrants The following table summarizes transactions involving the Company’s outstanding warrants to purchase common stock for the years ended December 31, 2021 and 2020: Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, January 1, 2020 46,016,840 $ 1.71 Warrants issued 11,270,013 $ 0.34 Warrants cancelled/expired (70 ) $ 1,068,423 Warrants exchanged (28,962,508 ) $ 0.04 Outstanding, December 31, 2020 28,324,275 $ 0.25 Warrants issued 7,982,223 $ 0.30 Warrants cancelled/expired (1,729,662 ) $ 0.04 Warrants exchanged (4,713,603 ) $ 0.20 Warrants exercised (2,193,599 ) $ 0.16 Outstanding, December 31, 2021 27,669,634 $ 0.29 Warrant Exchanges - 2021 During the year ended December 31, 2021, the Company entered into various agreements with holders of the Company’s $0.20 strike price warrants, pursuant to which each holder separately agreed to exchange 4,713,603 common stock warrants with a strike price of $0.20 for 4,477,923 common stock warrants with a strike price of $0.16 and a contractual term of 15 days. During the year ended December 31, 2021, the Company received approximately $351,000 from the holders for the exercise of 2,193,599 warrants, which was included in Accrued Liabilities as of December 31, 2021, pending issuance of the common shares. The Company measured the effect of the exchange as the excess of fair value of the exchanged instruments over the fair value of the original instruments and determined the effect of the exchange was nil. Management estimated the fair value of the warrants issued utilizing the Black-Scholes Option Pricing model with the following assumptions: December 31, 2021 Expected term 15 days Volatility 143.2 % Risk-free interest rate 0.0 % Dividend yield 0.00 % During the year ended December 31, 2021, the Company entered into various agreements with holders of the Company’s $0.25 strike price warrants, pursuant to which each holder separately agreed that in the event the Company obtains financing of at least $4.0 million, 1,802,161 of common stock warrants with a strike price of $0.25 will be exchanged for 901,081 warrants with terms identical to the warrants granted in the financing and cash payments totaling approximately $90,000, which are due within ten (10) business days of closing of the new financing. In the event Company is not successful in obtaining financing greater than $4.0 million, the warrant’s terms remain unchanged and the common share warrants will expire on their original date. The warrants will have a one-year lockup restriction and a 10% blocker such that the warrant holders will be restricted from owning more than 10% of the total number of the Company’s outstanding common shares at any one point in time after completion of the financing. During the year ended December 31, 2021, the Company entered into various agreements with holders of the Company’s $0.75 strike price warrants, pursuant to which each holder separately agreed that in the event the Company obtains financing of at least $4.0 million, 1,802,161 of common stock warrants with a strike price of $0.75 will be exchanged for 1,802,161 warrants with the same price but with terms identical to the new warrants granted in the financing. In the event Company is not successful in obtaining financing greater than $4.0 million, the warrant’s terms will remain unchanged and the common share warrants will expire on their original date. The new warrants will have a one-year lockup restriction and a 10% blocker such that the warrant holders will be restricted from owning more than 10% of the total number of the Company’s outstanding common shares at any one point in time after completion of the financing. During the year ended December 31, 2021, the Company entered into an agreement with GPB Debt Holdings II LLC (“GPB”), pursuant to which GPB agreed that in the event the Company obtains financing of at least $4.0 million, 7,185,000 of common stock warrants with a strike price of $0.20 will be exchanged for 3,592,500 warrants with terms identical to the warrants granted in the financing and a cash payment of $350,000. In the event Company is not successful in obtaining financing greater than $4.0 million, the warrant’s terms remain unchanged and the common share warrants will expire on their original date. The new warrants, which will vest six months after the closing of a financing greater than $4.0 million, will have a 4.99% blocker such that the warrant holders will be restricted from owning more than 4.99% of the total number of the Company’s outstanding common shares at any one point in time after completion of the financing. Other Warrant Transactions During 2021, the Company issued 10% debenture unit investments in the amount of $1,130,000 and incurred fees due on these debentures of $86,400. The Company issued the finders 263,000 warrants for the Company’s common stock shares which expire on May 31, 2023 and an additional 150,000 warrants to purchase the Company’s common stock shares which expire on May 31, 2024. The investors received a total of 1,130,000 warrants for common stock shares, which expire on May 17, 2023. During 2021, the Company issued equity investments in the amount of $2,114,000 and incurred fees due on these investments of $139,000. The Company also issued the finders 98,000 of the Company’s common stock shares and 643,700 warrants, which expire in the first half of 2024. On January 16, 2020, the Company entered into an exchange agreement with GPB. This exchange agreement canceled the existing outstanding warrants, which were subject to anti-dilution and ratchet provisions, to purchase 35,937,500 shares of common stock at an exercise price of $0.04 per share and resulted in the issuance of new warrants to purchase 7,185,000 shares of common stock at a price of $0.20 per share. The new warrants have fixed exercise prices of $0.20. On January 8, 2021, the Company made a payment of $750,000, as required by the exchange agreement with GPB, which canceled the previously issued warrants. On January 6, 2020, the Company entered into a finder’s fee agreement. The finder will receive 5% cash and 5% warrants on all funds it raises including bridge loans. The three-year common stock share warrants will have an exercise price of $0.25. During 2019 and 2020, the finder helped the Company raise $300,000, therefore a fee of $31,650 was paid and 126,600 warrants were issued. On January 22, 2020, the Company entered into a promotional agreement with a related party, which is partially owned by Mr. Blum

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
STOCK OPTIONS
STOCK OPTIONS	5. STOCK OPTIONS The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The plan provides for stock options to be granted up to 10% of the outstanding common stock shares. There was no stock option activity during the three months ended March 31, 2022. The following table summarizes the Company’s outstanding and exercisable stock options as of March 31, 2022: Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of March 31, 2022 1,500,000 $ 0.49 8.3 years $ 240 Options exercisable as of March 31, 2022 1,045,227 $ 0.49 8.3 years $ 167 The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price as of March 31, 2022 and the exercise price, multiplied by the number of options. As of March 31, 2022, there was $219,558 of unrecognized stock-based compensation expense. Such costs are expected to be recognized over a weighted average period of approximately 1.25 years. The weighted-average fair value of awards granted was nil and $0.47 during the three months ended March 31, 2022 and 2021, respectively. The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The Black-Scholes option pricing model and the following weighted-average assumptions were used to estimate the fair value of awards granted during the three months ended March 31, 2021: March 31, 2021 Expected term (years) 10 years Volatility 153.12 % Risk-free interest rate 0.98 % Dividend yield 0.00 %	5. STOCK OPTIONS The new Stock Plan (the “Plan”) allows for the issuance of incentive stock options, nonqualified stock options, and stock purchase rights. The exercise price of options was determined by the Company’s board of directors, but incentive stock options were granted at an exercise price equal to the fair market value of the Company’s common stock as of the grant date. Options historically granted have generally become exercisable over four years and expire ten years from the date of grant. The plan provides for stock options to be granted up to 10% of the outstanding common stock shares. During the years ended December 31, 2021 and 2020, the Company recognized stock-based compensation expense of $226,717 and $309,905, respectively. The following table summarizes the Company’s stock option activity and related information for the year ended December 31, 2021: Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of January 1, 2021 1,800,000 $ 0.49 Options granted 25,000 $ 0.48 Options forfeited (167,614 ) $ 0.49 Options expired (157,386 ) $ 0.49 Options outstanding as of December 31, 2021 1,500,000 $ 0.49 8.5 years $ 135 Options exercisable as of December 31, 2021 954,273 $ 0.49 8.5 years $ 86 The aggregate intrinsic value is calculated as the difference between the Company’s closing stock price as of December 31, 2021 and the exercise price, multiplied by the number of options. As of December 31, 2021, there was $263,470 total unrecognized stock-based compensation expense. Such costs are expected to be recognized over a weighted average period of approximately 1.5 years. The weighted-average fair value of awards granted was $0.47 and $0.48 during the years December 31, 2021 and 2020, respectively. The Company recognizes compensation expense for stock option awards on a straight-line basis over the applicable service period of the award. The service period is generally the vesting period. The following weighted-average assumptions were used to calculate stock-based compensation expense: December 31, December 31, 2021 2020 Expected term (years) 10 years 10 years Volatility 153.12 % 153.12 % Risk-free interest rate 0.98 % 0.98 % Dividend yield 0.00 % 0.00 %

LITIGATION AND CLAIMS

LITIGATION AND CLAIMS	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
LITIGATION AND CLAIMS
LITIGATION AND CLAIMS	6. LITIGATION AND CLAIMS From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in the aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year. As of March 31, 2022, and December 31, 2021, there was no accrual recorded for any potential losses related to pending litigation.	6. LITIGATION AND CLAIMS From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in the aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular year. As of December 31, 2021 and 2020, there was no accrual recorded for any potential losses related to pending litigation.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
LITIGATION AND CLAIMS
COMMITMENTS AND CONTINGENCIES	7. COMMITMENTS AND CONTINGENCIES Operating Leases The below table presents total operating lease right-of-use assets and lease liabilities as of March 31, 2022: (in thousands) Three Months Ended March 31, 2022 Operating lease right-of-use assets $ 355 Operating lease liabilities $ 377 The table below presents the maturities of operating lease liabilities as of March 31, 2022: (in thousands) Operating Leases 2022 (remaining) $ 82 2023 112 2024 115 2025 118 2026 50 Total future lease payments 477 Less: discount (100 ) Total lease liabilities $ 377 The table below presents the weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities: Three Months Ended March 31, 2022 Weighted average remaining lease term (years) 4.2 Weighted average discount rate 11.4 % Related Party Contracts On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee). On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company). On January 22, 2020, the Company entered into a promotional agreement with a related party, which is partially owned by Mr. Blumberg, to provide investor and public relations services for a period of two years. As compensation for these services, the Company will issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP. If the minimum share price per the terms of the agreement is not achieved, the warrants will expire three years after the issuance date. The warrants were valued using the Black Scholes model on the grant date of January 22, 2020, which resulted in a total fair value of $715,000. The Company did not appropriately expense the services received in connection with this agreement in 2020. During the three months ended March 31, 2022, the Company recognized $79,444 of consulting expenses as a result of this agreement. Unrecognized consulting expense to be recognized under this agreement is nil as of March 31, 2022. On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided $350,000, which was recorded to subscription receivable, to the Company in exchange for the following: (1) on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares. During the year ended December 31, 2021, the consulting agreement was amended to clarify that $350,000 is not intended to be debt and will not be required to be repaid in cash. Additionally, issuance of the warrants is now predicated on the Company receiving funding receipts of $1,000,000, whether from a financing, series of financing, or gross sales. The amended agreement clarified that the warrants issued to Mr. Blumberg are compensation for services, which involve obtaining financing. The Company will recognize expense for the services equal to the fair value of the warrants issued to Mr. Blumberg as the services are provided, which will coincide with the successful execution of a financing agreement over $1,000,000. Other Commitments On July 24, 2019, Shandong Yaohua Medical Instrument Corporation (“SMI”), agreed to modify its existing agreement. Under the terms of this modification, the Company agreed to grant (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the following terms and conditions. First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 common stock shares. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs to purchase cervical guides, then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after CFDA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacturing. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per device chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: filing an application with the Chinese FDA for the approval of LuViva; any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions. On August 12, 2021, the Company executed an amendment to its agreement with SMI, which established a payment schedule for the balance owed by SMI to the Company for outstanding purchase orders. The remaining balance owed for outstanding purchase orders was $23,445 as of March 31, 2022. Under the terms of the amended agreement, the parties agreed that if by October 30, 2022, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Contingencies The current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, could result in additional repercussions to the Company’s operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patient monitoring and clinical trial data retrieval at investigational study sites. The future impact of the outbreak is highly uncertain and cannot be predicted, and the Company cannot provide any assurance that the outbreak will not have a material adverse impact on the Company’s operations or future results or filings with regulatory health authorities. The extent of the impact to the Company, if any, will depend on future developments, including actions taken to contain the coronavirus. The Russia-Ukraine conflict and the sanctions imposed in response to this crisis could result in repercussions to our operating business, including delays in obtaining regulatory approval to market our products in Russia. The future impact of the conflict is highly uncertain and cannot be predicted, and we cannot provide any assurance that the conflict will not have a material adverse impact on our operations or future results or filings with regulatory health authorities.	7. COMMITMENTS AND CONTINGENCIES Operating Leases Our corporate offices, which also comprise our administrative, research and development, marketing and production facilities, are located on a 12,835 square foot leased property. Total operating lease cost recognized for this lease was $110,701 and $114,591 for the years ended December 31, 2021 and 2020, respectively. The below table presents total operating lease right-of-use assets and lease liabilities as of December 31, 2021: (in thousands) Year Ended December 31, 2021 Operating lease right-of-use assets $ 372 Operating lease liabilities $ 392 The table below presents the maturities of operating lease liabilities as of December 31, 2021: (in thousands) Operating Leases 2022 $ 108 2023 112 2024 115 2025 118 2026 50 Total future lease payments 503 Less: discount (111 ) Total lease liabilities $ 392 The table below presents the weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities: Year Ended December 31, 2021 Weighted average remaining lease term (years) 4.4 Weighted average discount rate 11.4 % Related Party Contracts On June 5, 2016, the Company entered into a license agreement with Shenghuo Medical, LLC pursuant to which the Company granted Shenghuo an exclusive license to manufacture, sell and distribute LuViva in Taiwan, Brunei Darussalam, Cambodia, Laos, Myanmar, Philippines, Singapore, Thailand, and Vietnam. Shenghuo was already the Company’s exclusive distributor in China, Macau and Hong Kong, and the license extended to manufacturing in those countries as well. Under the terms of the license agreement, once Shenghuo was capable of manufacturing LuViva in accordance with ISO 13485 for medical devices, Shenghuo would pay the Company a royalty equal to $2.00 or 20% of the distributor price (subject to a discount under certain circumstances), whichever is higher, per disposable distributed within Shenghuo’s exclusive territories. In connection with the license grant, Shenghuo was to underwrite the cost of securing approval of LuViva with Chinese Food and Drug Administration. At its option, Shenghuo also would provide up to $1.0 million in furtherance of the Company’s efforts to secure regulatory approval for LuViva from the U.S. Food and Drug Administration, in exchange for the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million. Pursuant to the license agreement, Shenghuo had the option to have a designee appointed to the Company’s board of directors (current director Richard Blumberg is the designee). On September 6, 2016, the Company entered into a royalty agreement with one of its directors, John Imhoff, and another stockholder, Dolores Maloof, pursuant to which the Company sold to them a royalty of future sales of single-use cervical guides for LuViva. Under the terms of the royalty agreement, and for consideration of $50,000, the Company will pay them an aggregate perpetual royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable that the Company sells (or that is sold by a third party pursuant to a licensing arrangement with the Company). On January 22, 2020, the Company entered into a promotional agreement with a related party, which is partially owned by Mr. Blumberg, to provide investor and public relations services for a period of two years. As compensation for these services, the Company will issue a total of 5,000,000 warrants, broken into four tranches of 1,250,000. The warrants have a strike price of $0.25 and are subject to vesting based upon the close of the Series D offering and a minimum share price based on the 30-day VWAP. If the minimum share price per the terms of the agreement is not achieved, the warrants will expire three years after the issuance date. The warrants were valued using the Black Scholes model on the grant date of January 22, 2020, which resulted in a total fair value of $715,000. The Company did not appropriately expense the services received in connection with this agreement in 2020. During the years December 31 2021, the Company recognized $556,111 of consulting expenses as a result of this agreement, which includes twelve months of expense for the year ended December 31, 2020. If the Company had properly accounted for the straight-line expensing of these services in 2020, net loss would have increased by $318,000 for a total net loss of $719,000 for the year ended December 31, 2020 and accumulated deficit would have increased to $140.2 million as of December 31, 2020. Unrecognized consulting expense to be recognized under this agreement is $79,444 as of December 31, 2021. On March 10, 2021, the Company entered into a consulting agreement with Richard Blumberg. As a result of the consulting agreement Mr. Blumberg provided cash of $350,000, which was recorded as a stock subscription payable, to the Company in exchange for the following: (1) on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares. During the year ended December 31, 2021, the consulting agreement was amended to clarify that $350,000 is not intended to be debt and will not be required to be repaid in cash. Additionally, issuance of the warrants is now predicated on the Company receiving funding receipts of $1,000,000, whether from a financing, series of financing, or gross sales. The amended agreement clarified that the warrants issued to Mr. Blumberg are compensation for services, which involve obtaining financing. The Company will recognize expense for the services equal to the fair value of the warrants issued to Mr. Blumberg as the services are provided, which will coincide with the successful execution of a financing agreement over $1,000,000. The Company concluded that as of September 30,2021, there was no longer a liability due to Mr. Blumberg of $350,000. The liability was written off in the third quarter of 2021 and a gain of $350,000 was recognized in non-operating income. Other Commitments On July 24, 2019, Shandong Yaohua Medical Instrument Corporation (“SMI”), agreed to modify its existing agreement. Under the terms of this modification, the Company agreed to grant (1) exclusive manufacturing rights, excepting the disposable cervical guides for the Republic of Turkey, and the final assembly rights for Hungary, and (2) exclusive distribution and sales for LuViva in jurisdictions, subject to the following terms and conditions. First, SMI shall complete the payment for parts, per the purchase order, for five additional LuViva devices. Second, in consideration for the $885,144 that the Company received, SMI will receive 12,147 common stock shares. Third, SMI shall honor all existing purchase orders it has executed to date with the Company, in order to maintain jurisdiction sales and distribution rights. If SMI needs to purchase cervical guides then it will do so at a cost including labor, plus ten percent markup. The Company will provide 200 cervical guides at no cost for the clinical trials. Fourth, the Company and SMI will make best efforts to sell devices after CFDA approval. With an initial estimate of year one sales of 200 LuViva devices; year two sales of 500 LuViva devices; year three sales of 1,000 LuViva devices; and year four sales of 1,250 LuViva devices. Fifth, SMI shall pay for entire costs of securing approval of LuViva with the Chinese FDA. Sixth, SMI shall arrange, at its sole cost, for a manufacturer in China to build tooling to support manufacturing. In addition, SMI retains the right to manufacture for China, Hong Kong, Macau and Taiwan, where SMI has distribution and sales rights. For each single-use cervical guide sold by SMI in the jurisdictions, SMI shall transfer funds to escrow agent at a rate of $1.90 per device chip. If within 18 months of the license’s effective date, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Commercialization is defined as: filing an application with the Chinese FDA for the approval of LuViva; any assembly or manufacture of the devices or disposables that begins in China; and purchase of at least 10 devices and disposables for clinical evaluations and regulatory use and or sales in the jurisdictions. On August 12, 2021, the Company executed an amendment to its agreement with SMI, which established a payment schedule for the balance owed by SMI to the Company for outstanding purchase orders. During the year ended December 31, 2021, the Company received $353,635 from SMI on the aforementioned purchase order. The remaining balance owed for outstanding purchase orders was $177,000 as of December 31, 2021. Under the terms of the amended agreement, the parties agreed that if by October 30, 2022, SMI fails to achieve commercialization of LuViva in China, SMI shall no longer have any rights to manufacture, distribute or sell LuViva. Contingencies Based on the current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets, there could be additional repercussions to the Company’s operating business, including but not limited to, the sourcing of materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which may include the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patient monitoring and clinical trial data retrieval at investigational study sites. The future impact of the outbreak is highly uncertain and cannot be predicted, and the Company cannot provide any assurance that the outbreak will not have a material adverse impact on the Company’s operations or future results or filings with regulatory health authorities. The extent of the impact to the Company, if any, will depend on future developments, including actions taken to contain the coronavirus. The conflict in Ukraine, which has already had an impact on financial markets, could result in additional repercussions in our operating business, including delays in obtaining regulatory approval to market our products in Russia. The future impact of the conflict is highly uncertain and cannot be predicted, and we cannot provide any assurance that the conflict will not have a material adverse impact on our operations or future results or filings with regulatory health authorities.

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
NOTES PAYABLE
NOTES PAYABLE	8. NOTES PAYABLE Short Term Notes Payable At March 31, 2022 and December 31, 2021, the Company maintained short term notes payable to related and non-related parties totaling approximately $43,253 and $87,615, respectively. These notes are short term, straight-line amortizing notes. The notes carry annual interest rates between 4.3% and 16%, or 18% in the event of default. On July 4, 2021, the Company entered into a premium finance agreement to finance its insurance policies totaling $117,560. The note requires monthly payments of $11,968, including interest at 4.3% and matured in April 2022. As of March 31, 2022, the balance on that note was $11,968. During 2019, the Company issued promissory notes to Mr. Cartwright totaling $45,829. The note was initially issued with 0% interest, however interest increased to 6.0% interest 90 days after the Company received $1,000,000 in financing proceeds. As of March 31, 2022, the balance on the notes was $31,285. On December 21, 2016 and January 19, 2017, the Company issued promissory notes to Mr. Fowler, in the amounts of approximately $12,500 and $13,900. The notes were initially issued with 0% interest and then went into default with an interest rate of 18%. As part of the March 22, 2021 exchange agreement these notes were combined into one short term note payable of $26,400 and $18,718 in principal and interest of the two previous notes, respectively, for the total balance of $45,118. The aforementioned agreement brought the note current and will accrue interest at a rate of 6.0%. The note carries a monthly payment of $3,850. As of March 31, 2022, the note was paid in full. The following table summarizes short-term notes payable, including related parties: Short-term notes payable, including related parties March 31, 2022 December 31, 2021 Dr. Cartwright $ 31 $ 34 Mr. Fowler - 6 Premium Finance (insurance) 12 48 Short-term notes payable $ 43 $ 88 The short-term notes payable due to related parties was $31,285 at March 31, 2022 and $40,000 of the $88,000 balance at December 31, 2021.	8. NOTES PAYABLE Notes Payable in Default At December 31, 2021 and 2020, the Company maintained notes payable to both related and non-related parties totaling approximately nil and $329,000, respectively. These notes are short term, straight-line amortizing notes. The notes carried annual interest rates between 0% and 10% and have default rates as high as 20%. As described in Note 4: “Stockholders’ Deficit,” During 2021, notes payable of $1,000 due to Dr. Cartwright were paid off and notes payable of $26,000 due to Mr. Fowler were brought current and not in default. The note payable to GPB was exchanged as described in Note 9 , Convertible Debt The following table summarizes notes payable in default, including related parties (in thousands): Notes payable in default, including related parties December 31, 2021 December 31, 2020 Mr. Mermelstein $ - $ 285 Dr. Cartwright - 1 Mr. Fowler - 26 GPB - 17 Notes payable in default $ - $ 329 The notes payable in default to related parties was $27,000 of the $329,000 balance as of December 31, 2020. Short Term Notes Payable At December 31, 2021 and 2020, the Company maintained short term notes payable to both related and non-related parties totaling $165,000 and $96,000, respectively. These notes are short term, straight-line amortizing notes. The notes carry annual interest rates between 4.3% and 6% (16% to 18% in the event of default). On July 4, 2021, the Company entered into a premium finance agreement to finance its insurance policies totaling $117,560. The note requires monthly payments of $11,968, including interest at 4.3% and matured in April 2022. As of December 31, 2021, the balance owed was $47,615. On July 4, 2020, the Company entered into a premium finance agreement to finance its insurance policies totaling $109,000. The note requires monthly payments of $11,299, including interest at 4.968% and matured in April 2021. As of December 31, 2021, the balance was paid. During 2019, the Company issued promissory notes to Dr. Cartwright and Dr. Faupel, in the amounts of approximately $41,000 and $5,000, respectively. The notes were initially issued with 0% interest, however interest increased to 6.0% interest 90 days after the Company received $1,000,000 in financing proceeds. On December 21, 2016 and January 19, 2017, the Company issued promissory notes to Mr. Fowler, in the amounts of approximately $12,500 and $13,900. The notes were initially issued with 0% interest and then went into default with an interest rate of 18%. During the year ended December 31, 2021, the Company entered into an exchange agreement with Mr. Fowler, which combined the notes into one short term note payable of $26,400 and $18,718 in principal and interest of the two previous notes, respectively, for the total balance of $45,118. The agreement brought the note current and will accrue interest at a rate of 6.0%. The note carries a monthly payment of $3,850. As of December 31, 2021, the outstanding principal balance on the note was $5,759. At December 31, 2020 this note was recorded in the Notes payable in default section of the consolidated Balance Sheet. The following table summarizes short-term notes payable, including related parties: Short-term notes payable, including related parties December 31, 2021 December 31, 2020 Dr. Cartwright $ 34 $ 46 Dr. Faupel - 5 Mr. Fowler 6 - Premium Finance (insurance) 48 45 Short-term notes payable $ 88 $ 96 The short-term notes payable due to related parties was $40,000 of the $88,000 balance at December 31, 2021 and $51,000 of the $96,000 balance at December 31, 2020.

SHORT-TERM CONVERTIBLE DEBT

SHORT-TERM CONVERTIBLE DEBT	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
SHORT-TERM CONVERTIBLE DEBT
SHORT-TERM CONVERTIBLE DEBT	9. SHORT-TERM CONVERTIBLE DEBT Short-term Convertible Notes Payable Auctus On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus. The convertible note issued to Auctus will be for a total of $2.4 million. The first tranche of $700,000 was received in December 2019 and matured December 17, 2021 and accrued interest at a rate of ten percent (10%). The note may not have been prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which was not paid when due shall bore interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices equaled the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020 the $0.15 price floor no longer applied. In connection with the first tranche of $700,000, the Company issued 7,500,000 warrants to purchase common stock at an exercise price of $0.20. The fair value of the warrants at the date of issuance was $745,972; $635,000 was allocated to the warrant liability and a loss of $110,972 was recorded at the date of issuance for the amount of the fair value in excess of the net proceeds received of $635,000. The $700,000 proceeds were received net of debt issuance costs of $65,000 (net proceeds of $635,000, after administrative and legal expenses Company received $570,000). The Company used $65,000 of the proceeds to make a partial payment of the $89,250 convertible promissory note issued on July 3, 2018 to Auctus. The Company made a $700,000 payment on June 1, 2021, which resulted in a prepayment penalty of $350,000 being assessed to the Company, which remained outstanding as of March 31, 2022. The Company recorded this prepayment penalty as interest expense. Interest will not be assessed on the prepayment penalty. As of March 31, 2022 and December 31, 2021, the outstanding amount of the note was nil. On May 27, 2020, the Company received the second tranche in the amount of $400,000, from the December 17, 2019 securities purchase agreement and convertible note with Auctus. The net amount paid to the Company was $313,000 This second tranche is part of the convertible note issued to Auctus for a total of $2.4 million of which $700,000 has already been provided by Auctus. The note maturity date is May 27, 2022 and the note accrues interest at a rate of ten percent (10%). The note may not be prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices shall equal the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price shall mean 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event shall the variable conversion price be less than $0.15. If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. The last tranche of $1.3 million will be received within 60 days of the S-1 registration statement becoming effective. The conversion price of the notes will be at market value with a minimum conversion amount of $0.15. In addition, as part of this transaction the Company was required to pay a 2.0% fee to a registered broker-dealer. As of March 31, 2022 and December 31, 2021, $400,000 of principal remained outstanding and accrued interest totaled $74,778 and $64,778, respectively. Further, as of March 31, 2022 and December 31, 2020, the Company had unamortized debt issuance costs of $5,211 and $13,586. As of March 31, 2022 and December 31, 2021, the estimated fair value of the derivative liability for the bifurcated conversion option was $38,129 and $31,889, respectively. Convertible Notes in Default On March 31, 2020, we entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $112,750 in aggregate principal amount of a 12% convertible promissory note. On June 30, 2020, we issued the note to Auctus and issued 250,000 five-year common stock warrants at an exercise price of $0.16. On April 3, 2020, we received net proceeds of $100,000. The note matured on January 26, 2021 and accrues interest at a rate of 12% per year. We may not prepay the note, in whole or in part. After the 90 th The following table summarizes the Short-term Convertible Notes Payable, including debt in default (in thousands): March 31, 2022 December 31, 2021 Auctus Tranche 2 $ 400 $ 400 Auctus prepayment penalty 350 350 Auctus (March 31, 2020 Note) 161 161 Debt discount and issuance costs to be amortized (5 ) (14 ) Convertible notes payable - short-term $ 906 $ 897 On June 2, 2021, we entered into an exchange agreement with Auctus, which was amended on February 1, 2022. Pursuant to this agreement, Auctus agreed to exchange an aggregate of $668,290 of outstanding notes (the “Notes”), including accrued interest, and the associated warrants issued in connection with the Notes (the warrants, for the purpose of the exchange, are valued at, in the aggregate, $1,681,707) into unregistered units of our common stock, warrants and prefunded warrants otherwise in the form and ratios issued in a proposed underwritten public offering on the Nasdaq Capital Markets (the “Nasdaq Offering”). The exchange price will be on a $1 for $1 basis such that Auctus will receive $2,349,997 of units consisting of common stock, warrants and prefunded warrants. The units being issued in the exchange with Auctus are unregistered and are being issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. Additionally, the units and the common stock underlying the units will be subject to a lock up agreement with the underwriters until the earlier of 120 days after the Nasdaq Offering and the date that the daily volume weighted average price of the common stock exceeds 200% of the Nasdaq Offering price for at least five consecutive trading days. Further, the termination date of the June 2, 2021 agreement was extended to April 15, 2022. The $350,000 related to default penalties will be exchanged into $350,000 of securities offered in the Nasdaq Offering.	9. CONVERTIBLE DEBT Short-term Convertible Notes Payable Auctus On December 17, 2019, the Company entered into a securities purchase agreement and convertible note with Auctus. The convertible note issued to Auctus will be for a total of $2.4 million. The first tranche of $700,000 was received in December 2019 and matures December 17, 2021 and accrues interest at a rate of ten percent (10%). The note may not be prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion prices shall equal the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price shall mean 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event shall the variable conversion price be less than $0.15. If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. In connection with the first tranche of $700,000, the Company issued 7,500,000 warrants to purchase common stock at an exercise price of $0.20. The fair value of the warrants at the date of issuance was $745,972 and was $635,000 allocated to the warrant liability and a loss of $110,972 was recorded at the date of issuance for the amount of the fair value in excess of the net proceeds received of $635,000. The $700,000 proceeds were received net of debt issuance costs of $65,000 (net proceeds of $635,000, after administrative and legal expenses Company received $570,000). The Company used $65,000 of the proceeds to make a partial payment of the $89,250 convertible promissory note issued on July 3, 2018 to Auctus. The Company made a $700,000 payment on June 1, 2021, which resulted in a prepayment penalty of $350,000 being assessed to the Company, which was outstanding as of December 31, 2021. The Company recorded this prepayment penalty as interest expense. Interest will not be assessed on the prepayment penalty. As of December 31, 2021 and 2020, nil and $700,000, respectively, remained outstanding. As of December 31, 2021, accrued interest was paid in full and at December 31, 2020, $73,889 remained outstanding. Further, as December 31, 2021 and 2020, the Company had unamortized debt issuance costs of nil and $31,146, respectively and an unamortized debt discount on warrants of nil and $179,623, respectively and providing a net balance of $350,000 and $489,231, respectively. On May 27, 2020, the Company received the second tranche in the amount of $400,000, from the December 17, 2019 securities purchase agreement and convertible note with Auctus. The net amount paid to the Company was $313,000 This second tranche is part of the convertible note issued to Auctus for a total of $2.4 million of which $700,000 has already been provided by Auctus. The note matures on May 27, 2022 and incurs interest at a rate of ten percent (10%). The note may not be prepaid in whole or in part except as otherwise explicitly allowed. Any amount of principal or interest on the note which is not paid when due shall bear interest at the rate of the lessor of 24% or the maximum permitted by law (the “default interest”). The variable conversion price is equal to 75% of the average of the five (5) day volume weighted average price of the common stock immediately prior to the issue date of the note (provided, however, that if the common stock is trading on a public market at a price greater than 0.50 per share on the issuance date, than 75% shall be replaced with 80%). If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. The last tranche of $1.3 million will be received within 60 days of the S-1 registration statement becoming effective. The conversion price of the notes will be at market value with a minimum conversion amount of $0.15. In addition, as part of this transaction the Company was required to pay a 2.0% fee to a registered broker-dealer. As of December 31, 2021 and 2020, $400,000 remained outstanding and accrued interest was $64,778 and $24,222, respectively. Further, as of December 31, 2021 and 2020, the Company had unamortized debt issuance costs of $13,586 and $47,086, providing a net balance of $451,192 and $377,136. As of December 31, 2021 the bifurcated derivative liability was $31,889. Convertible Notes in Default On March 31, 2020, we entered into a securities purchase agreement with Auctus Fund, LLC for the issuance and sale to Auctus of $112,750 in aggregate principal amount of a 12% convertible promissory note. During the year ended December 31, 2020, we issued the note to Auctus and issued 250,000 five-year common stock warrants at an exercise price of $0.16. On April 3, 2020, we received net proceeds of $100,000. The note matured on January 26, 2021 and accrues interest at the default rate of 24% per year. We may not prepay the note, in whole or in part. After the 90 th The following table summarizes the Short-term Convertible Notes Payable, including debt in default (in thousands): Short-term convertible notes payable , including debt in default December 31, 2021 December 31, 2020 Auctus Tranche 1 - 700 Auctus Tranche 2 $ 400 $ 400 Auctus prepayment penalty 350 - Auctus (March 31, 2020 Note) 161 113 Debt discount and issuance costs to be amortized (14 ) (262 ) Convertible notes payable - short-term $ 897 $ 951 Troubled Debt Restructuring During 2021, the prepayment penalty to Auctus was recorded as debt extinguished for Short-term Convertible Notes Payable. This prepayment penalty resulted in a loss of $350,000. In addition, the gain recognized for the extinguishment of the derivative liability due to the payoff of the $700,000 loan to Auctus of $84,000 was recorded. This debt extinguished met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Senior Secured Promissory Note On February 12, 2016, the Company entered into a securities purchase agreement with GPB Debt Holdings II LLC (“GPB”) for the issuance of a $1,437,500 senior secured convertible note for an aggregate purchase price of $1,029,000 (representing an original issue discount of $287,500 and debt issuance costs of $121,000). On May 28, 2016, the balance of the note was increased by $87,500 for a total principal balance of $1,525,000. On December 7, 2016, the Company entered into an exchange agreement with GPB and as a result the principal balance increased by $312,500 for a total principal balance of $1,837,500. In addition, GPB received warrants for 2,246 shares of the Company’s common stock. The Company allocated proceeds totaling $359,555 to the fair value of the warrants at issuance and recorded an additional discount on the debt. The warrants expired during the year ended December 31, 2021. On January 16, 2020, we entered into an exchange agreement with GPB. Under the terms of this exchange agreement, we exchanged $3,360,811 of debt outstanding for the following: (1) cash payments of $1,500,000, (2) 7,185,000 warrants to purchase common stock, previously outstanding, would be exchanged for new warrants to purchase common stock shares at a strike price of $0.20 and (3) a certain amount of preferred stock shares for the remaining balance outstanding upon the final exchange date. During 2021, we made the final payments totaling $800,000 out of the total $1,500,000 and issued 2,236 shares of Series F-2 preferred stock in accordance with the terms of the agreement. In addition, 7,185,000 of common stock purchase warrants outstanding were exchanged for new warrants with a strike price of $0.20. As of December 31, 2020, the balance due on the convertible debt was $1,709,414 Interest accrued on the note total $1,233,637 at December 31, 2020 and is included in accrued expenses on the accompanying consolidated balance sheet. Other Convertible Debt GHS On May 19, 2017, the Company entered into a securities purchase agreement with GHS for the purchase of a $66,000 convertible promissory note for the purchase of $60,000 in net proceeds (representing a 10% original issue discount of $6,000). The accrued interest rate of 8% per year until it matured in December 31, 2017. Beginning February 2018, the note is convertible, in whole or in part, at the holder’s option, into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price during the 25 trading days prior to conversion. Upon the occurrence of an event of default, the note bore interest at a rate of 20% per year and the holder of the note may have required the Company to redeem or convert the note at 150% of the outstanding principal balance. As of December 31, 2020, the balance due on this note was $63,520 including a default penalty of $37,926. Interest accrued on the note totaled $17,816, at December 31, 2020 and is included in accrued expenses on the accompanying consolidated balance sheet. As of December 31, 2021, the note was paid in full. Effective May 17, 2018, the Company entered into a securities purchase agreement with GHS for the purchase of a convertible promissory note with a principal of $9,250 for a purchase price of $7,500 (representing an original issue discount of $750 and debt issuance costs of $1,000). The note accrued interest at a rate of 8% per year until its matured June 17, 2019. Beginning February 2018, the note is convertible, in whole or in part, at the holder's option, into shares of the Company's stock at a conversion price equal to 70% of the lowest trading price during the 25 trading days prior to conversion (if the note cannot be converted due to Depository Trust Company freeze then rate decreases to 60%). Upon the occurrence of an event of default, the note bore interest at a rate of 20% per year and the holder of the note may have required the Company to redeem or convert the note at 150% of the outstanding principal balance. As of December 31, 2020, the balance due on this note was $14,187, including a default penalty of $4,937. Interest accrued on the note totaled $5,006 at December 31, 2020 and is included in accrued expenses on the accompanying consolidated balance sheet. As of December 31, 2021, the note was paid in full. Effective June 22, 2018, the Company entered into a securities purchase agreement with GHS for the purchase of a $68,000 convertible promissory note for a purchase price of $60,000 (representing an original issue discount of $6,000 and debt issuance costs of $2,000). The note accrued interest at a rate of 10% per year until it matured on June 22, 2019. Beginning May 2019, the note was convertible, in whole or in part, at the holder's option, into shares of the Company's stock at a conversion price equal to 70% of the lowest trading price during the 25 trading days prior to conversion (if the note cannot be converted due to Depository Trust Company freeze then rate decreases to 60%). Upon the occurrence of an event of default, the note bore interest at a rate of 20% per year and the holder of the note may have required the Company to redeem or convert the note at 150% of the outstanding principal balance. As of December 31, 2020, the balance due on this note was $103,285, including a default penalty of $35,285. Interest accrued on the note totaled $39,644 at December 31, 2020, respectively, and is included in accrued expenses on the accompanying consolidated balance sheet. As of December 31, 2021, the note was paid in full. Auctus On May 22, 2020, the Company entered into an exchange agreement with Auctus. Based on this agreement the Company exchanged three outstanding notes, in the amounts of $150,000, $89,250, and $65,000 for a total amount $328,422 of debt outstanding, as well as any accrued interest and default penalty, for: $160,000 in cash payments (payable in monthly payments of $20,000), 500,000 shares of restricted common stock and 700,000 warrants to purchase common shares at a strike price of $0.15. The fair value of the common stock shares was $250,000 and the fair value of the warrants to purchase common shares was $196,818 (based on an estimated fair value of $0.281 as determined utilizing the Black-Scholes option pricing model). At December 31, 2020, a balance of $40,000 remained to be paid for these exchanged loans. As of December 31, 2021, the loans were paid in full. The following table summarizes the convertible notes, including convertible debt in default (in thousands): Convertible notes payable, including debt in default December 31, 2021 December 31, 2020 GBP $ - $ 1,709 GHS - 181 Auctus - 40 Convertible notes payable $ - $ 1,930 Troubled Debt Restructuring During 2021, the Company restructured debt with GPB resulting in the exchange of $1,709,414 of convertible debt. This debt restructure met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor.

LONG TERM DEBT

LONG TERM DEBT	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
LONG TERM DEBT
LONG-TERM DEBT	10. LONG-TERM DEBT Long-term Debt - Related Parties On July 14, 2018, the Company entered into an exchange agreement with Dr. Faupel, whereby Dr. Faupel agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $660,895 for a $207,111 promissory note dated September 4, 2018. On July 20, 2018, the Company entered into an exchange agreement with Dr. Cartwright, whereby Dr. Cartwright agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,499 for a $319,000 promissory note dated September 4, 2018 that incurs interest at a rate of 6% per annum. On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement and to modify the terms of the original exchange agreement. Under this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement. On February 19, 2021, the Company entered into new promissory notes replacing the original notes from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, matures on February 18, 2023, and will accrue interest at a rate of 6.0%. For Dr. Faupel the principal amount on the new note was $153,178, matures on February 18, 2023, and will accrue interest at a rate of 6.0%. The modifications extended the maturity date on both of the notes. On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F2 Preferred Stock, respectively. The table below summarizes the detail of the exchange agreement: For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven in prior years (454 ) Amount exchanged for Series F-2 Preferred Stock (85 ) Total interest accrued through December 31, 2021 39 Balance outstanding at December 31, 2021 $ 161 Interest accrued through March 31, 2022 2 Balance outstanding at March 31, 2022 $ 163 For Dr.Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven in prior years (1,302 ) Amount exchanged for Series F-2 Preferred Stock (100 ) Total interest accrued through December 31, 2021 62 Balance outstanding at December 31, 2021 $ 281 Interest accrued through March 31, 2022 4 Balance outstanding at March 31, 2022 $ 285 On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). The Company exchanged $50,000 of the amount owed of $546,214 for 50 share of Series F-2 Preferred Shares (convertible into 200,000 common stock shares), and a $150,000 unsecured note. The note accrues interest at the rate of 6% (18% in the event of default) beginning on March 22, 2022 and is payable in monthly installments of $3,580 for four years, with the first payment due on March 15, 2022. The effective interest rate of the note is 6.18%. During the three months ended March 31, 2022, Mr. Fowler forgave $6,232 of the outstanding balance and may forgive up to $253,429 of the remaining principal and accrued interest if the Company complies with the repayment plan described above. The reduction in the outstanding balance met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. The outstanding principal amount owed on the note was $146,400 as of March 31, 2022, of which $26,586 is included in “Current portion of long-term debt, related parties” and the remainder of which is included in “Long-term debt, related parties” on the consolidated balance sheets. Future debt obligations as shown below include: $284,867, $163,376, and $146,400 for a total of $594,643 for Dr. Cartwright, Dr. Faupel, and Mr. Fowler, respectively. Future debt obligations as of March 31, 2022 for debt owed to related parties is as follows (in thousands): Year Amount 2022 $ 27 2023 485 2024 39 2025 41 2026 3 Thereafter - Total $ 595 Small Business Administration Loan On May 4, 2020, the Company received a loan from the Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in the amount of $50,184. The loan bears interest at a rate of 1.00%, and matures in 24 months, with the principal and interest payments being deferred until the date of forgiveness with interest accruing, then converting to monthly principal and interest payments, at the interest rate provided herein, for the remaining eighteen (18) months. Lender will apply each payment first to pay interest accrued to the day Lender received the payment, then to bring principal current, and will apply any remaining balance to reduce principal. Payments must be made on the same day as the date of this Note in the months they are due. Lender shall adjust payments at least annually as needed to amortize principal over the remaining term of the Note. Under the provisions of the PPP, the loan amounts will be forgiven as long as: the loan proceeds are used to cover payroll costs, and most mortgage interest, rent, and utility costs over a 24-week period after the loan is made; and employee and compensation levels are maintained. In addition, payroll costs are capped at $100,000 on an annualized basis for each employee. Not more than 40% of the forgiven amount may be for non-payroll costs. As of March 31, 2022 and December 31, 2021, the outstanding balance was $4,491 (this amount is presented in current portion of long-term debt) and $11,181, including $407 and $385 in accrued interest, respectively. 10% Senior Unsecured Convertible Debenture On May 17, 2021, the Company issued 10% Senior Unsecured convertible debentures to investors, which mature on May 17, 2024 (the “Maturity Date”). The Company subscribed $1,130,000 of the $1,000 convertible debentures. The terms of the debentures are as follows: 1) the principal amount of some or all of the convertible debentures and accrued interest are convertible into common stock shares at the holder’s option, at a price of $0.50 per common stock share (the “conversion price”), subject to adjustment in certain events, at any time prior to maturity date; 2) upon successful uplist to a U.S. National Exchange, the note will automatically convert into the uplisting financing; 3) each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023; 4) if a Change of Control (as defined in the Convertible Debenture Certificate) occurs prior to the Maturity Date, unless the holder elects in writing to convert the Convertible Debentures into common shares, the Company will repay in cash upon the closing of such Change of Control all outstanding principal and accrued interest under each Convertible Debenture plus a Change of Control premium equal to an additional 3% of the outstanding principal sum under such Convertible Debenture. Prior to the closing of an Change of Control, in lieu of repayment as set forth in the preceding sentence, the holder has the right to elect in writing to convert, effective immediately prior to the effective date of such Change of Control, all outstanding principal and accrued Interest under the Convertible Debentures into common shares at the Conversion Price; 5) Subject to a holder’s option of electing conversion prior to the Redemption Date (as such term is defined below), on or after the date that is 24 months from the Closing Date if the daily volume weighted average trading price of the common shares is $1.50 per common share or more for each trading day over a 30 consecutive trading day period, the Company may, at any time (the “Redemption Date”), at its option, redeem all, or any portion of the Convertible Debentures for either: (i) a cash payment (in the form of a certified cheque or bank draft) that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date; or (ii) by issuing and delivering common shares to the holders of Convertible Debentures at a deemed price of US$0.50 per common share that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date, or any combination of (i) or (ii), upon not less than 30 days and not more than 60 days prior written notice in the manner provided in the Debenture Certificate, to the holder of Convertible Debentures. At March 31, 2022 and December 31, 2021, the balance due on the 10% Senior Secured Convertible Debenture was $1,130,000 and total accrued interest was $28,250 and $73,326, respectively. The bond payable discount and unamortized debt issuance costs as of March 31, 2022 and December 31, 2021 are presented below (in thousands): March 31, 2022 December 31, 2021 10% Senior Unsecured Convertible Debentures $ 1,130 $ 1,130 Debt Issuance costs to be amortized (62 ) (69 ) Debt Discount (216 ) (241 ) Long-term convertible debt $ 852 $ 820 6% Unsecured Promissory Note On July 9, 2020, we entered into an exchange agreement with Mr. Bill Wells (a former employee). In lieu of agreeing to dismiss approximately half of what was owed to him, or $220,000, Mr. Wells received the following: (i) cash payments of $ 20,000; (ii) an unsecured promissory note in the amount of $90,000 to be executed within 30 days of completing new financing(s) totaling at least $3.0 million, (iii) 66,000 common share stock options that vest at a rate of 3,667 per month and have a $0.49 exercise price (if two consecutive payments in (ii) are not made the stock options will be canceled and a cash payment will be required; and (iv) the total amount of forgiveness by creditor of approximately $110,000 shall be prorated according to amount paid. During the year ended December 31, 2021, the Company closed a financing round that exceeded the $3.0 million threshold and issued an unsecured promissory note in the amount of $97,052 to Mr. Wells. The note, for which monthly installment payments of $5,000 are due, matures 18 months after the issuance date and incurs interest at a rate of 6.0% per annum. During the three months ended March 31, 2022, the Company made payments of $35,000 to Mr. Wells, which resulted in forgiveness of $35,000 of the remaining balance of accrued compensation. The reduction in the outstanding balance met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of March 31, 2022, the total amount owed to Mr. Wells (principal and accrued interest), was $65,299, which is included in “Current portion of long-term debt” on the consolidated balance sheet.	10. LONG-TERM DEBT Long-term Debt - Related Parties On July 14, 2018, the Company entered into an exchange agreement with Dr. Faupel, whereby Dr. Faupel agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $660,895 for a $207,111 promissory note dated September 4, 2018. On July 20, 2018, the Company entered into an exchange agreement with Dr. Cartwright, whereby Dr. Cartwright agreed to exchange outstanding amounts due to him for loans, interest, bonus, salary and vacation pay in the amount of $1,621,499 for a $319,000 promissory note dated September 4, 2018 that incurs interest at a rate of 6% per annum. On July 24, 2019, Dr. Faupel and Mr. Cartwright agreed to an addendum to the debt restructuring exchange agreement and to modify the terms of the original exchange agreement. Under this modification Dr. Faupel and Mr. Cartwright agreed to extend the note to be due in full on the third anniversary of that agreement. On February 19, 2021, the Company entered into new promissory notes replacing the original notes from September 4, 2018, with Mark Faupel and Gene Cartwright. For Dr. Cartwright the principal amount on the new note was $267,085, matures on February 18, 2023, and will accrue interest at a rate of 6.0%. For Dr. Faupel the principal amount on the new note was $153,178, matures on February 18, 2023, and will accrue interest at a rate of 6.0%. The modifications extended the maturity date on both of the notes. On February 19, 2021, the Company exchanged $100,000 and $85,000 of long-term debt for Dr. Cartwright and Dr. Faupel in exchange for 100 and 85 shares of Series F-2 Preferred Stock, respectively. The table below summarizes the detail of the exchange agreement: For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven (454 ) Total Interest accrued through December 31, 2020 29 Balance outstanding at December 31, 2020 $ 236 Exchange for Series F-2 Preferred Stock (85 ) Interest and salaries accrued through December 31, 2021 10 Balance outstanding at December 31, 2021 $ 161 For Dr.Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven (1,302 ) Total Interest accrued through December 31, 2020 45 Balance outstanding at December 31, 2020 $ 364 Exchange for Series F-2 Preferred Stock (100 ) Interest and salaries accrued through December 31, 2021 17 Balance outstanding at December 31, 2021 $ 281 On March 22, 2021, the Company entered into an exchange agreement with Richard Fowler. As of December 31, 2020, the Company owed Mr. Fowler $546,214 ($412,624 in deferred salary and $133,590 in accrued interest). Mr. Fowler exchanged $50,000 of the amount owed of $546,214 for 50 shares of Series F-2 Preferred Shares (convertible into 200,000 shares of common stock) and a $150,000 unsecured note. The note accrues interest at the rate of 6.0% (18.0% in the event of default) beginning on March 1, 2022 and is payable in monthly installments of $3,600 for four years, with the first payment being due on March 15, 2022. The effective interest rate of the note is 6.18%. Mr. Fowler forgave $86,554 and may forgive up to $259,661 of debt if the Company complies with the repayment plan described above. At the time of the exchange agreement with Mr. Fowler, the Company was in default to the creditor on two notes in the amounts of $12,500 and $13,900 dated December 21, 2016 and January 19, 2017, respectively. The March 22, 2021 exchange agreement modified the notes to current status, payable in full within one year from the date of the agreement, in monthly payments of at least $3,850. The notes accrue at an interest rate of 6% (18% in the event of default). Future debt obligations as shown below include: $281,000, $161,000 and $150,000 for a total of $592,000 for Dr. Cartwright, Dr. Faupel, and Mr. Fowler, respectively. Future debt obligations at December 31, 2021 for debt owed to related parties is as follows: Year Amount 2022 $ 30 2023 479 2024 39 2025 41 2026 3 Thereafter - Total $ 592 Troubled Debt Restructuring The debt extinguished for Dr. Cartwright, Mr. Fowler and Dr. Faupel meet the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being in default on several of its loans the debt is considered troubled debt. During the year ended December 31, 2021, the Company recorded a gain of $86,554 for Mr. Fowler’s debt exchange. Small Business Administration Loan On May 4, 2020, the Company received a loan from the Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) in the amount of $50,184. The loan bears interest at a rate of 1.00%, and matures in 24 months, with the principal and interest payments being deferred until the date of forgiveness with interest accruing, then converting to monthly principal and interest payments, at the interest rate provided herein, for the remaining eighteen (18) months. Lender will apply each payment first to pay interest accrued to the day Lender received the payment, then to bring principal current, and will apply any remaining balance to reduce principal. Payments must be made on the same day as the date of this Note in the months they are due. Lender shall adjust payments at least annually as needed to amortize principal over the remaining term of the Note. Under the provisions of the PPP, the loan amounts will be forgiven as long as: the loan proceeds are used to cover payroll costs, and most mortgage interest, rent, and utility costs over a 24 week period after the loan is made; and employee and compensation levels are maintained. In addition, payroll costs are capped at $100,000 on an annualized basis for each employee. Not more than 40% of the forgiven amount may be for non-payroll costs. As of December 31, 2021 and 2020, the outstanding balance was $11,000 (this amount is recorded in current portion of long-term debt) and $50,477, including $385 and $293 in accrued interest, respectively. During the year ended December 31, 2021, the Company was notified that the application for loan forgiveness was approved in the amount of $23,742 in principal and $234 in interest. 10% Senior Unsecured Convertible Debenture On May 17, 2021, the Company issued 10% Senior Unsecured convertible debentures to investors, which mature on May 17, 2024 (the “Maturity Date”). The Company subscribed $1,130,000 of the $1,000 convertible debentures. The terms of the debentures are as follows: 1) the principal amount of some or all of the convertible debentures and accrued interest are convertible into common stock shares at the holder’s option, at a price of $0.50 per common share (the “conversion price”), subject to adjustment in certain events, at any time prior to maturity date; 2) prior to successful uplist to a U.S. National Exchange, the Company may, at its election, convert the note at the conversion price, or in the event the Company undertakes a capital raise in connection with the uplisting, the holder may, at their election, exchange some or all of the debentures for securities issued in such capital raise on a $1.00 for $1.00 basis; 3) each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023; 4) if a Change of Control (as defined in the Convertible Debenture Certificate) occurs prior to the Maturity Date, unless the holder elects in writing to convert the Convertible Debentures into common shares, the Company will repay in cash upon the closing of such Change of Control all outstanding principal and accrued interest under each Convertible Debenture plus a Change of Control premium equal to an additional 3% of the outstanding principal sum under such Convertible Debenture. Prior to the closing of an Change of Control, in lieu of repayment as set forth in the preceding sentence, the holder has the right to elect in writing to convert, effective immediately prior to the effective date of such Change of Control, all outstanding principal and accrued Interest under the Convertible Debentures into common shares at the Conversion Price; 5) Subject to a holder's option of electing conversion prior to the Redemption Date (as such term is defined below), on or after the date that is 24 months from the Closing Date if the daily volume weighted average trading price of the common shares is $1.50 per common share or more for each trading day over a 30 consecutive trading day period, the Company may, at any time (the "Redemption Date"), at its option, redeem all, or any portion of the Convertible Debentures for either: (i) a cash payment (in the form of a certified cheque or bank draft) that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date; or (ii) by issuing and delivering common shares to the holders of Convertible Debentures at a deemed price of $0.50 per common share that is equal to all outstanding principal and accrued interest under each Convertible Debenture up to the Redemption Date, or any combination of (i) or (ii), upon not less than 30 days and not more than 60 days prior written notice in the manner provided in the Debenture Certificate, to the holder of Convertible Debentures. At December 31, 2021, the balance due on the 10% Senior Secured Convertible Debenture was $1,130,000 and total interest accrued was $73,326. At December 31, 2021, the Company had also recorded a bond payable discount of $240,856 and unamortized debt issuance costs of $69,120, for a net balance of $819,024. Interest is payable at the rate of 10% compounded quarterly, payable semi-annually on July 1 and January 1, beginning on January 1, 2022, each conversion date and on the maturity date. 6% Unsecured Promissory Note On July 9, 2020, we entered into an exchange agreement with Mr. Bill Wells (a former employee). In lieu of agreeing to dismiss approximately half of what was owed to him, or $220,000, Mr. Wells received the following: (i) cash payments of $20,000; (ii) an unsecured promissory note in the amount of $90,000 to be executed within 30 days of completing new financing(s) totaling at least $3.0 million, (iii) 66,000 common share stock options that vest at a rate of 3,667 per month and have a $0.49 exercise price (if two consecutive payments in (ii) are not made the stock options will be canceled and a cash payment will be required; and (iv) the total amount of forgiveness by creditor of approximately $110,000 shall be prorated according to amount paid. During the year ended December 31, 2021, the Company closed a financing round that exceeded the $3.0 million threshold and issued an unsecured promissory note in the amount of $97,052 to Mr. Wells. The note, for which monthly installment payments of $5,000 are due, matures 18 months after the issuance date and incurs interest at a rate of 6.0% per annum. As of December 31, 2021, the total amount owed to Mr. Wells (principal and accrued interest), was $99,158, of which $77,087 was classified as short-term and is included in “Current portion of long-term debt” on the consolidated balance sheet. The remaining balance is classified as long-term and is included in “Long-term debt” on the consolidated balance sheet.

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
INCOME (LOSS) PER COMMON SHARE
INCOME (LOSS) PER COMMON SHARE	11. INCOME (LOSS) PER COMMON SHARE Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year. Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C, Series D, Series E, Series F and Series F-2 convertible preferred stock, Series G preferred stock, convertible debt, convertible preferred dividends and warrants convertible into common stock shares. The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except for per-share data): March 31, 2022 2021 Net loss (1,055 ) (572 ) Basic weighted average number of shares outstanding 20,683 13,172 Net loss per share (basic) (0.05 ) (0.04 ) Diluted weighted average number of shares outstanding 20,683 13,172 Net loss per share (diluted) (0.05 ) (0.04 ) Dilutive equity instruments (number of equivalent units): Stock options 917 - Preferred stock 15,572 17,994 Convertible debt 2,018 315 Warrants 13,609 17,400 Total Dilutive instruments 32,116 35,709 For period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt are anti-dilutive. Troubled Debt Restructurings - 2022 During the three months ended March 31, 2022, two of the Company’s creditors forgave $41,232 of debt. The reductions in the outstanding balances met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of March 31, 2022, the troubled debt restructurings in total would have decreased the net loss by $41,232, with no impact to net loss per share. Troubled Debt Restructurings - 2021 During the three months ended March 31, 2021, the Company restructured several debt agreements that met the criteria for troubled debt. The basic criteria are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. As of March 31, 2022, the troubled debt restructurings in total would have decreased the net loss by $972,000, causing the per share calculation to change from .04 to .11 net loss per share.	11. INCOME (LOSS) PER COMMON SHARE Basic net income (loss) per share attributable to common stockholders, amounts are computed by dividing the net income (loss) plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of shares outstanding during the year. Diluted net income (loss) per share attributable to common stockholders amounts are computed by dividing the net income (loss) plus preferred stock dividends, deemed dividends on preferred stock, after-tax interest on convertible debt and convertible dividends by the weighted average number of shares outstanding during the year, plus Series C, Series C-1, Series C-2, Series D, Series E, Series F and Series F-2 convertible preferred stock, Series G preferred stock, convertible debt, convertible preferred dividends and warrants convertible into common stock shares. The following table sets forth pertinent data relating to the computation of basic and diluted net loss per share attributable to common shareholders (in thousands, except for per-share data): December 31, 2021 2020 Net loss (2,431 ) (401 ) Basic weighted average number of shares outstanding 13,377 10,767 Net loss per share (basic) (0.18 ) (0.04 ) Diluted weighted average number of shares outstanding 13,377 10,767 Net loss per share (diluted) (0.18 ) (0.04 ) Dilutive equity instruments (number of equivalent units): Stock options 1,867 - Preferred stock 18,253 - Convertible debt 964 62,095 Warrants 15,655 7,683 Total Dilutive instruments 36,739 69,778 For period of net loss, basic and diluted earnings per share are the same as the assumed exercise of warrants and the conversion of convertible debt and preferred stock are anti-dilutive. Troubled Debt Restructuring As provided in the preceding footnotes, several transactions met the basic criteria for troubled debt, which are that the borrower is troubled, i.e., they are having financial difficulties, and a concession is granted by the creditor. Due to the Company being past due or in default on several of its loans, the debt is considered troubled debt. As of December 31, 2021, the troubled debt restructuring in total would have decreased the net loss by $85,000, causing the per share calculation to change from .18 to .19 net loss per share. This includes $94,392 of accounts payables forgiven during the year ended December 31, 2021 in accordance with an agreement executed on September 30, 2021.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2021
INCOME TAXES
Income Taxes	12. INCOME TAXES The Company has incurred net operating losses ("NOLs") since inception. As of December 31, 2021, the company had NOL carryforwards available through 2038 of approximately $58.0 million to offset its future income tax liability. The company has recorded deferred tax assets but reserved against, due to uncertainties related to utilization of NOLs as well as calculation of effective tax rate. Utilization of existing NOL carryforwards may be limited in future years based on significant ownership changes. The company is in the process of analyzing their NOL and has not determined if the company has had any change of control issues that could limit the future use of NOL. NOL carryforwards that were generated after 2017 of approximately $9.9 million may only be used to offset 80% of taxable income and are carried forward indefinitely. Components of deferred taxes are as follow at December 31 (in thousands): The following is a summary of the items that caused recorded income taxes to differ from taxes computed using the statutory federal income tax rate for the years ended December 31: 2021 2020 Statutory federal tax rate 21 % 21 % State taxes, net of federal benefit 4 % 4 % Nondeductible expenses - - Valuation allowance 25 % 25 % Effective tax rate 0 % 0 % The Company applies the applicable authoritative guidance which prescribes a comprehensive model for the manner in which a company should recognize, measure, present and disclose in its financial statements all material uncertain tax positions that the Company has taken or expects to take on a tax return. As of December 31, 2021, the Company has no uncertain tax positions. There are no uncertain tax positions for which it is reasonably possible that the total amounts of unrecognized tax benefits will significantly increase or decrease within twelve months from December 31, 2021. The Company files federal income tax returns and income tax returns in various state tax jurisdictions with varying statutes of limitations. The Company has filed its 2020 federal and state corporate tax returns. The last three tax years are subject to examination. The provision for income taxes as of the dates indicated consisted of the following (in thousands) December 31: 2021 2020 Current $ - $ - Deferred - - Deferred provision (credit) (1,728 ) 1,623 Change in valuation allowance 1,728 (1,623 ) Total provision for income taxes $ - $ - In 2021 and 2020, our effective tax rate differed from the U.S. federal statutory rate due to the valuation allowance over our deferred tax assets. 2021 2020 Deferred tax assets: Warrant liability $ - $ 617 Accrued executive compensation 288 519 Reserves and other 273 289 Stock options 134 132 Net operating loss carryforwards 16,985 17,851 17,680 19,408 Valuation allowance (17,680 ) (19,408 ) Net deferred tax assets $ - $ -

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS Auctus Exchange Agreement On April 14, 2022, we entered into an agreement with Auctus that extended the April 15, 2022 deadline to May 15, 2022. See Footnote 9 – “Short-Term Convertible Debt” for information on the exchange agreement. On June 1, 2022, we entered into a third exchange agreement with Auctus. As of the date of the agreement, Auctus was owed $692,114 of Notes and accrued interest. Pursuant to this third agreement, as long as we complete the Nasdaq Offering prior to July 15, 2022, the total amount owed to Auctus will be payable in cash 13 months subsequent to the consummation of the Offering. The $350,000 prepayment penalty and warrants issued in connection with the Notes (for the purpose of the third exchange agreement, are valued at, in the aggregate, $2,031,710) will be exchanged into unregistered units of our common stock, warrants and prefunded warrants otherwise in the form and ratios issued in the Offering. The exchange price will be on a $1 for $1 basis such that Auctus will receive $2,031,710 of units consisting of common stock, warrants and prefunded warrants. The units being issued in the exchange with Auctus are unregistered and are being issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. Additionally, the units and the common stock underlying the units will be subject to a lock up agreement with the underwriters until the earlier of 120 days after the Nasdaq Offering and the date that the daily volume weighted average price of the common stock exceeds 200% of the Nasdaq Offering price for at least five consecutive trading days. In the event the Nasdaq Offering is not consummated by July 15, 2022, the third exchange agreement will be null and void. Ellenoff Grossman & Schole LLP (“EGS”) Exchange Agreement On June 6, 2022, we entered into an exchange agreement with EGS. Currently, we owe $304,879 to EGS, for legal services performed. Pursuant to the agreement, EGS will forgive $104,879 of the balance owed after we successfully complete a financing of at least $3,000,000 (the “Financing”), make a cash payment of $200,000 from the proceeds of the financing and (upon closing of the Financing), we will negotiate a one-year agreement for EGS to provide legal representation under a retained agreement with a monthly rate to be agreed upon by both parties. In the event the Financing does not occur by August 31, 2022, the Company agreed to make a partial payment of 50,000 to EGS in exchange for forgiveness, upon which $50,000 of the outstanding debt will be forgiven. Any remaining amounts will be due to EGS. Executive Exchange Agreements On June 22, 2022, we entered into exchange agreements with two of our executives. Pursuant to the agreements, $29,776 of related-party payables, $31,285 of short-term related-party debt and $8,939 of accrued expenses owed to executives will be converted into shares of common stock and/or warrants valued at $70,000, upon successful completion of a financing of at least $4,000,000. Series D Exchange Agreements Subsequent to March 31, 2022, the Company entered into various agreements with Series D Preferred shareholders, pursuant to which each holder separately agreed to exchange their Series D Preferred shares into the Company’s common shares (in accordance with their existing Series D Preferred Share Agreements). In addition, the holders agreed to exchange 650,000 common stock warrants with a strike price of $0.25 for 650,000 warrants with a strike price of $0.20, which were required to be immediately exercised. The Company received $130,000 from the holders for exercises of the aforementioned warrants. Common Stock Issuances Subsequent to March 31, 2022, we issued 1,864,000 shares of common stock for the conversion of Series F-2 Preferred shares. Subsequent to March 31, 2022, we issued 1,360,000 shares of common stock for the conversion of Series F Preferred shares. Subsequent to March 31, 2022, we issued 320,000 shares of common stock for the conversion of Series E Preferred shares. Subsequent to March 31, 2022, we issued 650,000 shares of common stock for warrant exercises. Subsequent to March 31, 2022, we issued 975,000 shares of common stock for the conversion of Series D Preferred shares. Subsequent to March 31, 2022, we issued 25,288 shares of common stock for Series D Preferred dividends. Subsequent to March 31, 2022, we issued 50,230 shares of common stock for Series E Preferred dividends. Subsequent to March 31, 2022, we issued 19,330 shares of common stock for Series F Preferred dividends. Subsequent to March 31, 2022, we issued 3,213 shares of common stock for Series F-2 Preferred dividends.	13. SUBSEQUENT EVENTS Auctus Exchange Agreement On June 2, 2021, we entered into an initial exchange agreement Auctus. On February 1, 2022, we entered into a second exchange agreement with Auctus. Pursuant to this second agreement, Auctus agreed to exchange an aggregate of $668,290 of outstanding notes (the "Notes"), including accrued interest, and the associated warrants issued in connection with the Notes (the warrants, for the purpose of the exchange, are valued at, in the aggregate, $1,681,707) into unregistered units of our common stock, warrants and prefunded warrants otherwise in the form and ratios issued in a proposed underwritten public offering on the Nasdaq Capital Markets (the “Nasdaq Offering”). The exchange price will be on a $1 for $1 basis such that Auctus will receive $2,349,997 of units consisting of common stock, warrants and prefunded warrants. The units being issued in the exchange with Auctus are unregistered and are being issued pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended. Additionally, the units and the common stock underlying the units will be subject to a lock up agreement with the underwriters until the earlier of 120 days after the Nasdaq Offering and the date that the daily volume weighted average price of the common stock exceeds 200% of the Nasdaq Offering price for at least five consecutive trading days. Further, the termination date of the June 2, 2021 was extended to April 15, 2022. The $350,000 related to default penalties will be exchanged into $350,000 of securities offered in the Nasdaq Offering. Common Stock Issuances Subsequent to December 31, 2021, we issued 4,477,923 shares of common stock for warrant exercises (see Note 4, “ Warrant Exchanges - 2021” Subsequent to December 31, 2021, we issued 307,000 shares of common stock for the conversion of Series E Preferred shares. Subsequent to December 31, 2021, we issued 625,686 shares of common stock for payment of a one-time 15% dividend to holders of our Series F and Series F-2 Preferred shares. Subsequent to December 31, 2021, we issued 121,262 shares of common stock for payment of interest accrued on the 10% Senior Unsecured Convertible Debenture. Subsequent to December 31, 2021, we issued 60,000 shares of common stock for the conversion of Series F Preferred shares. Subsequent to December 31, 2021, we issued 23,109 shares of common stock for payment of Series D Preferred share dividends. Subsequent to December 31, 2021, we issued 12,432 shares of common stock for payment of Series E Preferred share dividends.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of embedded conversion options and freestanding warrants.	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and binomial calculations. The Company uses the Monte Carlo simulations and binomial calculations in the calculation of the fair value of the warrant liabilities and the valuation of freestanding warrants.
Accounting Standards Update	A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.	Accounting Standard Updates FASB ASU 2021-04, “ Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” - FASB ASU NO. 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” FASB ASU NO. 2019-12, “ Simplifying the Accounting for Income Taxes A variety of proposed or otherwise potential accounting standards are currently under consideration by standard-setting organizations and certain regulatory agencies. Because of the tentative and preliminary nature of such proposed standards, management has not yet determined the effect, if any that the implementation of such proposed standards would have on the Company’s consolidated financial statements.
Cash Equivalents	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.	Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Accounts Receivable	The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable.	Accounts Receivable The Company performs periodic credit evaluations of its distributors’ financial conditions and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. Uncollectibility is determined based on the determination that a distributor will not be able to make payment and the time frame has exceeded one year. The Company does not accrue interest receivables on past due accounts receivable.
Concentrations of Credit Risk	The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.	Concentrations of Credit Risk The Company, from time to time during the years covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Inventory Valuation	All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. As of March 31, 2022 and December 31, 2021, our inventories were as follows: (in thousands) March 31, 2022 December 31, 2021 Raw materials $ 1,254 $ 1,255 Work-in-progress 69 69 Finished goods 32 32 Inventory reserve (785 ) (785 ) Total inventory $ 570 $ 571 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.	Inventory Valuation All inventories are stated at lower of cost or net realizable value, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when incurred. As of December 31, 2021 and 2020, our inventories were as follows: (in thousands) December 31, December 31, 2021 2020 Raw materials $ 1,255 $ 1,276 Work-in-progress 69 80 Finished goods 32 7 Inventory reserve (785 ) (758 ) Total inventory $ 571 $ 605 The company periodically reviews the value of items in inventory and provides write-downs or write-offs of inventory based on its assessment of market conditions. Write-downs and write-offs are charged to cost of goods sold.
Property and Equipment	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at March 31, 2022 and December 31, 2021: (in thousands) March 31, 2022 December 31, 2021 Equipment $ 1,049 $ 1,048 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress 21 8 Subtotal 1,775 1,761 Less accumulated depreciation (1,747 ) (1,747 ) Property, equipment and leasehold improvements, net $ 28 $ 14 Depreciation expense related to property and equipment for the three months ended March 31, 2022 and 2021 was not material.	Property and Equipment Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are amortized at the shorter of the useful life of the asset or the remaining lease term. Depreciation and amortization expense are included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred. Property and equipment are summarized as follows at December 31, 2021 and 2020: (in thousands) December 31, December 31, 2021 2020 Equipment $ 1,048 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress 8 - Subtotal 1,761 1,747 Less accumulated depreciation (1,747 ) (1,746 ) Property, equipment and leasehold improvements, net $ 14 $ 1 Depreciation expense related to property and equipment for the years ended December 31, 2021 and 2020 was not material.
Debt Issuance Costs	Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.	Debt Issuance Costs Debt issuance costs are capitalized and amortized over the term of the associated debt. Debt issuance costs are presented in the balance sheet as a direct deduction from the carrying amount of the debt liability consistent with the debt discount.
Patent Costs (Principally Legal Fees)	Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs were not material for the three months ended March 31, 2022 and 2021.	Patent Costs Costs incurred in filing, prosecuting, and maintaining patents are recurring, and expensed as incurred. Maintaining patents are expensed as incurred as the Company has not yet received U.S. FDA approval and recovery of these costs is uncertain. Such costs aggregated to approximately $14,800 and $17,000 for the years ended December 31, 2021 and 2020, respectively.
Leases	A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 7 - Commitments and Contingencies.	Leases A lease provides the lessee the right to control the use of an identified asset for a period of time in exchange for consideration. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and operating lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The Company determines if an arrangement is a lease at inception. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Where an operating lease contains extension options that the Company is reasonably certain to exercise, the extension period is included in the calculation of the right-of-use assets and lease liabilities. The discount rate used to determine the commencement date present value of lease payments is the interest rate implicit in the lease, or when that is not readily determinable, the Company utilizes its secured borrowing rate. Right-of-use assets include any lease payments required to be made prior to commencement and exclude lease incentives. Both right-of-use assets and lease liabilities exclude variable payments not based on an index or rate, which are treated as period costs. The Company’s lease agreements do not contain significant residual value guarantees, restrictions or covenants. See Note 7 - Commitments and Contingencies.
Accrued Liabilities	Accrued liabilities as of March 31, 2022 and December 31, 2021 are summarized as follows: (in thousands) March 31, 2022 December 31, 2021 Compensation $ 573 $ 621 Professional fees 41 98 Stock Subscription Payable - 351 Interest 232 261 Vacation 42 39 Preferred dividends 299 349 Other accrued expenses 41 49 Total $ 1,228 $ 1,768	Accrued Liabilities Accrued liabilities as of December 31, 2021 and 2020 are summarized as follows: (in thousands) December 31, December 31, 2021 2020 Compensation $ 621 $ 1,094 Professional fees 98 83 Interest 261 1,517 Vacation 39 34 Preferred dividends 349 202 Stock subscription payable 351 - Other accrued expenses 49 65 Total $ 1,768 $ 2,995
Stock Subscription Payable	Cash received from investors for common stock shares that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet.	Stock Subscription Payable Cash received from investors for common stock shares that have not yet been issued is recorded as a liability, which is presented within Accrued Liabilities on the consolidated balance sheet.
Revenue Recognition	ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue-based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 - Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. · Step 2 - Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. · Step 3 - Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. · Step 4 - Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. · Step 5 - Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company did not recognize material revenues during the three-month periods ended March 31, 2022 or 2021. The Company’s revenues do not require significant estimates or judgments. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of March 31, 2022 and December 31, 2021, the Company had $514,000 and $337,000 in deferred revenue, respectively.	Revenue Recognition ASC 606, Revenue from Contracts with Customers, establishes a single and comprehensive framework which sets out how much revenue is to be recognized, and when. The core principle is that a vendor should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the vendor expects to be entitled in exchange for those goods or services. Revenue will now be recognized by a vendor when control over the goods or services is transferred to the customer. In contrast, revenue-based revenue recognition around an analysis of the transfer of risks and rewards; this now forms one of a number of criteria that are assessed in determining whether control has been transferred. The application of the core principle in ASC 606 is carried out in five steps: · Step 1 – Identify the contract with a customer: a contract is defined as an agreement (including oral and implied), between two or more parties, that creates enforceable rights and obligations and sets out the criteria for each of those rights and obligations. The contract needs to have commercial substance and it is probable that the entity will collect the consideration to which it will be entitled. • Step 2 – Identify the performance obligations in the contract: a performance obligation in a contract is a promise (including implicit) to transfer a good or service to the customer. Each performance obligation should be capable of being distinct and is separately identifiable in the contract. • Step 3 – Determine the transaction price: transaction price is the amount of consideration that the entity can be entitled to, in exchange for transferring the promised goods and services to a customer, excluding amounts collected on behalf of third parties. • Step 4 – Allocate the transaction price to the performance obligations in the contract: for a contract that has more than one performance obligation, the entity will allocate the transaction price to each performance obligation separately, in exchange for satisfying each performance obligation. The acceptable methods of allocating the transaction price include adjusted market assessment approach, expected cost plus a margin approach, and the residual approach in limited circumstances. Discounts given should be allocated proportionately to all performance obligations unless certain criteria are met and reallocation of changes in standalone selling prices after inception is not permitted. • Step 5 – Recognize revenue as and when the entity satisfies a performance obligation: the entity should recognize revenue at a point in time, except if it meets any of the three criteria, which will require recognition of revenue over time: the entity’s performance creates or enhances an asset controlled by the customer, the customer simultaneously receives and consumes the benefit of the entity’s performance as the entity performs, and the entity does not create an asset that has an alternative use to the entity and the entity has the right to be paid for performance to date. The Company did not recognize material revenues during the years ended December 31, 2021 or 2020. The Company’s revenues do not require significant estimates or judgments. The Company is not party to contracts that include multiple performance obligations or material variable consideration. Contract Balances The Company defers payments received as revenue until earned based on the related contracts and applying ASC 606 as required. As of December 31 2021 and 2020, the Company had $337,000 and $42,000 of deferred revenue, respectively.
Significant Distributors	As of March 31, 2022, accounts receivable outstanding was $165,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $39,000 which was from two distributors. As of December 31, 2021, accounts receivable outstanding was $172,000; the outstanding amount was netted against a $126,000 allowance, leaving a balance of $46,000, which was from two distributors.	Significant Distributors As of December 31, 2021, accounts receivable outstanding was $172,000; the outstanding amount was netted against a $126,000 allowance, leaving a balance of $46,000 which was from two distributors. As of December 31, 2020, accounts receivable outstanding was $150,000, the outstanding amount was netted against a $126,000 allowance, leaving a balance of $24,000 which was from one distributor.
Research and Development	Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.	Research and Development Research and development expenses consist of expenditures for research conducted by the Company and payments made under contracts with consultants or other outside parties and costs associated with internal and contracted clinical trials. All research and development costs are expensed as incurred.
Income Taxes	The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed its 2021 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At March 31, 2022, the Company had approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations.	Income Taxes The provision for income taxes is determined in accordance with ASC 740, “ Income Taxes The Company has filed its 2020 federal and state corporate tax returns. The Company has entered into an agreed upon payment plan with the IRS for delinquent payroll taxes. The Company has an established payment arrangement for its delinquent state income taxes with the State of Georgia. Although the Company has been experiencing recurring losses, it is obligated to file tax returns for compliance with IRS regulations and that of applicable state jurisdictions. At December 31, 2021, the Company had approximately $61.6 million of net operating losses carryforward available. This net operating loss will be eligible to be carried forward for tax purposes at federal and applicable states level. A full valuation allowance has been recorded related the deferred tax assets generated from the net operating losses. The Company recognizes uncertain tax positions based on a benefit recognition model. Provided that the tax position is deemed more likely than not of being sustained, the Company recognizes the largest amount of tax benefit that is greater than 50.0% likely of being ultimately realized upon settlement. The tax position is derecognized when it is no longer more likely than not of being sustained. The Company classifies income tax related interest and penalties as interest expense and selling, general and administrative expense, respectively, on the consolidated statements of operations.
Warrants	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.	Warrants The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at the date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation or Binomial model.
Stock Based Compensation	The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation - Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future.	Stock Based Compensation The Company accounts for its stock-based awards in accordance with ASC Subtopic 718, “ Compensation - Stock Compensation The Black-Scholes option pricing model requires the input of certain assumptions that require the Company’s judgment, including the expected term and the expected stock price volatility of the underlying stock. The assumptions used in calculating the fair value of stock-based compensation represent management’s best estimates, but these estimates involve inherent uncertainties and the application of judgment. As a result, if factors change resulting in the use of different assumptions, stock-based compensation expense could be materially different in the future.
Derivatives	The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.	Derivatives The Company reviews the terms of convertible debt issued to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one embedded derivative instrument, including the conversion option, that is required to be bifurcated, the bifurcated derivative instruments are accounted for as a single, compound derivative instrument. Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as non-operating income or expense. When the equity or convertible debt instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first allocated to the fair value of all the bifurcated derivative instruments. The remaining proceeds, if any, are then allocated to the host instruments themselves, usually resulting in those instruments being recorded at a discount from their face value. The discount from the face value of the convertible debt, together with the stated interest on the instrument, is amortized over the life of the instrument through periodic charges to interest expense.
Beneficial Conversion Features Of Convertible Securities		Beneficial Conversion Features of Convertible Securities The Company has adopted the provisions of ASU 2017-11 to account for the down round features of warrants issued with private placements effective as of January 1, 2020. In doing so, warrants with a down round feature previously treated as derivative liabilities in the consolidated balance sheet and measured at fair value are henceforth treated as equity, with no adjustment for changes in fair value at each reporting period. Previously, the Company accounted for conversion options embedded in convertible notes in accordance with ASC 815. ASC 815 generally requires companies to bifurcate conversion options embedded in convertible notes from their host instruments and to account for them as free-standing derivative financial instruments. ASC 815 provides for an exception to this rule when convertible notes, as host instruments, are deemed to be conventional, as defined by ASC 815-40. The Company accounts for convertible notes deemed conventional and conversion options embedded in non-conventional convertible notes which qualify as equity under ASC 815, in accordance with the provisions of ASC 470-20, which provides guidance on accounting for convertible securities with beneficial conversion features. Accordingly, the Company records, as a discount to convertible notes, the intrinsic value of such conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt. Conversion options that are not bifurcated as a derivative pursuant to ASC 815 and not accounted for as a separate equity component under the cash conversion guidance are evaluated to determine whether they are beneficial to the investor at inception (a beneficial conversion feature) or may become beneficial in the future due to potential adjustments. The beneficial conversion feature guidance in ASC 470-20 applies to convertible stock as well as convertible debt which are outside the scope of ASC 815. A beneficial conversion feature is defined as a nondetachable conversion feature that is in the money at the commitment date. The beneficial conversion feature guidance requires recognition of the conversion option’s in-the-money portion, the intrinsic value of the option, in equity, with an offsetting reduction to the carrying amount of the instrument. The resulting discount is amortized as a dividend over either the life of the instrument, if a stated maturity date exists, or to the earliest conversion date, if there is no stated maturity date. If the earliest conversion date is immediately upon issuance, the dividend must be recognized at inception. When there is a subsequent change to the conversion ratio based on a future occurrence, the new conversion price may trigger the recognition of an additional beneficial conversion feature on occurrence. During 2021, the Company adopted ASU No. 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
SIGNIFICANT ACCOUNTING POLICIES
Inventory valuation	(in thousands) March 31, 2022 December 31, 2021 Raw materials $ 1,254 $ 1,255 Work-in-progress 69 69 Finished goods 32 32 Inventory reserve (785 ) (785 ) Total inventory $ 570 $ 571	(in thousands) December 31, December 31, 2021 2020 Raw materials $ 1,255 $ 1,276 Work-in-progress 69 80 Finished goods 32 7 Inventory reserve (785 ) (758 ) Total inventory $ 571 $ 605
Property and equipment	(in thousands) March 31, 2022 December 31, 2021 Equipment $ 1,049 $ 1,048 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress 21 8 Subtotal 1,775 1,761 Less accumulated depreciation (1,747 ) (1,747 ) Property, equipment and leasehold improvements, net $ 28 $ 14	(in thousands) December 31, December 31, 2021 2020 Equipment $ 1,048 $ 1,042 Software 652 652 Furniture and fixtures 41 41 Leasehold improvements 12 12 Construction in progress 8 - Subtotal 1,761 1,747 Less accumulated depreciation (1,747 ) (1,746 ) Property, equipment and leasehold improvements, net $ 14 $ 1
Accrued liabilities	(in thousands) March 31, 2022 December 31, 2021 Compensation $ 573 $ 621 Professional fees 41 98 Stock Subscription Payable - 351 Interest 232 261 Vacation 42 39 Preferred dividends 299 349 Other accrued expenses 41 49 Total $ 1,228 $ 1,768	(in thousands) December 31, December 31, 2021 2020 Compensation $ 621 $ 1,094 Professional fees 98 83 Interest 261 1,517 Vacation 39 34 Preferred dividends 349 202 Stock subscription payable 351 - Other accrued expenses 49 65 Total $ 1,768 $ 2,995

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
FAIR VALUE OF FINANCIAL INSTRUMENTS
Schedule of fair value for liabilities measured on a recurring basis	Fair Value at March 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 $ - $ - $ (38 ) $ (38 ) Total short-term liabilities at fair value $ - $ - $ (38 ) $ (38 ) Fair Value at December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (32 ) (32 ) Total long-term liabilities at fair value $ - $ - $ (32 ) $ (32 )	Fair Value at December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 $ - $ - $ (32 ) $ (32 ) Total long-term liabilities at fair value $ - $ - $ (32 ) $ (32 ) Fair Value at December 31, 2020 (in thousands) Level 1 Level 2 Level 3 Total Warrants issued in connection with Senior Secured Debt $ $ $ (2,203 ) $ (2,203 ) Derivative liability/bifurcated conversion option in connection with Auctus $400,000 loan on December 17, 2019 - - (25 ) (25 ) Total long-term liabilities at fair value $ - $ - $ (2,228 ) $ (2,228 )
Summary of changes to Level 3 instruments	(in thousands) Senior Secured Debt Derivative Total Balance, December 31, 2021 $ - $ (32 ) $ (32 ) Change in fair value during the period - (6 ) (6 ) Balance, March 31, 2022 $ - $ (38 ) $ (38 )	(in thousands) Senior Secured Debt Derivative Total Balance, December 31, 2020 $ (2,203 ) $ (25 ) $ (2,228 ) Change in the terms of warrants previously recorded as a liability and now reclassified to equity 1,755 - 1,755 Change in value due to warrants expiring during the year 448 - 448 Extinguishment of derivative liability due to payoff of $700,000 loan to Auctus - 84 84 Change in fair value during the year - (91 ) (91 ) Balance, December 31, 2021 $ - $ (32 ) $ (32 )

STOCKHOLDERS DEFICIT (Tables)

STOCKHOLDERS DEFICIT (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Stockholders' Deficit:
Common stock issued	Number of Shares Common stock warrants exercised 4,477,923 Issuance of common stock for payment of Series D preferred dividends 23,109 Issuance of common stock for payment of Series E preferred dividends 12,432 Issuance of common stock for payment of Series F preferred dividends 158,662 Issuance of common stock for payment of Series F-2 preferred dividends 95,535 Issuance of common stock for payment of interest 121,262 Issuance of common stock for Series F one-time 15% dividend 255,401 Issuance of common stock for Series F-2 one-time 15% dividend 368,505 Conversion of Series E preferred stock to common stock 3,070,000 Conversion of Series F preferred stock to common stock 60,000 Issued during the three months ended March 31, 2022 8,642,829 Summary table of common stock share transactions: Balance at December 31, 2021 13,673,583 Issued in 2022 8,642,829 Balance at March 31, 2022 22,316,412	Number of Shares Conversion of debt into common shares - exchange agreements 7,957,013 Conversion of debt into common shares 175,000 Shares issued for manufacturing agreements 12,147 Shares issued for payment of Series D dividends 148,653 Shares issued to investors 1,526,000 Issued during the year ended December 31, 2020 9,818,813 Shares issued for payment of Series D dividends 109,039 Shares issued for payment of Series E dividends 288,262 Shares issued for payment of finder fee 98,000 Conversion of Series F Preferred shares into common stock 40,000 Issued during the year ended December 31, 2021 535,301 Summary table of common stock share transactions: Outstanding at December 31, 2019 3,319,469 Issued in 2020 9,818,813 Outstanding at December 31, 2020 13,138,282 Issued in 2021 535,301 Outstanding at December 31, 2021 13,673,583
Outstanding warrants to purchase common stock	Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, December 31, 2021 27,669,634 $ 0.29 Warrants exercised (2,284,324 ) $ 0.16 Outstanding, March 31, 2022 25,385,310 $ 0.30
Debt Exchanges		Total Debt and Accrued Interest Total Debt Total Accrued Interest Common Stock Shares Warrants (Exercise $0.15) Warrants (Exercise $0.20) Warrants (Exercise $0.25) Warrants (Exercise $0.50) Warrants (Exercise $0.75) Aquarius $ 145,544 $ 107,500 $ 38,044 291,088 - - 145,544 - 145,544 K2 Medical (Shenghuo) 3 803,653 771,927 31,726 1,905,270 - 496,602 704,334 - 704,334 Mr. Blumberg 305,320 292,290 13,030 1,167,630 - 928,318 119,656 - 119,656 Mr. Case 179,291 150,000 29,291 896,456 - 896,456 - - - Mr. Grimm 51,110 50,000 1,110 255,548 - 255,548 - - - Mr. Gould 111,227 100,000 11,227 556,136 - 556,136 - - - Mr. Mamula 15,577 15,000 577 77,885 - 77,885 - - - Dr. Imhoff 2 400,417 363,480 36,937 1,699,255 - 1,497,367 100,944 - 100,944 Ms. Rosenstock 1 50,000 50,000 - 100,000 - - 50,000 - 50,000 Mr. James 2 2,286 2,000 286 7,745 - 5,291 1,227 - 1,227 Auctus 328,422 249,119 79,303 500,000 700,000 - - - Mr. Clavijo 125,000 125,000 - 500,000 - - - 250,000 - Mr. Wells 4 220,000 220,000 - - - - - - - $ 2,737,847 $ 2,496,316 $ 241,531 7,957,013 700,000 4,713,603 1,121,705 250,000 1,121,705
Shares Reserved For Warrants		Warrants (Underlying Shares) Weighted-Average Exercise Price Per Share Outstanding, January 1, 2020 46,016,840 $ 1.71 Warrants issued 11,270,013 $ 0.34 Warrants cancelled/expired (70 ) $ 1,068,423 Warrants exchanged (28,962,508 ) $ 0.04 Outstanding, December 31, 2020 28,324,275 $ 0.25 Warrants issued 7,982,223 $ 0.30 Warrants cancelled/expired (1,729,662 ) $ 0.04 Warrants exchanged (4,713,603 ) $ 0.20 Warrants exercised (2,193,599 ) $ 0.16 Outstanding, December 31, 2021 27,669,634 $ 0.29
Schedule Of Fair Value Warrants Issued Under Black-scholes Option Pricing Model		December 31, 2021 Expected term 15 days Volatility 143.2 % Risk-free interest rate 0.0 % Dividend yield 0.00 %

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
STOCK OPTIONS
Stock option activity	Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of March 31, 2022 1,500,000 $ 0.49 8.3 years $ 240 Options exercisable as of March 31, 2022 1,045,227 $ 0.49 8.3 years $ 167	Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Life Aggregate Intrinsic Value of In-the-Money Options (in thousands) Options outstanding as of January 1, 2021 1,800,000 $ 0.49 Options granted 25,000 $ 0.48 Options forfeited (167,614 ) $ 0.49 Options expired (157,386 ) $ 0.49 Options outstanding as of December 31, 2021 1,500,000 $ 0.49 8.5 years $ 135 Options exercisable as of December 31, 2021 954,273 $ 0.49 8.5 years $ 86
Stock options vested, unvested and granted	March 31, 2021 Expected term (years) 10 years Volatility 153.12 % Risk-free interest rate 0.98 % Dividend yield 0.00 %	December 31, December 31, 2021 2020 Expected term (years) 10 years 10 years Volatility 153.12 % 153.12 % Risk-free interest rate 0.98 % 0.98 % Dividend yield 0.00 % 0.00 %

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
LITIGATION AND CLAIMS
Operating lease right-of-use assets and lease liabilities	(in thousands) Three Months Ended March 31, 2022 Operating lease right-of-use assets $ 355 Operating lease liabilities $ 377 (in thousands) Operating Leases 2022 (remaining) $ 82 2023 112 2024 115 2025 118 2026 50 Total future lease payments 477 Less: discount (100 ) Total lease liabilities $ 377	(in thousands) Year Ended December 31, 2021 Operating lease right-of-use assets $ 372 Operating lease liabilities $ 392
Weighted-average remaining lease term and discount rate used in the calculation of operating lease right-of-use assets and lease liabilities	Three Months Ended March 31, 2022 Weighted average remaining lease term (years) 4.2 Weighted average discount rate 11.4 %	Year Ended December 31, 2021 Weighted average remaining lease term (years) 4.4 Weighted average discount rate 11.4 %
Future Minimum Rental Payments Under Non-cancellable Operating Leases		(in thousands) Operating Leases 2022 $ 108 2023 112 2024 115 2025 118 2026 50 Total future lease payments 503 Less: discount (111 ) Total lease liabilities $ 392

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
NOTES PAYABLE
Short-term notes payable, including related parties	Short-term notes payable, including related parties March 31, 2022 December 31, 2021 Dr. Cartwright $ 31 $ 34 Mr. Fowler - 6 Premium Finance (insurance) 12 48 Short-term notes payable $ 43 $ 88	Short-term notes payable, including related parties December 31, 2021 December 31, 2020 Dr. Cartwright $ 34 $ 46 Dr. Faupel - 5 Mr. Fowler 6 - Premium Finance (insurance) 48 45 Short-term notes payable $ 88 $ 96
Notes Payable In Default, Including Related Parties		Notes payable in default, including related parties December 31, 2021 December 31, 2020 Mr. Mermelstein $ - $ 285 Dr. Cartwright - 1 Mr. Fowler - 26 GPB - 17 Notes payable in default $ - $ 329

SHORT-TERM CONVERTIBLE DEBT (Ta

SHORT-TERM CONVERTIBLE DEBT (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
SHORT-TERM CONVERTIBLE DEBT
Schedule of short-term convertible notes payable	March 31, 2022 December 31, 2021 Auctus Tranche 2 $ 400 $ 400 Auctus prepayment penalty 350 350 Auctus (March 31, 2020 Note) 161 161 Debt discount and issuance costs to be amortized (5 ) (14 ) Convertible notes payable - short-term $ 906 $ 897	Short-term convertible notes payable , including debt in default December 31, 2021 December 31, 2020 Auctus Tranche 1 - 700 Auctus Tranche 2 $ 400 $ 400 Auctus prepayment penalty 350 - Auctus (March 31, 2020 Note) 161 113 Debt discount and issuance costs to be amortized (14 ) (262 ) Convertible notes payable - short-term $ 897 $ 951
Convertible Notes In Default		Convertible notes payable, including debt in default December 31, 2021 December 31, 2020 GBP $ - $ 1,709 GHS - 181 Auctus - 40 Convertible notes payable $ - $ 1,930

LONG TERM DEBT (Tables)

LONG TERM DEBT (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
LONG TERM DEBT
Long-term debt, related parties	For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven in prior years (454 ) Amount exchanged for Series F-2 Preferred Stock (85 ) Total interest accrued through December 31, 2021 39 Balance outstanding at December 31, 2021 $ 161 Interest accrued through March 31, 2022 2 Balance outstanding at March 31, 2022 $ 163 For Dr.Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven in prior years (1,302 ) Amount exchanged for Series F-2 Preferred Stock (100 ) Total interest accrued through December 31, 2021 62 Balance outstanding at December 31, 2021 $ 281 Interest accrued through March 31, 2022 4 Balance outstanding at March 31, 2022 $ 285	For Dr. Faupel: Salary $ 134 Bonus 20 Vacation 95 Interest on compensation 67 Loans to Company 196 Interest on loans 149 Total outstanding prior to exchange 661 Amount forgiven (454 ) Total Interest accrued through December 31, 2020 29 Balance outstanding at December 31, 2020 $ 236 Exchange for Series F-2 Preferred Stock (85 ) Interest and salaries accrued through December 31, 2021 10 Balance outstanding at December 31, 2021 $ 161 For Dr.Cartwright Salary $ 337 Bonus 675 Loans to Company 528 Interest on loans 81 Total outstanding prior to exchange 1,621 Amount forgiven (1,302 ) Total Interest accrued through December 31, 2020 45 Balance outstanding at December 31, 2020 $ 364 Exchange for Series F-2 Preferred Stock (100 ) Interest and salaries accrued through December 31, 2021 17 Balance outstanding at December 31, 2021 $ 281
Long-term debt, related parties debt obligations	Year Amount 2022 $ 27 2023 485 2024 39 2025 41 2026 3 Thereafter - Total $ 595	Year Amount 2022 $ 30 2023 479 2024 39 2025 41 2026 3 Thereafter - Total $ 592
Bond payable discount and unamortized debt issuance costs	March 31, 2022 December 31, 2021 10% Senior Unsecured Convertible Debentures $ 1,130 $ 1,130 Debt Issuance costs to be amortized (62 ) (69 ) Debt Discount (216 ) (241 ) Long-term convertible debt $ 852 $ 820

INCOME (LOSS) PER COMMON SHARE

INCOME (LOSS) PER COMMON SHARE (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
INCOME (LOSS) PER COMMON SHARE
Earnings per share	March 31, 2022 2021 Net loss (1,055 ) (572 ) Basic weighted average number of shares outstanding 20,683 13,172 Net loss per share (basic) (0.05 ) (0.04 ) Diluted weighted average number of shares outstanding 20,683 13,172 Net loss per share (diluted) (0.05 ) (0.04 ) Dilutive equity instruments (number of equivalent units): Stock options 917 - Preferred stock 15,572 17,994 Convertible debt 2,018 315 Warrants 13,609 17,400 Total Dilutive instruments 32,116 35,709	December 31, 2021 2020 Net loss (2,431 ) (401 ) Basic weighted average number of shares outstanding 13,377 10,767 Net loss per share (basic) (0.18 ) (0.04 ) Diluted weighted average number of shares outstanding 13,377 10,767 Net loss per share (diluted) (0.18 ) (0.04 ) Dilutive equity instruments (number of equivalent units): Stock options 1,867 - Preferred stock 18,253 - Convertible debt 964 62,095 Warrants 15,655 7,683 Total Dilutive instruments 36,739 69,778

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2021
INCOME TAXES
Components Of Deferred Taxes	2021 2020 Deferred tax assets: Warrant liability $ - $ 617 Accrued executive compensation 288 519 Reserves and other 273 289 Stock options 134 132 Net operating loss carryforwards 16,985 17,851 17,680 19,408 Valuation allowance (17,680 ) (19,408 ) Net deferred tax assets $ - $ -
Income Taxes	2021 2020 Statutory federal tax rate 21 % 21 % State taxes, net of federal benefit 4 % 4 % Nondeductible expenses - - Valuation allowance 25 % 25 % Effective tax rate 0 % 0 %
Provision For Income Taxes	2021 2020 Current $ - $ - Deferred - - Deferred provision (credit) (1,728 ) 1,623 Change in valuation allowance 1,728 (1,623 ) Total provision for income taxes $ - $ -

ORGANIZATION BACKGROUND AND B_2

ORGANIZATION BACKGROUND AND BASIS OF PRESENTATION (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Jan. 16, 2020
Decrease in authorized common share			500,000,000
Accumulated deficit	$ (143,400)		$ 142,400
Working capital	(3,700)		(4,100)
Net loss including preferred dividend	1,100		2,400
Total stockholders' deficits	(5,000)		5,400
Proceeds from exercise of warrants	400
Accumulated Deficit	(143,400)		$ 142,400
Decrease In Authorized Common Share			500,000,000
Warrants exercisable for common stock outstanding				7,185,000
Proceeds from exercise of warrants	$ 365	$ 0
Warrants exercise price per share				$ 0.04
10% Convertible Debentures
Proceeds From Sale Of Stocks			$ 3,200
Warrants [Member]
Warrants exercisable for common stock outstanding			27,700,000
Proceeds from exercise of warrants			$ 5,100
Warrants [Member] | Minimum
Warrants exercise price per share	$ 0.15		$ 0.15
Warrants [Member] | Maximum
Warrants exercise price per share	$ 0.80		$ 0.80
Warrants [Member] | Exchange Agreement With GPB [Member]
Warrants exercisable for common stock outstanding	25,400,000
Proceeds from exercise of warrants	$ 4,700

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Raw materials	$ 1,254	$ 1,255	$ 1,276
Work in process	69	69	80
Finished goods	32	32	7
Inventory reserve	(785)	(785)	(758)
Total	$ 570	$ 571	$ 605

SIGNIFICANT ACCOUNTING POLICI_5

SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Less accumulated depreciation and amortization	$ (1,747,000)	$ (1,747,000)	$ (1,746,000)
Property and equipment, net	28,000	14,000	1,000
Property And Equipment, Gross		1,761	1,747
Furniture and Fixtures
Property And Equipment, Gross	41,000	41,000	41,000
Leasehold Improvement
Property And Equipment, Gross	12,000	12,000	12,000
Construction in Progress
Property And Equipment, Gross	21,000	8,000	0
Equipment
Property And Equipment, Gross	1,049,000	1,048,000	1,042,000
Software
Property And Equipment, Gross	$ 652,000	$ 652,000	$ 652,000

SIGNIFICANT ACCOUNTING POLICI_6

SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
SIGNIFICANT ACCOUNTING POLICIES
Compensation	$ 573	$ 621	$ 1,094
Professional fees	41	98	83
Stock Subscription Payable	0	351	0
Interest	232	261	1,517
Vacation	42	39	34
Preferred dividends	299	349	202
Other accrued expenses	41	49	65
Total	$ 1,228	$ 1,768	$ 2,995

SIGNIFICANT ACCOUNTING POLICI_7

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Dec. 31, 2017
SIGNIFICANT ACCOUNTING POLICIES
Accounts receivable outstanding	$ 172,000	$ 150,000	$ 165,000,000
Outstanding amount balance	46,000	24,000	39,000
Accounts receivable, net of allowance	126,000	126,000	126,000,000
Deferred revenue	337,000	42,000	514,000,000
Net operating loss carry forward	58,000,000	61,600,000	$ 61,600,000	$ 9,900,000
Patent Costs	$ 14,800	$ 17,000

FAIR VALUE OF FINANCIAL INSTR_3

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Derivative Liability	$ (38,000)	$ (32,000)	$ (2,228,000)
Fair Value, Inputs, Level 3 [Member]
Derivative Liability	(38,000)	(32,000)	(2,228,000)
Fair Value, Inputs, Level 2 [Member]
Derivative Liability	0	0	0
Fair Value, Inputs, Level 1 [Member]
Derivative Liability	0	0	0
Senior Secured Debt
Derivative Liability			(2,203,000)
Senior Secured Debt | Fair Value, Inputs, Level 3 [Member]
Derivative Liability			(2,203,000)
Auctus Loan
Derivative Liability	(38,000)	(32,000)	(25,000)
Auctus Loan | Fair Value, Inputs, Level 3 [Member]
Derivative Liability	(38,000)	(32,000)	(25,000)
Auctus Loan | Fair Value, Inputs, Level 2 [Member]
Derivative Liability	0	0	0
Auctus Loan | Fair Value, Inputs, Level 1 [Member]
Derivative Liability	$ 0	$ 0	$ 0

FAIR VALUE OF FINANCIAL INSTR_4

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details 1) - Fair Value, Inputs, Level 3 [Member] - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Beginning Balance, Warrants	$ (32)	$ (2,228)
Change in fair value during the year	(6)	(91)
Ending Balance, Warrants	(38)	(32)
Change In The Terms Of Warrants Previously Recorded As A Liability And Now Reclassified To Equity		1,755
Change In Value Due To Warrants Expiring During The Year		448
Extinguishment Of Derivative Liability Due To Payoff Of $700,000 Loan To Auctus		84
Senior Secured Debt
Beginning Balance, Warrants	0	(2,203)
Change in fair value during the year	0	0
Ending Balance, Warrants	0	0
Change In The Terms Of Warrants Previously Recorded As A Liability And Now Reclassified To Equity		1,755
Change In Value Due To Warrants Expiring During The Year		448
Extinguishment Of Derivative Liability Due To Payoff Of $700,000 Loan To Auctus		0
Derivative
Beginning Balance, Warrants	(32)	(25)
Change in fair value during the year	(6)	(91)
Ending Balance, Warrants	$ (38)	(32)
Change In The Terms Of Warrants Previously Recorded As A Liability And Now Reclassified To Equity		0
Change In Value Due To Warrants Expiring During The Year		0
Extinguishment Of Derivative Liability Due To Payoff Of $700,000 Loan To Auctus		$ 84

FAIR VALUE OF FINANCIAL INSTR_5

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Mar. 31, 2022
Derivative Liability/bifurcated Conversion Option In Connection With Auctus Loan	$ 1,100,000
Extinguishment Of Derivative Liability Due To Payoff Of Loan To Auctus	700,000
Derivative Liability	400,000		$ 400,000
December 17, 2019 [Member]
Derivative Liability/bifurcated Conversion Option In Connection With Auctus Loan	400,000	$ 400,000
Fair Value, Inputs, Level 3 [Member]
Extinguishment Of Derivative Liability Due To Payoff Of Loan To Auctus	$ 700,000

STOCKHOLDERS DEFICIT (Details)

STOCKHOLDERS DEFICIT (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Stockholders' Deficit:
Common stock warrants exercised	4,477,923
Issuance of common stock for payment of Series D preferred dividends	23,109	109,039	148,653
Issuance of common stock for payment of Series E preferred dividends	12,432
Issuance of common stock for payment of Series F-2 preferred dividends	95,535
Issuance of common stock for payment of interest	121,262
Issuance of common stock for Series F one-time 15% dividend	255,401
Issuance of common stock for Series F-2 one-time 15% dividend	368,505
Conversion of Series E preferred stock to common stock	3,070,000
Conversion of Series F Preferred shares into common stock	60,000	40,000
Issued during the three months ended March 31, 2022	8,642,829	535,301	9,818,813
Share issued	8,642,829	535,301	9,818,813
Outstanding	22,316,412	13,673,583	13,138,282	3,319,469
Conversion Of Debt Into Common Shares - Exchange Agreements			7,957,013
Conversion Of Debt Into Common Shares			175,000
Shares Issued For Manufacturing Agreements			12,147
Shares Issued For Payment Of Series E Dividends		288,262
Shares Issued For Payment Of Finder Fee		98,000
Shares Issued To Investors			1,526,000

STOCKHOLDERS DEFICIT (Details 1

STOCKHOLDERS DEFICIT (Details 1) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total Debt And Accrued Interest		$ 2,737,847
Total Debt		2,496,316
Total Accrued Interest		$ 241,531
Common Stock Shares		7,957,013
Warrants (exercise $0.15)		700,000
Warrants outstanding, beginning	27,669,634	28,324,275	46,016,840
Warrants (exercise $0.20)		4,713,603
Warrants (exercise $0.25)		1,121,705
Warrants exercised	(2,284,324)	(2,193,599)
Warrants (exercise $0.50)		250,000
Warrants outstanding, ending	25,385,310	27,669,634	28,324,275
Warrants (exercise $0.75)		1,121,705
Weighted Average Exercise Price Per Share, beginning	$ 0.29	$ 0.25	$ 1.71
Weighted Average Exercise Price Per Share, Warrants exercised	0.16
Weighted Average Exercise Price Per Share, ending	$ 0.30	$ 0.29	$ 0.25
Mr. Mamula
Total Debt And Accrued Interest		$ 15,577
Total Debt		15,000
Total Accrued Interest		$ 577
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		77,885
Warrants (exercise $0.25)		0
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		0
Common Stock Shares		77,885
Mr. Clavijo
Total Debt And Accrued Interest		$ 125,000
Total Debt		125,000
Total Accrued Interest		$ 0
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		0
Warrants (exercise $0.25)		0
Warrants (exercise $0.50)		250,000
Warrants (exercise $0.75)		0
Common Stock Shares		500,000
Mr. Wells
Total Debt And Accrued Interest		$ 220,000
Total Debt		220,000
Total Accrued Interest		$ 0
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		0
Warrants (exercise $0.25)		0
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		0
Common Stock Shares		0
K2 Medical (Shenghuo)
Total Debt And Accrued Interest		$ 803,653
Total Debt		771,927
Total Accrued Interest		$ 31,726
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		496,602
Warrants (exercise $0.25)		704,334
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		704,334
Common Stock Shares		1,905,270
Auctus [Member]
Total Debt And Accrued Interest		$ 328,422
Total Debt		249,119
Total Accrued Interest		$ 79,303
Warrants (exercise $0.20)		0
Warrants (exercise $0.25)		0
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		0
Common Stock Shares		500,000
Warrants (exercise $0.15)		700,000
Aquarius
Total Debt And Accrued Interest		$ 145,544
Total Debt		107,500
Total Accrued Interest		$ 38,044
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		0
Warrants (exercise $0.25)		145,544
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		145,544
Common Stock Shares		291,088
Mr. Blumberg
Total Debt And Accrued Interest		$ 305,320
Total Debt		292,290
Total Accrued Interest		$ 13,030
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		928,318
Warrants (exercise $0.25)		119,656
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		119,656
Common Stock Shares		1,167,630
Mr. Case
Total Debt And Accrued Interest		$ 179,291
Total Debt		150,000
Total Accrued Interest		$ 29,291
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		896,456
Warrants (exercise $0.25)		0
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		0
Common Stock Shares		896,456
Mr. Grimm
Total Debt And Accrued Interest		$ 51,110
Total Debt		50,000
Total Accrued Interest		$ 1,110
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		255,548
Warrants (exercise $0.25)		0
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		0
Common Stock Shares		255,548
Mr. Gould
Total Debt And Accrued Interest		$ 111,227
Total Debt		100,000
Total Accrued Interest		$ 11,227
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		556,136
Warrants (exercise $0.25)		0
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		0
Common Stock Shares		556,136
Dr. Imhoff
Total Debt And Accrued Interest		$ 400,417
Total Debt		363,480
Total Accrued Interest		$ 36,937
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		1,497,367
Warrants (exercise $0.25)		100,944
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		100,944
Common Stock Shares		1,699,255
Ms. Rosenstock
Total Debt And Accrued Interest		$ 50,000
Total Debt		50,000
Total Accrued Interest		$ 0
Warrants (exercise $0.15)		0
Warrants (exercise $0.20)		0
Warrants (exercise $0.25)		50,000
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		50,000
Common Stock Shares		100,000
Mr. James
Total Debt And Accrued Interest		$ 2,286
Total Debt		2,000
Total Accrued Interest		$ 286
Warrants (exercise $0.15)		0
Warrants (exercise $0.25)		1,227
Warrants (exercise $0.50)		0
Warrants (exercise $0.75)		1,227
Common Stock Shares		7,745
Warrants (exercise $0.20)ab		5,291

STOCKHOLDERS DEFICIT (Details 2

STOCKHOLDERS DEFICIT (Details 2) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Deficit:
Warrants outstanding, beginning	27,669,634	28,324,275	46,016,840
Warrants Issued		7,982,223	11,270,013
Warrants Cancelled/expired		(1,729,662)	(70)
Warrants Exchanged		$ (4,713,603)	$ (28,962,508)
Warrants exercised	(2,284,324)	(2,193,599)
Warrants outstanding, ending	25,385,310	27,669,634	28,324,275
Weighted Average Exercise Price Per Share, beginning	$ 0.29	$ 0.25	$ 1.71
Weighted Average Exercise Price Per Share, Warrants Issued		0.30	0.34
Weighted Average Exercise Price Per Share, Warrants Cancelled/expired		0.04	1,068,423
Weighted Average Exercise Price Per Share, Warrants Exchanged		0.20	0.04
Weighted Average Exercise Price Per Share, Warrants Exercised	0.49	0.16
Weighted Average Exercise Price Per Share, ending	$ 0.30	$ 0.29	$ 0.25

STOCKHOLDERS DEFICIT (Details 3

STOCKHOLDERS DEFICIT (Details 3)	12 Months Ended
	Dec. 31, 2021
Stockholders' Deficit:
Expected Term	15 years
Volatility	143.20%
Risk-free Interest Rate	0%
Dividend Yield	0%

STOCKHOLDERS DEFICIT (Details N

STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)							1 Months Ended		3 Months Ended		6 Months Ended	12 Months Ended
	Jul. 08, 2021	Jul. 09, 2020	Jun. 03, 2020	Jan. 08, 2020	Aug. 02, 2018	Sep. 10, 2014	Feb. 28, 2021	Jan. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2020	Dec. 31, 2021	Dec. 31, 2020	Jan. 08, 2021	Jan. 22, 2020	Jan. 16, 2020	Jul. 24, 2019
Cash Payment												$ 350,000
Warrants												3,592,500
Warrants Price Per Share												$ 0.20
Successful In Obtaining Financing Greater Than Amount												$ 4,000,000
Financing Amount												4,000,000
Warrants Closing Of Financing Greater Than Amount												$ 4,000,000
Warrant Holders Percentage Description												4.99% blocker such that the warrant holders will be restricted from owning more than 4.99% of the total number
Common Stock Warrants												7,185,000			1,250,000
Additional Warrants To Purchase Common Stock Shares												150,000			1,250,000
Additional Warrants To Purchase Common Stock Shares Expire Date												May 31, 2024
Warratns Issued												263,000			5,000,000
Issued Equity Investments												$ 2,114,000
Issued Common Stock Shares To Finders												98,000
Warrants To Purchase Shares Of Common Stock																35,937,500
Warrants To Purchase Shares Of Common Stock Exercise Price																$ 0.04
Issuance Of New Warrants To Purchase Shares Of Common Stock																7,185,000
Issuance Of New Warrants To Purchase Shares Of Common Stock Exercise Price																$ 0.20
Payment												$ 750,000
Finder Compensation In Percentage												The finder will receive 5% cash and 5% warrants on all funds it raises including bridge loans. The three-year common stock share warrants will have an exercise price of $0.25.
Raise Funds												$ 300,000
Fee Payment												$ 31,650
Warrants Issued To Finder												126,600
Common Stock, Shares Authorized									500,000,000			500,000,000
Common Stock, Share Price															$ 0.50
Additional Warrants To Purchase Common Stock Shares Price															$ 1
Additional Common Stock Warrants															1,250,000
Additional Common Stock Warrants Price Per Share															$ 1.25
Common Stock Shares Issued									22,316,412			13,673,583	13,138,282
Common Stock Shares Outstanding									22,316,412			13,673,583	13,138,282
Common Stock, Par Value									$ 0.001			$ 0.001	$ 0.001
Common Stock Issued During Period												535,301	9,818,813
Shares Exchange										13,180,417		13,607,609	13,138,282
Strike Price Of Warrants															$ 0.25
Warrants Holders Percentage Description												The consultant agrees to a 10.0% blocker at any single point in time it cannot own 10.0% of the total common stock shares outstanding. The Company issued 1,250,000 common stock warrants during the year ended December 31, 2021, in accordance with the agreement. Refer to Note 7, “Commitments and Contingencies” for additional information.
Common Stock issued									8,642,829			535,301	9,818,813
Preferred stock shares surrendered									3,262
Preferred Stock Shares Converts Into Common Stock									60,000			40,000
Common Stock Warrants									650,000			4,477,923
Debt												$ 2,496,316
Forgive Repayment Amount									$ 41,232			94,392
Principal Amount Of Promissory Note									39,000			46,000	$ 24,000
Gain Loss On Extinguishment Of Debt									41,000	$ 87,000		578,000	(296,000)
Convertible Debt Estimated Fair Value												$ 2,737,847
Common Stock Shares												7,957,013
GHS Investments, LLC [Member]
Principal Amount Of Promissory Note						$ 1,275,000							$ 50,454
Common Stock Shares													175,000
Purchase Price						570,000
Original Issue Discount						560,000
Debt Issuance Costs						$ 145,000
Lowest Daily Volume Average Price						75%
Investments
Warrants To Purchase Shares Of Common Stock												643,700
Issuance Of New Warrants To Purchase Shares Of Common Stock												1,130,000
Common Stock, Issued Public Shares												98,000
Total Investment Amount												$ 2,114,000
Equity Investments Fee												139,000
Proceeds From Debenture Unit Investments												1,130,000
Debenture Fee												$ 86,400
Debentures Convertible Into Common Stock Shares												2,260,000
2020 Exchange Agreements [Member]
Warrants To Purchase Shares Of Common Stock Exercise Price				$ 0.25
Gain Loss On Extinguishment Of Debt			$ 118,396	$ 1,183							$ 224,963
Convertible Debt			$ 328,422	2,064,366							$ 125,000
Convertible Debt Estimated Fair Value				$ 2,065,548
Warrants To Purchase Common Stock Shares			700,000	6,957,013							250,000
Exercise Price Of Warrants To Purchased Common Stock Share Issued, Two				$ 0.75
Exercise Price Of Warrants To Purchased Common Stock Share Issued, Three				$ 0.20
Debt				$ 29,000
Common Stock Shares			500,000								500,000
Fair Value Of The Common Stock Shares			$ 250,000								$ 250,000
Fair Value Of The Warrants			$ 196,818								$ 99,963
Estimated Fair Value Price			$ 0.281								$ 0.40
Fair Value			$ 446,818								$ 349,963
Mr. Bill Wells
Forgive Repayment Amount		$ 110,000							35,000			$ 40,000
Salary		220,000
Received Cash Payment		20,000							$ 35,000			20,000
Principal Amount Of Promissory Note		90,000										97,052
Total Amount To Be Receive		$ 3,000,000										$ 3,000,000
Common Share Stock Option		66,000
Shares Vested Per Month		3,667
Common Stock Exercise Price		$ 0.49
Promissory Note Interest Rate									6.0%			6.0%
Loan Maturity Term									P18Y			18 months
Gain Loss On Extinguishment Of Debt												$ 20,000
Ms. Rosenstock
Debt												50,000
Convertible Debt Estimated Fair Value												50,000
Ms. Rosenstock | 2020 Exchange Agreements [Member]
Forgive Repayment Amount												28,986
Shandong Yaohua Medical Instrument Corporation [Member]
Shares Exchange													12,147				12,147
Debt Exchanges - 2021
Debt														$ 1,500,000
Debt Final Payment														$ 75,000
Warrants Exchanges - 2021 - 1
Financing Amount												4,000,000
Warrants Closing Of Financing Greater Than Amount												$ 4,000,000
Common Stock Warrants												1,802,161
Payment												$ 90,000
Strike Price Of Warrants												$ 0.25
Warrants Holders Percentage Description												The warrants will have a one-year lockup restriction and a 10% blocker such that the warrant holders will be restricted from owning more than 10% of the total number of the Company’s outstanding common shares at any one point in time after completion of the financing.
Exchange Common Stock Warrants												901,081
Common Stock Warrants Strike Price Per Share												$ 0.25
Warrants Exchanges - 2021
Common Stock Warrants												4,477,923
Strike Price Of Warrants												$ 0.20
Exchange Common Stock Warrants												4,713,603
Common Stock Warrants Strike Price Per Share												$ 0.16
Exercise Of Warrants, Value												$ 351,000
Exercise Of Warrants, Shares												2,193,599
Warrants Exchanges - 2021 - 2
Financing Amount												$ 4,000,000
Warrants Closing Of Financing Greater Than Amount												$ 4,000,000
Common Stock Warrants												1,802,161
Strike Price Of Warrants												$ 0.75
Warrants Holders Percentage Description												The new warrants will have a one-year lockup restriction and a 10% blocker such that the warrant holders will be restricted from owning more than 10% of the total number of the Company’s outstanding common shares at any one point in time after completion of the financing.
Exchange Common Stock Warrants												1,802,161
Common Stock Warrants Strike Price Per Share												$ 0.75
Series C Convertible Preferred Shares
Preferred Stock Shares Designated									9,000			9,000
Conversion Price Per Share									$ 0.50			$ 0.50
Preferred Stock Shares Converts Into Common Stock									200			2,000
Liquidation Preference												$ 1,000
Preferred Stock Shares Issued									300			300	300
Total Convertible Of Common Stock Shares					6,524,500				572,000			572,000
Preferred Stock Shares Outstanding									300			300	300
Preferred Stock Shares Par Value									$ 0.001			$ 0.001	$ 0.001
Preferred stock, liquidation preference									$ 286,000			$ 286,000	$ 286,000
Convertible Of Common Stock Shares Description												The conversion price will automatically adjust downward to 80% of the then-current market price of the Company’s common stock 15 trading days after any reverse stock split of the Company’s common stock, and 5 trading days after any conversions of the Company’s outstanding convertible debt. Holders of the Series C preferred stock are entitled to quarterly cumulative dividends at an annual rate of 12.0% until 42 months after the original issuance date
Unpaid Accrued Dividends												$ 120,120
Preferred Stock Shares Authorized									9,000			9,000	9,000
Series C1 Convertible Preferred Shares
Shares Exchange									3,262
Preferred Stock Shares Designated									20,250			20,250
Conversion Price Per Share									$ 0.50			$ 0.50
Preferred Stock Shares Converts Into Common Stock									2,000			2,000
Preferred Stock Shares Issued									1,049			1,049	1,049
Total Convertible Of Common Stock Shares									2,098,500			2,098,500
Preferred Stock Shares Outstanding									1,049			1,049	1,049
Shares Outstanding													1,024,925
Series C2 Convertible Preferred Shares
Shares Exchange									3,262			3,262
Preferred stock shares surrendered									3,262
Conversion Price Per Share									$ 0.50			$ 0.50	$ 0.50
Preferred Stock Shares Converts Into Common Stock									2,000
Dividing The Stated Value									$ 10,000			$ 1
Total Convertible Of Common Stock Shares									6,524,500			2,000	2,000
Series F Convertible Preferred Shares
Preferred Stock Shares Converts Into Common Stock												40,000
Preferred Stock Shares Issued									1,400			1,400	0
Preferred Stock Shares Outstanding									1,400			1,400	0
Preferred Stock Shares Par Value									$ 0.001			$ 0.001	$ 0.001
Preferred stock, liquidation preference									$ 1,411,000			$ 1,426,000	$ 0
Preferred Stock Shares Authorized									1,500			1,500	1,500
Number Of Shares Converted												10
Series F-2 Convertible Preferred Shares
Preferred Stock Shares Designated									3,500			3,500
Conversion Price Per Share									$ 0.25
Preferred Stock Shares Converts Into Common Stock									4,000			4,000
Liquidation Preference									$ 3,237			$ 3,237
Increased Beneficial Ownership Percentage									9.99			9.99%
Preferred Stock Shares Issued									3,200			3,200	0
Common Stock Primary Trading Shares Exceed									1,000			1,000
Exceeds Percentage									200%			200%
Preferred Stock Shares Outstanding									3,200			3,200	0
Preferred Stock Shares Par Value									$ 0.001			$ 0.001	$ 0.001
Conversion Beneficial Ownership Limitation									4.99%			4.99%
Maturity Period									5 years
Preferred Stock Shares Authorized												92,500,000	5,000
Preferred Stock Shares Outstanding												2,559
Preferred Stock Shares Issued												3,237
Shares Issued												678
Convertible Preferred Stock Description 1												Each share of Series F-2 Preferred is convertible, at any time for a period of 5 years after issuance, into that number of shares of Common Stock, determined by dividing the Stated Value by $0.25, subject to certain adjustments set forth in the Series F-2 Certificate of Designation (the “Series F-2 Conversion Price”). The conversion of Series F-2 Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holders of the Series F-2 Preferred. If the average of the VWAPs (as defined in the Series F-2 Certificate of Designation) for any consecutive 5 trading day period (“Measurement Period”) exceeds 200% of the then Series F-2 Conversion Price and the average daily trading volume of the Common Stock on the primary trading market exceeds 1,000 shares per trading day during the Measurement Period (subject to adjustments), the Company may redeem the then outstanding Series F-2 Preferred, for cash in an amount equal to aggregate Stated Value then outstanding plus accrued but unpaid dividends. As of December 31, 2021, the Company had not issued shares as payment of Series F-2 Preferred Stock dividends. As of December 31, 2021, the Company had accrued dividends of $94,907.
Preferred Stock Shares Received									678,000			678,000
Outstanding Debt												$ 2,559,000
Final Payment				750,000								750,000
Exchange Agreement Payment				$ 1,500,000
Dividends Paid Amount												94,907
Accrued dividend amount									$ 91,592
Issuance of common stock for payment pf annual series									95,535
Additional stock issued during period for payment of non recurring dividend									368,505
Preferred stock, liquidation preference									$ 3,237,000			$ 3,237,000	$ 0
Preferred Stock Shares Authorized									5,000			3,500	3,500
Series G Convertible Preferred Shares
Preferred Stock Shares Issued									0			0	0
Preferred Stock Shares Outstanding									0			0	0
Preferred Stock Shares Par Value									$ 0.001			$ 0.001	$ 0.001
Preferred Stock Shares Received												153,000
Preferred stock, liquidation preference									$ 0			$ 0	$ 0
Preferred Stock Shares Authorized									1,000,000			1,000,000	1,000,000
Convertible Preferred Stock Description												During February 2021, the Company finalized an investment by Power Up Lending Group Ltd. Power Up invested $53,500, net to the Company is $50,000, for 62,000 shares of Series G preferred stock with additional tranches of financing up to $925,000 in the aggregate over the terms of the Series G preferred stock. Series G will be non-voting on any matters requiring shareholder vote. The Series G Preferred Stock will have cumulative dividends at the rate per share of 8% per annum. At any time during the period indicated below, after the date of the issuance of shares of Series G preferred stock, the Company will have the right, at the Company’s option, to redeem all of the shares of Series G preferred stock by paying an amount equal to: (i) the number of shares of Series G preferred stock multiplied by then stated value (including accrued dividends); (ii) multiplied by the corresponding percentage as follows: Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%. After the expiration of the 180 days following the issuance date, except for mandatory redemption, the Company shall have no right to redeem the Series G preferred stock. Mandatory redemption occurs within 24 months. In addition, if the Company does not redeem the Series G preferred stock then Power Up will have the option to convert to common stock shares. The variable conversion price will be the value equal to a discount of 19% off of the trading price; which is calculated as the average of the three lowest closing bid prices over the last fifteen trading days. The conversion of Series G Preferred is subject to a 4.99% beneficial ownership limitation, which may be increased to 9.99% at the election of the holder of the Series G Preferred.
Preferred Stock Shares Issued												0	0
Investment Net									$ 114,597			$ 114,597
Preferred Stock Redeemed									91,000			91,000
Series G Convertible Preferred Shares | Power Up Lending Group Ltd [Member]
Total Investment Amount									$ 75,000			$ 75,000
Investment Net							$ 53,500	$ 78,500	$ 53,500			53,500
Preferred Stock Redeemed									91,000
Additional Series G Preferred Stock Shares, Amount							50,000	75,000
Additional Tranches Of Financing								925,000	$ 925,000			$ 925,000
Financing Cost							$ 925,000	$ 925,000
Discount Rate									19%			19%
Discounted Rate							19%	19%
Redemption Of February 2021 Investment, Amount	$ 78,094
Difference Of Interest Expense	$ 28,094								$ 39,597			$ 39,597
Conversion Beneficial Ownership Limitation							4.99%	4.99%
Increased Election Holders							9.99%	9.99%
Cumulative Dividends Rate							8%	8%
Corresponding Percentage Description							Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%.	Day 1-60, 105%; Day 61-90, 110%; Day 91-120, 115%; and Day 121-180, 122%.
Additional Series G Preferred Stock Shares							62,000
Net Proceeds									125,000			125,000
Outstanding Amount									$ 50,000			$ 50,000
Series D Preferred Shares
Shares Exchange												109,039	1,526,000
Common Stock, Issued Public Shares									1,526,000			1,526,000
Preferred Stock Shares Designated									6,000			1,436,000
Conversion Price Per Share									$ 0.25			$ 0.25
Preferred Stock Shares Converts Into Common Stock									763			763
Liquidation Preference									$ 763			$ 763
Beneficial Ownership Percentage									4.99			4.99%
Increased Beneficial Ownership Percentage									9.99			9.99
Preferred Stock Shares Issued									763,000			763,000
Common Stock Warrants 1									1,526,000			1,526,000
Warrant Exercise Price Per Share									0.25			0.25
Common Stock Warrants									1,526,000			1,526,000
Common Stock Warrants Exercise Price 1									$ 0.75			$ 0.75
Conversion Of Investor Shares									763			763
Preferred Stock Dividends Accrued									$ 14,306			$ 14,306
Common Stock Primary Trading Shares Exceed									1,000			1,000
Exceeds Percentage									200%			200%
Series E Preferred Shares
Preferred Stock Shares Designated									5,000			5,000
Conversion Price Per Share									$ 0.25			$ 0.25
Liquidation Preference									$ 968			$ 1,736
Common Stock Primary Trading Shares Exceed									1,000			1,000
Exceeds Percentage									200%			200%
Preferred Stock Shares Par Value									$ 0.001			$ 0.001
Preferred Stock Stated Value									$ 1,000			$ 1,000
Common Stock Shares Issued For Preferred Stock Dividends									12,432			288,262
Accrued Dividends									$ 71,099			$ 54,521
Increased Election Holder									9.99%			9.99%
Conversion Beneficial Ownership Limitation									4.99%			4.99%
Maturity Period									5 years			5 years
Issuance of common stock for conversion of Series E Convertible Preferred Stock									3,070,000
Series F Preferred Shares
Preferred Stock Shares Designated									1,500			1,500
Conversion Price Per Share									$ 0.25			$ 0.25
Preferred Stock Shares Converts Into Common Stock									4,000			4,000
Liquidation Preference									$ 1,411			$ 1,436
Preferred Stock Shares Issued									1,411			1,426
Common Stock Primary Trading Shares Exceed									1,000			1,000
Exceeds Percentage									200%			200%
Preferred Stock Shares Outstanding												1,426
Increased Election Holder									9.99%			9.99%
Conversion Beneficial Ownership Limitation									4.99%			4.99%
Maturity Period									5 years			5 years
Accrued dividend amount									$ 1,998			$ 65,718
Issuance of common stock for payment pf annual series									158,662
Additional stock issued during period for payment of non recurring dividend									255,401
Number Of Shares Converted Into Common Stock									15			10
Shares Converted Into Common Stock									60,000			40,000
Cumulative Dividend Rate									6%			6%
Accredited Investors									$ 1,436,000			$ 1,436,000
Preferred stock shares outstanding									1,436
Series F and Series F-2 Preferred Shares
Preferred Stock Shares Converts Into Common Stock												4,000
Preferred Stock [Member]
Preferred Stock Shares Par Value									$ 0.001			$ 0.001
Preferred Stock Shares Authorized									500,000,000			500,000,000

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
STOCK OPTIONS
Outstanding at ending of year	1,500,000	1,500,000
Number of shares exercisable	1,045,227	954,273
Options outstanding weighted average exercise price, ending	$ 0.49
Options exercisable weighted average exercise price	$ 0.49	$ 0.16
Weighted average remaining contractual life outstanding	8 years 3 months 18 days	8 years 6 months
Weighted average remaining contractual life exercisable	8 years 3 months 18 days	8 years 6 months
Agrregate intrensic value outstanding	$ 240	$ 135
Agrregate intrensic value exercisable	$ 167	$ 86
Outstanding At Beginning Of Year		1,800,000
Options Granted		25,000
Options Forfeited		(167,614)
Options Expired		(157,386)
Options Outstanding Weighted Average Exercise Price, Beginning	$ 0.49	$ 0.49
Options Granted Weighted Average Exercise Price		0.48
Options Forfeited Weighted Average Exercise Price		0.49
Options Expired Weighted Average Exercise Price		0.49
Options Outstanding Weighted Average Exercise Price, Ending		0.49
Weighted Average Exercise Price Per Share Exercisable		$ 0.49

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
STOCK OPTIONS
Expected term (years)	10 years	10 years	10 years
Volatility	153.12%	153.12%	153.12%
Risk-free interest rate	0.98%	0.98%	0.98%
Dividend yield	0%	0%	0%

STOCK OPTION (Details Narrative

STOCK OPTION (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
STOCK OPTIONS
Weighted average period	1 year 3 months		1 year 6 months
Unrecognized stock-based compensation expense	$ 219,558		$ 263,470
Weighted-average fair value of awards granted	$ 0	$ 0.47	$ 0.47	$ 0.48
Stock options granted outstanding common stock shares percentage	10%		10%
Options granted expiration term	ten years		ten years
Options granted exercisable term	four years		four years
Weighted Average Period	1 year 3 months		1 year 6 months
Stock-based Compensation Expense			$ 226,717	$ 309,905

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
LITIGATION AND CLAIMS
Operating Lease Right-of-use Assets	$ 355	$ 372	$ 453
Total Lease Liabilities	$ 377	$ 392

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details 1) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
LITIGATION AND CLAIMS
2022 (remaining)	$ 82	$ 108
2023	112	112
2024	115	115
2025	118	118
2026	50	50
Total future lease payments	477	503
Less: discount	(100)	(111)
Total Lease Liabilities	$ 377	$ 392

COMMITMENTS AND CONTINGENCIES_4

COMMITMENTS AND CONTINGENCIES (Details 2)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
LITIGATION AND CLAIMS
Weighted average remaining lease term (years)	4 years 2 months 12 days	4 years 4 months 24 days
Weighted average discount rate	11.40%	11.40%

COMMITMENTS AND CONTINGENCIES_5

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)				1 Months Ended			3 Months Ended		12 Months Ended
	Mar. 10, 2021	Sep. 06, 2016	Jun. 05, 2016	Jan. 22, 2022	Jan. 22, 2020	Dec. 31, 2009	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Sep. 30, 2021	Jul. 24, 2019
Financing agreement amount							$ 1,000,000		$ 1,000,000
Area Of Operating Leases						12,835
Escrow Agent Rate Per Share												$ 1.90
Consideration Received												$ 885,144
Operating Lease Cost									$ 110,701	$ 114,591
Royalty Percent			20
Licences			$ 1,000,000
Warrants					5,000,000
Warrants Broken Into Four Tranches					1,250,000
Strike Price					$ 0.25
Net Loss Increased					$ 318,000
Sales			$ 4,000,000
Shares exchange								13,180,417	13,607,609	13,138,282
Netl Loss							(507,000)	$ (517,000)	$ (2,070,000)	$ (279,000)
Accumulated Deficit							(143,400,000)		142,400,000
Shenghuo Medical, LLC [Member]
Payment Receive Descriptions			the right to receive payments equal to 2% of the Company’s future sales in the United States, up to an aggregate of $4.0 million.
Shandong Yaohua Medical Instrument Corporation [Member]
Balance due for outstanding purchase order							23,445		177,000
Shares exchange										12,147		12,147
Consulting Agreement [Member] | Mr. Blumberg
Related party liability written off								$ 350,000			$ 350,000
Terms Of Amendment To Agreement	the consulting agreement was amended to clarify that $350,000 is not intended to be debt and will not be required to be repaid in cash. Additionally, issuance of the warrants is now predicated on the Company receiving funding receipts of $1,000,000,
Gain On Writing Off The Liability	$ 350,000
Description Of Exchange Of Subscription	(1) on September 26, 2021, 900,000 3-year warrants with an exercise price of $0.30 and 400,000 common stock shares; (2) on March 26, 2022, 900,000 3-year warrants with an exercise price of $0.40 and 400,000 common stock shares; (3) on September 26, 2022, 900,000 3-year warrants with an exercise price of $0.50 and 400,000 common stock shares; and (4) on March 26, 2023, 900,000 3-year warrants with an exercise price of $0.60 and 400,000 common stock shares.
Subscription Receivable	$ 350,000
Promotional Agreement [Member]
Consulting expenses							79,444		556,111
Fair vaue of warrants				$ 715,000	$ 715,000
Unrecognized consulting expense							$ 0		$ 79,444
Netl Loss										$ 719,000,000
Accumulated Deficit										$ 140,200,000
Royalty Agreement [Member]
Royalty Paid Description		royalty initially equal to $0.10, and from and after October 2, 2016, equal to $0.20, for each disposable
Royalty Consideration		$ 50,000

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes payable in default, including related parties	$ 43,000	$ 0	$ 329,000
GPB
Notes payable in default, including related parties		0	17,000
Premium Finance insurance
Notes payable in default, including related parties	12,000		48,000
Dr. Cartwright
Notes payable in default, including related parties	31,000	0	1,000
Mr. Fowler
Notes payable in default, including related parties	$ 0	0	26,000
Mr. Mermelstein
Notes payable in default, including related parties		$ 0	$ 285,000

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Short-term Notes Payable, Including Related Parties	$ 88	$ 96
Dr. Cartwright
Short-term Notes Payable, Including Related Parties	34	46
Mr. Fowler
Short-term Notes Payable, Including Related Parties	6	0
Dr. Faupel
Short-term Notes Payable, Including Related Parties	0	5
Premium Finance (Insurance)
Short-term Notes Payable, Including Related Parties	$ 48	$ 45

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)			3 Months Ended	12 Months Ended
	Jul. 04, 2021	Jul. 04, 2020	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2021	Mar. 22, 2021	Feb. 19, 2021	Jan. 19, 2017	Dec. 21, 2016
Short-term notes payable			$ 43,253	$ 165,000	$ 96,000
Annual interest rate description			The notes carry annual interest rates between 4.3% and 16%, or 18% in the event of default.	The notes carry annual interest rates between 4.3% and 6% (16% to 18% in the event of default).
Short-term Notes Payable			$ 43,253	$ 165,000	96,000
Notes Payable				$ 27,000	329,000		$ 285,244
Annual Interest Rate Description				The notes carried annual interest rates between 0% and 10% and have default rates as high as 20%.
Short-term Notes Payable, Including Related Parties				$ 88,000	96,000
Notes Payable In Default, Including Related Parties Others				0	329,000
Outstanding Principal Balance			39,000	46,000	24,000
Accrued Interest			1,228,000	1,768,000	2,995,000		$ 32,945
Promissory Notes Issued				$ 323,000	0
Short-term Debt [Member]
Annual Interest Rate Description				The notes carried annual interest rates between 0% and 10% and have default rates as high as 20%.
Short-term Notes Payable, Including Related Parties				$ 40,000	51,000
Dr. Cartwright
Annual Interest Rate Description						The notes were initially issued with 0% interest, however interest increased to 6.0% interest
Notes Payable In Default, Including Related Parties Others					1,000,000
Outstanding Principal Balance				1,621,000					$ 1,621,000
Line of credit, balance			11,968
Promissory Notes Issued				100,000		$ 41,000
Financing Proceeds Received By Company						$ 1,000,000
Mr. Fowler
Annual Interest Rate Description						The notes were initially issued with 0% interest and then went into default with an interest rate of 18%.
Notes Payable In Default, Including Related Parties Others					$ 26,000,000
Outstanding Principal Balance			146,400	12,601						$ 13,900	$ 12,500
Mr. Fowler | Long-Term Debt - Related Parties
Outstanding Principal Balance			26,400					$ 26,400
Dr. Faupel
Annual Interest Rate Description						The notes were initially issued with 0% interest, however interest increased to 6.0% interest
Outstanding Principal Balance				661,000					$ 661,000
Promissory Notes Issued				85,000		$ 5,000
Financing Proceeds Received By Company						$ 1,000,000
March 22, 2021 exchange agreement [Member] | Mr. Fowler
Annual Interest Rate Description						The agreement brought the note current and will accrue interest at a rate of 6.0%.
Accrued Interest			18,718	18,718
Monthly payment of insurance			3,850	3,850
Short term promissory note			45,118	45,118
Short term promissory note, principal			26,400	26,400
Premium Finance Agreement [Member]
Monthly payment of insurance	$ 11,968	$ 11,299
Line of credit, balance			$ 11,968	$ 47,615
Line Of Credit Facility, Maximum Borrowing Capacity	$ 117,560	$ 109,000
Interest And Maturity Date Description	interest at 4.3% and matured in April 2022	interest at 4.968% and matured in April 2021

SHORTTERM CONVERTIBLE DEBT (Det

SHORTTERM CONVERTIBLE DEBT (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	May 27, 2020	May 22, 2020
Debt Discount And Issuance Costs To Be Amortized	$ 5,211	$ (14,000)	$ (262,000)
Convertible Notes Payable - Short Term		897,000	951,000
Convertible notes payable		0	1,930,000
Convertible Notes Payable - Short Term	161,000	161,000	0
Total Convertible Notes Payable
Convertible notes payable	906,000		897,000
Auctus March 31 2020 Note [Member]
Convertible Notes Payable - Short Term		161,000	113,000
Auctus Member
Convertible notes payable	161,000		161,000
Convertible Notes Payable - Short Term					$ 328,422
Auctus Prepayment Penalty
Convertible notes payable	350,000		350,000
Convertible Notes Payable - Short Term		350,000	0
Auctus Tranche 1 [Member]
Convertible Notes Payable - Short Term		0	700,000
AuctusTranche 2 [Member]
Convertible notes payable	400,000		400,000
Convertible Notes Payable - Short Term		$ 400,000	400,000	$ 400,000
Debt Discount and Issuance Costs to be Amortized
Convertible notes payable	$ 5		$ 14

SHORTTERM CONVERTIBLE DEBT (D_2

SHORTTERM CONVERTIBLE DEBT (Details 1) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Convertible Notes In Default	$ 0	$ 1,930
Auctus [Member]
Convertible Notes In Default	0	40
GPB
Convertible Notes In Default	0	1,709
GHS [Member]
Convertible Notes In Default	$ 0	$ 181

SHORTTERM CONVERTIBLE DEBT (D_3

SHORTTERM CONVERTIBLE DEBT (Details Narrative) - USD ($)			1 Months Ended										3 Months Ended	12 Months Ended
	Apr. 03, 2020	Feb. 12, 2016	Jun. 30, 2021	May 27, 2020	May 22, 2020	Mar. 31, 2020	Jan. 16, 2020	Dec. 17, 2019	Jun. 22, 2018	May 17, 2018	May 17, 2017	May 28, 2016	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jan. 22, 2020	Dec. 31, 2019	May 19, 2017	Dec. 07, 2016
Accrued interest													$ 74,778	$ 64,778
Outstanding remaining principal amount													400,000	400,000
Fair value of derivative liability													38,129	31,889
Unamortized debt issuance costs													5,211	(14,000)	$ (262,000)
Exercise price							$ 0.04
Warrants issued																5,000,000
Proceeds from warrant issued													400,000
Debt Issuance Costs														86,000	0
Outstanding Principal Balance													39,000	46,000	24,000
Convertable Note													161,000	161,000	0
Derivative Liabilities													(38,000)	(32,000)	(2,228,000)
Strike Price																$ 0.25
Accured Interest													232,000	261,000	1,517,000
First Tranche [Member]
Convertible note received								$ 700,000
Interest rate of lessor								24%
Description of variable conversion prices								The variable conversion prices equaled the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price was 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event could the variable conversion price be less than $0.15. If an event of default under this note occurred and/or the note was not extinguished in its entirety prior to December 17, 2020 the $0.15 price floor no longer applied
Rate of interest								10%
Fair value of warrants								$ 745,972
Warrants issued																	7,500,000
Warrant liability								$ 635,000
Exercise price								$ 0.20
Proceeds from warrant issued								$ 635,000
Debt issuance cost								65,000
Administrative and legal expenses								570,000
Payment to convertible promissory note								89,250
Prepayment penalty			$ 700,000					$ 350,000					350,000				$ 700,000
unamortized debt discount on warrants, balance													350,000
Matured date								Dec. 17, 2021
Second Tranche [Member]
Total Convertible note issued				$ 2,400,000
Convertible note received				400,000
Net payment amount				$ 313,000
Interest rate of lessor				24%
Description of variable conversion prices				The variable conversion prices shall equal the lesser of: (i) the lowest trading price on the issue date, and (ii) the variable conversion price. The variable conversion price shall mean 95% multiplied by the market price (the market price means the average of the five lowest trading prices during the period beginning on the issue date and ending on the maturity date), minus $0.04 per share, provided however that in no event shall the variable conversion price be less than $0.15. If an event of default under this note occurs and/or the note is not extinguished in its entirety prior to December 17, 2020 the $0.15 price shall no longer apply. The last tranche of $1.3 million will be received within 60 days of the S-1 registration statement becoming effective. The conversion price of the notes will be at market value with a minimum conversion amount of $0.15. In addition, as part of this transaction the Company was required to pay a 2.0% fee to a registered broker-dealer.
Rate of interest				10%
Note maturity date				May 27, 2022
Auctus Fund, LLC [Member]
Accrued interest													46,099	36,428
Outstanding remaining principal amount													161,184	161,184
Total Convertible note issued								$ 2,400,000
Exchange of aggregate outstanding notes													668,290
Unregistered units of our common stock													1,681,707
Default penalty													$ 48,434
Notes issued			250,000
Net proceeds			$ 100,000
Exercise price			$ 0.16
Accrues interest rate			12%
Description of conversion price						the lesser of: (i) the lowest Trading Price during the twenty-five (25) trading day period on the last trading prior to the issue date and (ii) the variable conversion price (55% multiplied by the market price, market price means the lowest trading price for the common stock during the twenty-five (25) trading day period ending on the latest complete trading day prior to the conversion date. Trading price is the lowest trade price on the trading market as reported. The note includes customary events of default provisions and a default interest rate of 24% per year.							The exchange price will be on a $1 for $1 basis such that Auctus will receive $2,349,997 of units consisting of common stock
Aggregate principal amount						$ 112,750
Convertible promissory note						12%
Troubled Debt Restructuring [Member]
Prepayment penalty								$ 350,000					$ 350,000	350,000
Convertible Debt Restructured														1,709,414
Convertable Note														700,000
Derivative Liabilities														$ 84,000
Senior Secured Promissory Note
Original Issue Discount		$ 287,500
Debt Issuance Costs		121,000,000
Interest Accrued															1,233,637
Issuance Of Debt		1,437,500										$ 87,500
Proceeds From Debt		$ 1,029,000										$ 1,525,000
Outstanding Principal Balance																			$ 1,837,500
Warrants Recieve		2,246
Convertible Debt															1,709,414
GPB
Exercise price														$ 0.20
Series F-2 Preferred Stock Issued Upon Conversion Of Debt														2,236
GPB | Senior Secured Promissory Note
Issuance Of Debt		$ 312,500
Exchange Agreement Description							we exchanged $3,360,811 of debt outstanding for the following: (1) cash payments of $1,500,000, (2) 7,185,000 warrants to purchase common stock, previously outstanding, would be exchanged for new warrants to purchase common stock shares at a strike price of $0.20 and (3) a certain amount of preferred stock shares for the remaining balance outstanding upon the final exchange date. During 2021, we made the final payments totaling $800,000 out of the total $1,500,000 and issued 2,236 shares of Series F-2 preferred stock in accordance with the terms of the agreement
GHS [Member]
Net proceeds									$ 68,000		$ 66,000
Original Issue Discount									6,000	$ 750								$ 6,000
Convertible Promissory Note									60,000	9,250				$ 50,000				$ 60,000
Debt Issuance Costs									$ 2,000	1,000
Proceeds From Debt										$ 7,500
Conversion Rate									70%	70%	60%
Bearing Interest Rate									20%	20%								20%
Interesr Rate									10%	8%	8%
Percent Of Outstanding Principal Balance									150%	150%								150%
Interestr Rate Decrease								60%	60%
GHS [Member] | June 22, 2018 [Member]
Original Issue Discount														2,000
Convertible Promissory Note														68,000
GHS [Member] | May 19 2017 [Member]
Default penalty															37,926
Convertable Note															63,520
Accured Interest															17,816
GHS [Member] | May 17 2018 [Member]
Default penalty															4,937
Convertable Note															14,187
Accured Interest															5,006
GHS [Member] | June 22 2018 [Member]
Default penalty															35,285
Convertable Note															103,285
Accured Interest															39,644
Auctus March 31 2020 Note [Member]
Convertable Note														161,000	$ 113,000
Auctus Member
Default penalty					$ 160,000									48,434
Exercise price															$ 0.16
Convertible Promissory Note								$ 2,400,000
Convertable Note					328,422
Conversion Rate						55%		95%
Bearing Interest Rate								24%
Lowest Trading Price								$ 0.04
Conversion Price								$ 0.15
Monthly Penalty Payment					$ 20,000
Restricted Common Stock					500,000
Warrant To Purchase Common Stock					700,000
Strike Price					$ 0.15
Last Tranche Of Covertiable Note								$ 1,300,000
Issuance And Sale Of Securities	$ 100,000					$ 112,750
Interesr Rate						12%
Common Stock Warrant Issued															250,000
Warrant Term															5 years
Percent Of Common Stock Outstanding						4.99%
Unamortized Debt Issuance Costs														0	$ 5,100
Accured Interest														36,428	10,260
Auctus Member | Note 2
Convertable Note					$ 89,250
Auctus Member | Note 3
Convertable Note					65,000
Auctus Member | Note 1
Convertable Note					150,000
Auctus Member | May 22, 2020 [Member]
Fair Value Of Common Stock					250,000
Fair Value Of Warrant To Purchase Common Stock					$ 196,818
Eastmated Fair Value					$ 0.281
Outstanding Balance Of Exchanged Loans					$ 40,000
Auctus Tranche 1 [Member]
Exercise price								$ 0.20
Proceeds from warrant issued								$ 635,000
Payment to convertible promissory note								89,250
Convertible Promissory Note								700,000						350,000	489,231
Debt Issuance Costs								$ 65,000
Convertable Note														0	700,000
Warrant To Purchase Common Stock								7,500,000
Interesr Rate								10%
Unamortized Debt Issuance Costs														0	31,146
Accured Interest														0	73,889
Maturity Date								Dec. 17, 2021
Fair Value Of Warrant								$ 745,972
Amount Allocated To The Warrant Liability								635,000
Fair Value Adjustment Of Warrants								(110,972)
Proceeds Recevied After Administrative And Legal Expenses								570,000
Prepayment Penlity								$ 350,000
Unamortized Debt Issuance Costs On Warrant														0	179,623
AuctusTranche 2 [Member]
Convertible Promissory Note														451,192	377,136
Convertable Note				$ 400,000										400,000	400,000
Derivative Liabilities														31,889
Conversion Price								$ 0.15
Interesr Rate				10%
Unamortized Debt Issuance Costs														13,586	47,086
Accured Interest														$ 64,778	$ 24,222
Maturity Date				May 27, 2022
Amount Paid To Company				$ 313,000
Variable Conversion Price				75%
Public Market Price				$ 0.50
Replaced Variable Conversion Price				80%
Broker Fees				2%

LONG TERM DEBT (Details)

LONG TERM DEBT (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Feb. 19, 2021
Bonus	$ 573,000	$ 621,000	$ 1,094,000
Vacation	42,000	39,000	34,000
Outstanding Principal Balance	39,000	46,000	24,000
Amount Forgiven	(41,232)	(94,392)
Exchange For Series F-2 Preferred Stock		323,000	0
Dr. Cartwright
Salary		337,000			$ 337,000
Bonus		675,000			675,000
Loans to Company		528,000			528,000
Interest on loans		81,000			81,000
Outstanding Principal Balance		1,621,000			1,621,000
Total interest accrued through December 31, 2021		62,000			45,000
Interest accrued through March 31, 2022	4
Balance outstanding, end of period	285,000	281,000	364,000		281,000
Amount Forgiven		(1,302,000)
Exchange For Series F-2 Preferred Stock		100,000		$ 41,000
Interest Accrued		17,000
Dr. Faupel
Salary		134,000			134,000
Bonus		20,000			20,000
Vacation		95,000			95,000
Interest on compensation		67,000			67,000
Loans to Company		196,000			196,000
Interest on loans		149,000			149,000
Outstanding Principal Balance		661,000			661,000
Total interest accrued through December 31, 2021		39,000			29,000
Interest accrued through March 31, 2022	2
Balance outstanding, end of period	$ 163,000	161,000	$ 236,000		$ 161,000
Amount Forgiven		(454,000)
Exchange For Series F-2 Preferred Stock		85,000		$ 5,000
Interest Accrued		$ 10,000

LONG TERM DEBT (Details 1)

LONG TERM DEBT (Details 1) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Total	$ 852	$ 820	$ 23
Long-Term Debt - Related Parties | Mr. Fowler
2022	27	30
2023	485	479
2024	39	39
2025	41	41
2026	3	3
Thereafter	0	0
Total	$ 595	$ 592

LONG TERM DEBT (Details 2)

LONG TERM DEBT (Details 2) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
LONG TERM DEBT
10% Senior Unsecured Convertible Debentures	$ 1,130	$ 1,130
Debt Issuance costs to be amortized	(62)	(69)
Debt Discount	(216)	(241)
Long-term convertible debt	$ 852	$ 820

LONG TERM DEBT (Details Narrati

LONG TERM DEBT (Details Narrative) - USD ($)			1 Months Ended			3 Months Ended		12 Months Ended
	Jul. 09, 2020	May 04, 2020	May 17, 2021	Mar. 22, 2021	Feb. 19, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2018	Sep. 04, 2018	Jan. 19, 2017	Dec. 21, 2016
Debt Issuance Costs								$ 86,000	$ 0
Outstanding Principal Balance						$ 39,000		46,000	24,000
Gain For Extinguishment Of Debt						41,000	$ 87,000	578,000	(296,000)
Current Portion Of Long-term Debt						67,000		88,000	28,000
Long-term Debt-related Parties								59,200
Debt forgiveness amount						41,232		94,392
Accrued Interest						232,000		261,000	1,517,000
Paycheck Protection Program
Outstanding Principal Balance						4,491,000
Current Portion Of Long-term Debt								11,000	50,477
Debt forgiveness amount								23,742
Accrued Interest						407		385	293
Payroll costs						100,000		100,000
Proceeds From Loan		$ 50,184
Loan Interest Rate		1.00
Loan Maturity Term		24 months
Debt Interest Forgiveness Amount								234
10% Senior Unsecured Convertible Debenture
Debt Issuance Costs								819,024
Accrued Interest						28,250		73,326	293
Convertible Debentures Right Description			each debenture unit will have a right to 1,000 warrants for common stock shares, warrants have an exercise price of $0.80 and an expiration date of May 17, 2023
Change Of Control Premium Percentage			3
Deemed Price			$ 0.50
Convertible Debentures			$ 1,000					1,130,000
Bond Payable Discount								240,856
Unamortized Debt Issuance Costs								69,120
Debt Maturity Date			May 17, 2024
Proceeds From Convertible Debenture			$ 1,130,000
Conversion Price			$ 0.50
Mr. Bill Wells
Outstanding Principal Balance	$ 90,000							97,052
Gain For Extinguishment Of Debt								20,000
Current Portion Of Long-term Debt						65,299		77,087
Debt forgiveness amount	$ 110,000					$ 35,000		$ 40,000
Promissory Note Interest Rate						6.0%		6.0%
Loan Maturity Term						P18Y		18 months
Exercise price	$ 0.49
Received cash payment	$ 20,000					$ 35,000		$ 20,000
Monthly payment due	$ 3,667							5,000
Common Share Stock Option	66,000
Salary	$ 220,000
Total Amount To Be Receive	$ 3,000,000							3,000,000
Shares Vested Per Month	3,667
Common Stock Exercise Price	$ 0.49
Principal And Accrued Interest								99,158
Dr. Cartwright
Outstanding Principal Balance					$ 1,621,000			1,621,000
Gain For Extinguishment Of Debt										$ 840,000
Long-term Debt-related Parties								281,000
Due to related party											$ 1,621,000
Future debt obligations						284,867
Debt forgiveness amount								1,302,000
Promissory Note Interest Rate					6.0%
Debt Instrument Converted Amount					$ 85,000
Series F-2 Preferred Stock Issued Upon Conversion Of Debt					100
Salary					$ 337,000			337,000
Principal Amount Of Promissory Note					$ 267,085				1,621,000
Loans, Interest, Bonus, Salary And Vacation Paid Amount											$ 1,621,499
Interest Rate Per Annum											6%
Issuance Of Promissory Note In Exchange Of Related Party Debt											$ 319,000
Capital Contribution										432,000
Promissory Note Maturity Date					February 18, 2023
Mr. Fowler
Outstanding Principal Balance						146,400		12,601				$ 13,900	$ 12,500
Long-term Debt-related Parties						26,586		150,000
Due to related party				$ 546,214		6,232
Future debt obligations						146,400
Debt forgiveness amount						253,429,000
Accrued Interest				133,590
Due To Related Party, Amount				$ 546,214
Promissory Note Interest Rate Description				The note accrues interest at the rate of 6.0% (18.0% in the event of default) beginning on March 1, 2022 and is payable in monthly installments of $3,600 for four years,
Accrued Interest Rate Description				The notes accrue at an interest rate of 6% (18% in the event of default).
Promissory Note Interest Rate				6.0
Debt Instrument Converted Amount				$ 50,000
Series F-2 Preferred Stock Issued Upon Conversion Of Debt				50
Promissory Note Default Interest Rate				18
Promissory Note Monthly Installment				$ 3,600
Preferred Shares Converted Into Common Stock				200,000
Effective Interest Rate				6.18
Deferred Salary				$ 412,624
Unsecured Note Issued Upon Conversion Of Debt				150,000
Mr. Fowler | Maximum | Debt Exchanges - 2021
Debt forgiveness amount				259,661
Mr. Fowler | Long-Term Debt - Related Parties
Outstanding Principal Balance				26,400		26,400
Debt forgiveness amount				86,554
Accrued Interest				$ 18,718
Dr. Faupel
Outstanding Principal Balance					$ 661,000			661,000
Gain For Extinguishment Of Debt										199,000
Long-term Debt-related Parties								161,000
Due to related party											660,895
Future debt obligations						$ 163,376
Debt forgiveness amount								454,000
Promissory Note Interest Rate					6.0%
Debt Instrument Converted Amount					$ 100,000
Series F-2 Preferred Stock Issued Upon Conversion Of Debt					85
Salary					$ 134,000			$ 134,000
Principal Amount Of Promissory Note					$ 153,178				$ 661,000				$ 3,850
Issuance Of Promissory Note In Exchange Of Related Party Debt											$ 207,111
Capital Contribution										$ 235,000
Promissory Note Maturity Date					February 18, 2023
Dr. Faupel and Mr. Cartwright [Member] | July 24, 2019 [Member]
Simple Interest Rate								6.0

INCOME (LOSS) PER COMMON SHAR_2

INCOME (LOSS) PER COMMON SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Basic weighted average number of shares outstanding	20,683	13,172	13,377	10,767
Net loss per share (basic)	$ (0.05)	$ (0.04)	$ (0.18)	$ (0.04)
Diluted weighted average number of shares outstanding	20,683	13,172	13,377	10,767
Net loss per share (diluted)	$ (0.05)	$ (0.04)	$ (0.18)	$ (0.04)
Net Loss	$ (1,055)	$ (572)	$ (2,431)	$ (401)
Dilutive Equity Instruments (number Of Equivalent Units):
Dilutive Equity Instruments (number Of Equivalent Units)			36,739	69,778
Convertible Debt [Member]
Dilutive Equity Instruments (number Of Equivalent Units):
Dilutive Equity Instruments (number Of Equivalent Units)	2,018	315	964	62,095
Preferred Stock [Member]
Dilutive Equity Instruments (number Of Equivalent Units):
Dilutive Equity Instruments (number Of Equivalent Units)	15,572	17,994	18,253	0
Stock Option [Member]
Dilutive Equity Instruments (number Of Equivalent Units):
Dilutive Equity Instruments (number Of Equivalent Units)	917		1,867	0
Warrants [Member]
Dilutive Equity Instruments (number Of Equivalent Units):
Dilutive Equity Instruments (number Of Equivalent Units)	13,609	17,400	15,655	7,683

INCOME (LOSS) PER COMMON SHAR_3

INCOME (LOSS) PER COMMON SHARE (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
INCOME (LOSS) PER COMMON SHARE
Decrease in net loss	$ 41,232	$ 972,000	$ 85,000
Account payable forgivness amount	$ 41,232		$ 94,392
Troubled debt restructuring description		the troubled debt restructurings in total would have decreased the net loss by $972,000, causing the per share calculation to change from .04 to .11 net loss per share.	the troubled debt restructuring in total would have decreased the net loss by $85,000, causing the per share calculation to change from .18 to .19 net loss per share.

INCOME TAXES (Details)

INCOME TAXES (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
INCOME TAXES
Statutory Federal Tax Rate	21%	21%
State Taxes, Net Of Federal Benefit	4%	4%
Nondeductible Expenses	0%	0%
Valuation Allowance	25%	25%
Effective Rate	0%	0%

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
INCOME TAXES
Current			$ 0	$ 0
Deferred			0	0
Deferred Provision (credit)			(1,728)	1,623
Change In Valuation Allowance			1,728	(1,623)
Total Provision For Income Taxes	$ 0	$ 0	$ 0	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Deferred Tax Assets:
Warrant Liability	$ 0	$ 617
Accrued Executive Compensation	288	519
Reserves And Other	273	289
Stock Options	134	132
Net Operating Loss Carryforwards	16,985	17,851
Gross Deferred Tax Assets	17,680	19,408
Valuation Allowance	(17,680)	(19,408)
Net Deferred Tax Assets	$ 0	$ 0

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Dec. 31, 2020	Dec. 31, 2017
INCOME TAXES
Nol Carryforwards	$ 58	$ 61.6	$ 61.6	$ 9.9
Offset Taxable Income Percentage	80%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)					3 Months Ended	12 Months Ended
	Jun. 22, 2022	Jun. 06, 2022	Jun. 01, 2022	Jun. 02, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Common stock warrants					$ 70,000
Common stock warrants					650,000	4,477,923
Common Stock Share Issued					22,316,000	13,673,000	13,138,000
Share Issued For Conversion					60,000	40,000
Ellen Of Grossman And Schole LLP [Member]
Financing		$ 3,000,000
Legal services		304,879
Balance of owing amount		104,879
Cash payment from proceeds of the financing		200,000
Partial payments for exchange of forgiveness		50,000
Outstanding debt		$ 50,000
10% Senior Unsecured Convertible Debenture
Common Stock Share Issued					3,213	121,262
Dividend Percentage						10%
Seried D Exchange Agreements
Amount Received Of Common Stock, Warrants And Prefunded Warrants					$ 130,000
Aggregate outstanding common stock warrants					650,000
Common stock warrants Strike price					$ 0.25
Warrants shares					650,000
Warants strike price					$ 0.20
Executive Exchange Agreements [Member] | Subsequent Event [Member]
Common stock warrants					$ 4,000,000
Related-party payables	$ 29,776
Short-term related-party debt	31,285
Accrued expenses	$ 8,939
Auctus | 2020 Exchange Agreements
Aggregate Outstanding Notes Exchange Value				$ 668,290
Exchange Price Basis				The exchange price will be on a $1 for $1 basis
Warrant Exchange Value				$ 1,681,707
Amount Received Of Common Stock, Warrants And Prefunded Warrants				2,349,997
Default Penalties				$ 350,000
Weighted Average Price Of Common Stock Exceeds Percentage Rate				200%
Securities				$ 350,000
Auctus One [Member] | 2020 Exchange Agreements
Aggregate Outstanding Notes Exchange Value			$ 692,114
Exchange Price Basis			The exchange price will be on a $1 for $1 basis
Warrant Exchange Value			$ 2,031,710
Amount Received Of Common Stock, Warrants And Prefunded Warrants			2,031,710
Default Penalties			$ 350,000
Weighted Average Price Of Common Stock Exceeds Percentage Rate			200%
Series D Preferred Shares
Common stock warrants					1,526,000	1,526,000
Common Stock Share Issued					975,000,000
Share Issued For Conversion					763	763
Series E Preferred shares
Common Stock Share Issued					320,000
Share Issued For Conversion						307,000
Series F and Series F-2 Preferred shares
Common Stock Share Issued						625,686
Dividend Percentage						15%
Series F Preferred shares
Common Stock Share Issued					1,360,000
Share Issued For Conversion						60,000
Series D Preferred share dividends
Common Stock Share Issued					25,288	23,109
Series E Preferred share dividends
Common Stock Share Issued					50,230	12,432
Series F-2 Preferred shares
Common Stock Share Issued					1,864,000
Series F Preferred share dividends
Common Stock Share Issued					19,330